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Abstract 
Influenza virus infection and the shikimic acid pathway are two of many examples of 
microbe-host interactions and microbial biosynthetic pathways that are interesting for 
investigation by means of small molecules. A particularly interesting structural motif 
common to both is the cyclohexenecarboxylic acid. In the former, this structural motif 
has been employed as a mimetic of the sialyl cation intermediate and forms the scaffold 
of the anti-influenza drug and neuraminidase inhibitor Oseltamivir (or Tamiflu
TM
). In 
the latter pathway, crucial modifications towards aromatic amino acids are carried out 
via shikimic acid, a cyclohexenecarboxylic acid, as a substrate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Strategic overview for the synthesis of important ‘phospha’-isosteres. 
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A straightforward method to replace the carboxylate moiety in such structures with a 
phosphonate would provide access to a wide variety of mimetics, for instance 
monoesters, that still retain a negative charge under physiological conditions usually 
required for bioactivity (Scheme 1). 
 
The aim of this research project, as presented in Scheme 1, was to develop an efficient 
synthesis of the cyclohexenephosphonate scaffold from chiral pool precursors via two 
key steps, a Hunsdiecker-Barton iododecarboxylation followed by a palladium-
mediated coupling step to introduce the phosphonate moiety, thus giving a convenient 
access to interesting bioactive molecules. This approach has successfully been applied 
to the shikimic acid to afford ‘phospha’-shikimic acids and 3-dehydro-‘phospha’-
shikimic acids, and further development of this strategy has led to the synthesis of 
‘phospha’-Tamiflu and its derivatives from an Oseltamivir precursor. 
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Towards a convenient synthesis of bioactive 
cyclohexenephosphonates 
I.1. Theoretical part 
I.1.1. Previous work 
Work by Streicher et al.
[1-6]
 has been focused on the synthesis of carbocyclic 
sialylmimetics and more specifically the use of cyclohexenephosphonates as scaffolds 
for sialidase inhibitor librairies, mainly oriented towards the inhibition of parasitic and 
bacterial sialidases. These cyclohexenephosphonates, which retain the half-chair 
conformation of the sialidase reaction transition state and retain a negative charge 
required for recognition by the enzyme, allow attachment of a spacer molecule or 
additional sugar moieties, which is of importance due to the more complex functionality 
of bacterial or protozoal sialidases in contrast to the influenza sialidase for which very 
potent inhibitors have already been developed.  
 
A strategy was developed to synthesize D- and L-xylo configured 
cyclohexenephosphonates from D- and L-xylose respectively, by chain elongation and 
cyclization utilizing an intramolecular Horner-Wadsworth-Emmons-type condensation 
as outlined in Scheme 2.
[6]
 This methodology was inspired by the synthesis of shikimic 
acid and analogs introduced  by both Fleet et al.
[7, 8]
 (synthesis of (-)-shikimic acid from 
D-mannose) and Vasella and coworkers 
[9, 10]
 (synthesis of (-)-shikimic acid from D-
lyxose).  
 
This synthetic approach towards cyclohexenephosphonates allowed further exploration 
of the structural space beyond the sialidase active site and was used for the design and 
synthesis of novel sialidase inhibitor libraries. It led to the synthesis of diethyl 
phosphonates,
[1-3]
 which was then extended to the synthesis of dibenzyl and dimethyl 
phosphonates.
[4, 5]
 These allowed, after partial saponification with thiophenol and 
triethylamine, the synthesis of mixed diesters containing aliphatic moieties or aglycon 
mimetics through a Mitsunobu condensation or alkylation with suitable triflates. Thus, 
introduction of a hydrophobic group or a sugar moiety to the phosphonate were 
12 
 
successfully achieved.
[4, 5]
 The synthesis of pseudo-sialosides via di-benzyl 
phosphonates
[4]
 is shown in Scheme 3 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Previous group work: 
Synthesis of D- and L-xylo configured cyclohexephosphonates from D- and L-Xylose. 
Scheme 3. Strategy for the synthesis of mixed diester phosphonates: 
Reagents & conditions: (i) PhSH/NEt3; (ii) sugar triflate, DMF; (iii) H2/Pd/C then 
NH3/MeOH; (iv) CF3COOH. 
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One shortcoming of the routes above (Scheme 3) is the relatively high total number of 
synthetic steps from the chiral-pool starting material, leading to moderate overall yields. 
A new synthetic approach towards phospha-isosteres of cyclohexenylcarboxylic acids, 
as described there-in, is the direct replacement of the carboxylic acid moiety by the 
phosphonic acid moiety. The most effective way to achieve this utilizes a 
halodecarboxylation of the carboxylic acid followed by a conversion of the resulting 
vinyl halide into a vinyl phosphonate diester. An overview of the halodecarboxylation 
and the phosphonylation steps is presented below. 
  
I.1.2. Barton-Hunsdiecker’s iododecarboxylation and Hirao’s coupling 
reaction 
 
 
 
 
 
 
 
 
I.1.2.1. The halodecarboxylation reaction 
The generation of carboxyl radicals and trapping of the ensuing alkyl radicals by 
various radical-trapping agents allows the transformation of carboxylic acids into a 
range of diverse functional groups. These reactions are known as reductive 
decarboxylation, oxidative decarboxylation, decarboxylative halogenation, 
chalcogenation, phosphorylation, oxygenation and amination and decarboxylation with 
subsequent C-C bond formation. Different methods exist for the generation of carboxyl 
radicals obtained by homolytic cleavage from suitable precursors containing a weak 
carboxyl-X bond.
[11]
 These carboxyl radical precursors are: 
 Acyl hypohalites used in the classical Hunsdiecker reaction.[12, 13] Acyl 
hypohalites are prepared in situ by reaction of a silver salt of the carboxylic acid 
with a halogen. This method is used for carbon-halogen bond formation. 
Scheme 4. Introduction to the iododecarboxylation and phosphonylation steps. 
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 Lead(IV) carboxylates used in the Kochi variant[14] of the Hunsdiecker reaction. 
Lead tetraacetate is employed to generate a weak bond between the acid and the 
lead by exchange of an acetate of lead tetraacetate for the acid. This method is 
used for the synthesis of alkyl halides from carboxylic acids. 
 O-Acyl oximes prepared by reaction of benzophenone oxime with acyl chlorides 
and used as synthetic precursors for photochemical arylation of aromatic 
compounds.
[15]
 
 O-Acyl thiohydroxamates developed by Barton et al.,[16] prepared by reaction of 
acyl chlorides with N-hydroxy-pyridine-2-thione. This method to generate the 
carboxyl radical tolerates a much wider range of functional groups as it operates 
under much milder conditions. After decarboxylation, the alkyl radical can be 
trapped with a variety of radical-trapping reagents. The reactions are initiated 
thermally in appropriate solvents or by white light photolysis. 
 
In the interest of the following research work, only the decarboxylative halogenation 
reaction will be discussed here. 
The discovery of the halodecarboxylation was made by Borodin in 1861 involving the 
preparation of methyl bromide from silver acetate.
[17]
 Hunsdiecker investigated the 
reaction for the synthesis of aliphatic halides in the early 1940’s.[12, 13] Since then, the 
common name given to the reaction has been the Hunsdiecker reaction. The 
Hunsdiecker reaction consists of the degradation of a silver salt of the carboxylic acid in 
anhydrous medium by means of halogen to obtain the corresponding halide of one less 
atom than the original acid. The reaction can be done with other salts than silver salts 
such as mercury(II),
[18]
 thallium(I)
[19]
 and lead(IV)
[14]
 salts. The reaction can be 
expressed by the following equation (M is metal and X is halogen): 
 
 
The classical Hunsdiecker reaction is carried out in tetrachloromethane under reflux and 
optimal yields are obtained with bromine, followed by chlorine and then iodine. An 
investigation by Barton of the halodecarboxylation showed that photochemical 
decarboxylation of acyl hypoiodites provided a method for the preparation of alkyl 
iodides by using lead tetraacetate and iodine as reagents
[20]
. The difficulties, expense 
and toxicity associated with the use of metal salts have led to the development of more 
wide-ranging and generally applicable conditions to carry out the decarboxylative 
RCOOM X
2
RX CO
2
MX+ + +
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halogenations such as the photolytic or thermal decomposition of O-acyl 
thiohydroxamates in halogen donor solvents developed by Barton in the 1980’s.[16, 21, 22] 
This decarboxylative halogenation proceeds by a radical chain mechanism (as shown in 
Scheme 5) under very mild conditions. Decarboxylative chlorination or bromination of 
thiohydroxamate esters is achieved using carbon tetrachloride or 
bromotrichloromethane respectively as the solvent and trapping species and the reaction 
is initiated by heating under reflux or by UV irradiation induced photolysis.  
 
 
 
 
 
 
 
 
 
 
Decarboxylative iodination by this method uses iodoform as an iodine donor in benzene 
or cyclohexene. So far, the halodecarboxylation had been investigated mainly on 
aliphatic carboxylic acids. Barton then extended the scope of his procedure to aromatic 
carboxylic acids.
[23]
 Following Barton’s procedures, the alkyl iodides are the halides 
formed in the lowest yield and although well investigated for aliphatic and aromatic 
carboxylic acids, very little has been reported on vinyl carboxylic acids.
[11, 22]
 More 
recently, Eaton and co-workers
[24]
 proposed 2,2,2-trifluoroiodoethane as a more 
convenient and efficient iodinating agent which they used successfully in their synthesis 
of iodocubanes.  
 
 
 
 
 
 
 
 
Scheme 5. Halodecarboxylation chain mechanism from the thiohydroxamate ester. 
Scheme 6. Iododecarboxylation step in the synthesis of prostaglandin phosphonic acids. 
Reagents & conditions: (i) oxalyl chloride, DMFcat, anhydrous CH2Cl2 then sodium salt of N-
hydroxypyridine-2-thione, DMAPcat, CF3CH2I, anhydrous CH2Cl2, hν, reflux, 56%. 
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Likewise, this source of iodide radical has been used in the iododecarboxylation 
reaction involved in the synthesis of prostaglandin phosphonic acids by Kende and co-
workers (Scheme 6).
[25]
  
Over the last decade, new protocols for the Hunsdiecker reaction have been developed, 
mainly for the synthesis of aromatic and aryl-substituted vinyl halides. Roy and co-
workers
[26, 27]
 developed a catalytic Hunsdiecker-like protocol, using N-
bromosuccinimide as halogenating reagent and lithium acetate as catalyst. Tokuda et 
al.
[28, 29]
 developed microwave induced halodecarboxylation of aromatic and α,β-
unsaturated carboxylic acids, leading to aryl halides and (E)-β-arylvinyl halides 
respectively, carried out in the presence of a catalytic amount of LiOAc and with N-
halosuccinimide as halogenating reagent.
[28, 29]
 Alternatively Jain et al.
[30]
 carried out the 
microwave irradiation using N-chlorobenzotriazole. Another procedure developed by 
Tokuda et al.
[31]
 led to the stereoselective synthesis of (Z)-1-bromo-1-alkenes from the 
corresponding 2,3-dibromoalkanoic acids using a triethylamine/DMF system and 
microwave irradiation. The development of more environmentally friendly ‘green’ 
Hunsdiecker reactions have as well been achieved, using inorganic bromide (KBr) and 
hydrogen peroxide in the presence of molybdenium (VI) as catalyst
[32]
 or using N-
halosuccinimide in micellar media.
[33]
 
 
The modified Barton-Hunsdiecker halodecarboxylation procedure, introduced by 
Eaton
[24]
 and Kende
[25]
, was chosen for the detailed investigation of the reaction 
conditions.  
 
I.1.2.2. Hirao’s palladium-promoted coupling reaction 
One of the most versatile pathways for the sp
3
-carbon-posphorus bond formation is the 
Michaelis-Arbuzov reaction.
[34]
 The reaction involves the SN2 reaction of esters of 
trivalent phosphorus with alkyl halides to yield dialkyl alkylphosphonates under heating 
conditions, it thus converts a trivalent phosphorus into a pentavalent phosphorus.  
 
 
 
 
P(OR)
3
XR' R XR' P(OR)
2
O
+ +
Scheme 7. Michaelis-Arbuzov reaction. 
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Due to the SN2–type mechanism of the reaction, aryl and vinyl halides are unreactive 
towards trialkyl phosphites. Nevertheless, Arbuzov products of aryl halides were 
obtained by free-radical chemistry, for example by photolysis and heating in presence of 
trialkyl phosphites
[35, 36]
 or by photostimulated reaction of halogenobenzene derivatives 
with dialkyl phosphite anions as nucleophiles in liquid ammonia
[37, 38]
 or in DMF.
[39]
  
More recently, vinyl and arylphosphonates were synthesized by Bentrude and co-
workers
[40]
 in good yields, following generation of vinyl and aryl radicals from the 
corresponding bromides, under typical AIBN/n-Bu3SnH conditions in refluxing benzene 
in the presence of an excess of P(OMe)3. The reaction was not stereospecific as the E or 
Z stereochemistry of the starting vinyl bromides was lost during the reaction and a 
mixture of the E/Z phosphonate compounds was obtained. 
 
The difficulty of the sp
2
-carbon-phosphorus bond formation has been mainly overcome 
by palladium-catalyzed coupling reactions. Hirao
[41]
 developed in the early 1980’s a 
methodology to convert vinyl bromides into dialkyl vinyl phosphonates 
stereoselectively,
[42]
 and aryl bromides into dialkyl arylphosphonates in good yields.
[43]
  
 
 
 
 
 
 
The reactions of vinyl and aryl bromides with O,O-dialkyl phosphonates (also called 
dialkyl phosphites) under Hirao’s experimental conditions are carried out in the 
presence of triethylamine and a catalytic amount of tetrakis(triphenylphosphine) 
palladium in toluene at 90°C under a nitrogen atmosphere. The palladium(0) species 
undergoes oxidative addition with vinyl or aryl bromides to give the aryl-palladium 
complex. The attack of dialkyl phosphite to the vinyl/aryl palladium complex leads to 
the formation of the dialkyl vinyl/aryl phosphonate. The base, triethylamine, regenerates 
the palladium(0) species, which is then available for another reaction cycle, by 
formation of the salt of NEt3 with HBr. This formation path of dialkyl vinyl/aryl 
phosphonates is outlined in Scheme 9. 
 
 
Scheme 8. Hirao’s reaction. 
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Hirao’s procedure has since been widely used for the synthesis of dialkyl 
alkenylphosphonates from alkenyl bromides and iodides.
[44-48]
 Notably, reactions using 
Hirao’s conditions have also been applied to (un)substituted cyclohexene ring systems 
carrying a vinylic bromide or iodide.
[42, 49]
 Some of these reactions have been carried out 
with variations to the original protocol by the use of different bases, for example 
DABCO
[50]
 or caesium carbonate and N,N-dimethylethylenediamine.
[51]
 
Holt and co-workers
[52]
 applied Hirao’s conditions to couple alkenyl triflates with 
dialkyl phosphites in good yields. Hirao’s conditions were also used by Xu et al. for the 
synthesis of unsymmetrical alkyl arylphenylphosphinates,
[53]
 functionalized alkyl 
alkylarylphosphinates,
[54]
 alkylarylphenylphosphine oxides
[55]
 from aryl halides and for 
the synthesis of alkyl alkenylmethyl and alkenylphenylphosphinates from arylvinyl and 
vinyl halides.
[56]
 
Moreover, an improved procedure for the synthesis of vinylphosphonate-linked nucleic 
acids has been developed by Hayes and co-workers (Scheme 10).
[57]
  
 
 
 
 
 
 
 
 
 
 
 
 
 
R = Aryl or vinyl group
R' = Alkyl group
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Scheme 9. Reaction cycle for the formation of dialkyl vinyl/aryl phosphonates. 
Scheme 10. Reagents & conditions: (i) Pd(OAc)2, dppf, THF, reflux, propylene oxide, 92% 
yield. 
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The couplings of hindered H-phosphonate diesters with vinylic bromides were achieved 
by using propylene oxide as an alternative HBr scavenger (replacing the triethylamine) 
and using a different catalyst system by generating the catalyst in situ from palladium 
acetate and 1,1’-bis(diphenylphosphino)ferrocene (dppf) in refluxing THF. 
 
Recently, Stawinski and co-workers developed a general and efficient method for the 
formation of the sp
2
-carbon-phosphorus bond by a microwave-assisted palladium-
catalyzed cross-coupling of aryl and vinyl halides with various H-phosphonate diesters 
in good yields,
[58]
 as outlined in Scheme 11. 
 
 
 
 
 
 
As a final example of a metal-catalyzed process to generate dialkyl arylphosphonates, 
Stockland et al. developed a room temperature Hirao reaction.
[59]
 The reaction still 
utilizes Pd (0) as catalyst, which is formed in situ from palladium acetate and bis(2-
diphenylphosphinophenyl)ether (dpephos) as supporting ligand, and silver 
phosphonates as transmetallating agents to afford diethyl arylphosphonates from aryl 
iodides in moderate to good yields, as described in Scheme 12. 
 
 
 
 
 
 
Bentrude’s conditions and subsequently Hirao’s conditions were chosen to be 
investigated as the second key step involved in the synthesis of the 
cyclohexenephosphonate scaffold and more specifically, to achieve the phosphonylation 
of our vinyl iodide.  
 
Scheme 11. Reagents & conditions: (i) 5 mol % Pd(PPh3)4, Cs2CO3 or NEt3, THF. 
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]
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Scheme 12. Hirao’s reaction at room temperature: 
Reagents & conditions: (i) Pd(OAc)2 5 mol %, dpephos 10 mol %, THF, 25°C. 
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I.1.3. Shikimic acid and the shikimate pathway 
I.1.3.1. Shikimic acid 
(-)-Shikimic acid was first isolated by Ekmann in 1885 from the fruit of Illicium 
religiosum. It is from this oriental plant, named shikimi-no-ki in Japanese that the name 
shikimic acid was derived.  
 
 
 
 
 
 
(-)-Shikimic acid has been selected as the starting material of choice (compared to 
quinic acid) for the industrial synthesis of Oseltamivir Phosphate (Tamiflu
TM
) by 
chemists at F. Hoffmann-La Roche Ltd. Indeed, (-)-Shikimic acid is now available in 
ton quantities either by extraction from the fruit Illicium verum (Chinese star anise) or 
by fermentation using a genetically engineered E. coli strain developed by Frost and co-
workers
[60, 61]
 and technically established at Roche. It was recently reported that 
Liquidambar styraciflua, more commonly known as the sweetgum tree, could be a 
renewable source of shikimic acid.
[62]
 In fact, it was shown that the sweetgum tree can 
yield shikimic acid in amounts comparable to that of Illicium verum, through the seeds 
of its annual fruit. 
Due to its biological importance, there has been a wide interest in finding alternative 
synthetic routes to (-)-shikimic acid. Its first total syntheses in a racemic form were 
performed by Raphael
[63]
 and Smissman
[64, 65]
 employing an identical synthetic route, 
using the Diels-Alder reaction of acrylic acid (or methyl acrylate in Smissman’s 
synthesis) with (1E,3E)-1,4-diacetoxy-1,3-butadiene as starting materials. Since then, 
many different syntheses of (-)-shikimic acid and its racemic form have been reported. 
Synthetic approaches based on the Diels-Alder reaction, syntheses from benzene and its 
derivatives, chiral pool-based syntheses from (-)-quinic acid and from carbohydrates 
were used to achieve the synthesis of (-)-shikimic acid. Two detailed reviews about this 
work, the first by Searle and co-workers 
[66]
 (1993) and the second by Singh and 
Jiang
[67]
 (1998), give a good overview of these synthetic approaches. Over the last 
COOHOH
OH
OH
Figure 1. (-)-shikimic acid 
(-)-Shikimic acid plays an important role in a 
biosynthetic pathway, known as the shikimate pathway, 
which leads ultimately to the biosynthesis of three 
aromatic amino acids, L-phenylalanine, L-tyrosine and L-
tryptophan. 
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decade, interest in the shikimic acid synthesis
[68-70]
 has declined as interest in novel 
synthetic routes to synthesize shikimic acid-like molecules have increased.
[71-76]
 
 
I.1.3.2. Shikimate pathway 
As mentioned previously, though in less detail, the shikimate pathway, a biosynthetic 
pathway which is absent in mammals, allows the biosynthesis of aromatic amino acids 
and aromatic compounds such as ubiquinones, naphthoquinones and folates. The 
shikimate pathway is found only in micro organisms (bacteria, parasites and microbial 
eukaryotes) and plants. As a consequence, the shikimic acid pathway provides a 
valuable roadmap for engineering new herbicides and herbicide-resistant crops, as well 
as new antibiotic and antiparasitic drugs by targeting inhibition of its enzymes. In this 
context, significant research is being undertaken to fully understand this pathway and to 
elucidate structural data of enzymes of importance implicated in the shikimate pathway 
in order to facilitate the direction of new small molecule inhibitor design.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The shikimate pathway (Corrected figure taken with permission from the Journal of 
Biological Chemistry 2005, 280, 7162). 
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In a sequence of seven metabolic steps the shikimate pathway transforms D-Erythrose-
4-phosphate and phosphoenolpyruvate into chorismate, the latter being the precursor to 
the synthesis of aromatic amino acids (Figure 2
[77]
). The pathway enzymes are: 2-keto-
3-deoxy-D-arabinoheptulosonate-7-phosphate synthase, dehydroquinate synthase, 5-
dehydroquinate dehydratase, shikimate dehydrogenase, shikimate kinase, 3-
enoylpyruvylshikimate-5-phosphate synthase and chorismate synthase, following the 
transformation of D-Erythrose-4-phosphate into chorismate. 
In this biological pathway, shikimic acid is the intermediate synthesized by the 
shikimate dehydrogenase which allows the reversible reduction of 3-dehydroshikimate 
into shikimate. This is the justification why designing and synthesizing new shikimic 
acid mimetics could lead to the discovery of new antimicrobials. 
 
I.1.3.3. Shikimate dehydrogenase 
Shikimate dehydrogenase (SDH) catalyses the fourth step of the shikimate pathway and 
is responsible for the reversible reduction of 3-dehydroshikimate to shikimate in the 
presence of the cofactor NAD(P)H (Scheme 13
[78]
). 
 
 
 
 
 
 
 
 
 
In fungi and yeast, SDH exists as a component of the pentafunctional AROM 
polypeptide which catalyses five of the seven steps of the shikimate pathway. In plants, 
SDH is associated with 3-dehydroquinate dehydratase as a bifunctional enzyme.
[79, 80]
 In 
bacteria, three types of SDH have been characterized to date, AroE, YdiB and SDH-
L.
[81]
 They are members of the quinate/shikimate 5-dehydrogenase family. Crystal 
structures of both the AroE and YdiB proteins reveal the presence of a NAD(P)-binding 
and catalytic site.  
Scheme 13. Overall reaction mechanism for the reduction of 3-dehydroshikimate to shikimate 
using NADH. 
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AroE is a monofunctional enzyme specific to the shikimate pathway (identified in 
Escherichia coli, Salmonella typhimurium and many other microbial species) and 
catalyses the reduction of 3-dehydroshikimate to shikimate in the presence of NADPH. 
In contrast, YdiB, which is represented in a lower percentage of organisms, is a 
bifunctional enzyme used in both shikimate and quinate pathway. YdiB reduces 3-
dehydroshikimate to shikimate and 3-dehydroquinate to quinate in the presence of either 
NADH or NADPH. Nevertheless, the biological function of YdiB is not fully clear as it 
is not known if 3-dehydroshikimate or quinate is its natural substrate.
[77, 79]
 The SDH-L 
(shikimate dehydrogenase-like) protein has been identified only in a small group of 
organisms and it has been shown that SDH-L requires NADPH for the reduction of 3-
dehydroshikimate to shikimate.
[81]
 Structural studies of dehydrogenases AroE and YdiB 
show a three-dimensional conserved protein structure and indicate that their substrate 
and nucleotide-binding sites are also highly conserved.
[81]
 
More especially, these enzymes contain two α/β domains connected by two α-helices 
and separated by a wide cleft which is the active site of these enzymes. This deep cavity 
is contiguous with the hydride acceptor NAD(P)
+
 co-factor which is binding to the C-
terminal domain being a Rossmann domain
[82]
 in the structure (Figure 3
[80]
). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Ribbon diagram of the AroE : NADPH complex structure. The NADPH binding 
domain is shown in green at the top, the catalytic domain is shown in red at the bottom, and 
NADPH is shown in a ball-and-stick representation (Figure taken with permission from the 
Journal of Bacteriology 2003, 185, 4144). 
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The key residues interacting with the substrate and with the co-factor are well conserved 
in all the SDH orthologues. Figure 4
[79]
 shows a view of AroE active site with 3-
dehydroshikimate and the cofactor NADP
+
 and Figure 5
[78]
 shows a view of YdiB active 
site with the shikimate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This therefore indicates that all the different types of SDH use a similar catalytic 
mechanism and that rational drug design of potent inhibitors may be possible. Even 
though the determination of several SDH crystal structures and the efforts being made 
to understand the reaction mechanism involved in SDH may provide enough structural 
information for rational drug discovery, no SDH efficient inhibitors have yet been 
found. However, some inhibitors of SDH from Helicobacter pylori have recently been 
discovered using a high throughput screening.
[83]
 These compounds are curcumin A, 3-
(2-naphthyloxy)-4-oxo-2-trifluoromethyl)-4H-chromen-7-yl 3-chlorobenzoate B, butyl 
2-{[3-(2-naphthyloxy)-4-oxo-2-(trifluoromethyl)-4H-chromen-7-yl]oxy}propanoate C, 
2-({2-[(2-{[2-(2,3-dimethylanilino)-2-oxoethyl]sulfanyl}-1,3-benzothiazol-6-yl)amino]-
Figure 4. Molecular model of the 
binding of dehydroshikimate to the 
active site of AroE (Figure taken with 
permission from the Journal of 
Biological Chemistry 2003, 278, 
19463).  
Figure 5. Proposed binding mode for a molecule 
of shikimate in the active site of YdiB. Distances 
are given in Å. All of the side chains shown here 
are 100% conserved in the shikimate 
dehydrogenase cluster of orthologous genes with 
the exception of Ser-67 (which is only 
substituted with threonine) and Tyr-234 (which 
is present in 37 of 43 sequences) (Figure taken 
with permission from the Journal of Biological 
Chemistry 2003, 278, 19176). 
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2-oxoethyl}sulfanyl)-N-(2-naphthyl) acetamide D, and maesaquinone diacetate E, with 
IC50 values of 15.4, 3.9, 13.4, 2.9, and 3.5μM, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
These inhibitors, which are not the result of rational drug discovery, possess new 
chemical scaffolds which could lead to the development of novel SDH inhibitors. 
 
I.1.3.4. Towards Shikimic acid mimetics 
The fundamental aim of this research work was to find a novel and effective synthetic 
approach towards cyclohexenephosphonates from chiral cyclohexene carboxylate 
precursors.  
It was thus decided to apply this approach to shikimic acid to afford ‘phospha’-shikimic 
acid and derivatives. Shikimic acid is a particularly interesting starting material to work 
with as it is both an important metabolite in its own right and a starting material in anti-
influenza drug synthesis.
[84, 85]
 Moreover, the replacement of the carboxylate 
functionality by a phosphonate moiety enables the retention of the necessary 
pharmacophores in the target molecules. This has some precedent, since the 
phosphonate moiety is frequently used as a bioisostere of carboxylate groups in drug 
design and synthesis,
[2-4, 86, 87]
 retaining the negative charge, present under physiological 
conditions, which is essential for activity and opening space to incorporate lateral 
functionality on phosphonate monoesters. 
 
Figure 6.  Chemical structure of compounds A-E. 
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As shown in Figure 7 the synthetic targets are the ammonium salts of [(3R,4S,5R)-
trihydroxy-1-cyclohexene-1-phosphonic acid] 1, [methyl (3R,4S,5R)-trihydroxy-1-
cyclohexene-1-phosphonate] 2, [(4S,5R)-dihydroxy-3-oxo-1-cyclohexene-1-phosphonic 
acid] 3 and [methyl (4S,5R)-dihydroxy-3-oxo-1-cyclohexene-1-phosphonate] 4. 
 
It is important to note that ‘phospha’-shikimic acid 1 has previously been synthesized 
by Mirza et al.
[9, 10]
 They designed a synthetic route leading to the synthesis of shikimic 
acid and its phosphonate analogue. As illustrated in Scheme 14, condensation of a 
suitably protected D-lyxose 5-aldehyde with tetraethyl methylenediphosphonate (or 
diethyl ethoxycarbonylmethylphosphonate) afforded the Knoevenagel product which 
after hydrogenation and intramolecular Horner-Wadsworth-Emmons olefination 
afforded the protected cyclohexene precursor to ‘phospha’-shikimic acid (or shikimic 
acid). Subsequent hydrolysis of the phosphonate ester (or carboxylic ester) and of the 
ketal afforded ‘phospha’-shikimic acid (or shikimic acid).  
 
 
Figure 7. Targeted phospha-isosteres of shikimic acid. 
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I.2. Results and discussion - Synthesis of phospha-isosteres of 
shikimic acid 
I.2.1. Retrosynthetic analysis and synthetic strategies towards phospha-
shikimic acids and derivatives 
The most effective route to achieve the synthesis of ‘phospha’-shikimic acid would 
proceed via the protection of the various shikimic acid hydroxyl groups followed by a 
halodecarboxylation of the carboxylic acid and a subsequent conversion of the resulting 
vinyl halide into the respective phosphonate diester, as shown in Scheme 15 below. 
 
 
 
 
 
 
 
 Scheme 15. Retrosynthetic analysis. 
Scheme 14. Mirza’s ‘phospha’-shikimic acid synthesis: 
Reagents & conditions: (i) N-methylmorpholine, TiCl4, CCl4, THF, 64%; (ii) H2, 10% Pd/C, 
EtOH; (iii) NaOEt, EtOH, 42%; (iv) Me3SiBr, CHCl3 then H2O, 93%. 
P(O)(OEt)
2
(EtO)
2
(O)P
P(O)(OEt)
2
O
O
OH
P(O)(OH)
2
OH
OH
OH
O
O
P(O)(OEt)
2
P(O)(OEt)
2
O
BnO
O
O
P(O)(OEt)
2
O
OBn
P(O)(OEt)
2
O
O
O
O
OBn
+
i
ii
iiiiv
COOHOH
OH
OH
IPGO
PGO
OPG
PPGO
PGO
OPG
O
OMe
OMe
Shikimic acid
Iododecarboxylation
Phosphonate
 introduction
PG = Protecting Group
28 
 
Two different routes have been explored. Route A was based on halodecarboxylation of 
a protected shikimic acid followed by a phosphonylation leading to phospha-shikimic 
acid 1 and its methyl ester 2. Oxidation of the 3-OH at a later stage (after 
phosphonylation) led to only the methyl ester of 3-dehydro phospha-shikimic acid 4. 
Route B, which has the oxidation step placed prior to the halodecarboxylation, allowed 
the synthesis of 3-dehydro ‘phospha’-shikimic acid 3 and its methyl ester 4. Route B 
was investigated to assess the effects of protecting groups in the synthetic process and 
to improve final deprotection of the dehydro derivative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I.2.2. Route A.  
I.2.2.1. Synthesis of 1-iodo-(3R,4S,5R)-tri-acetoxy-1-cyclohexene 6 from shikimic acid. 
In order to carry out the halodecarboxylation step, the various hydroxyl groups first 
needed to be protected. Shikimic acid was thus acetylated. Acetylation was achieved 
with acetic anhydride and a catalytic amount of sulphuric acid, but the protected 
shikimic acid was only obtained in a moderate yield of 34%. The protection was 
improved using standard conditions, acetic anhydride in pyridine,
[88]
 to give acetylated 
compound 5 in good yield (Scheme 17).  
 
 
Scheme 16. Strategies towards phospha-isosteres of shikimic acid. 
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During the early stages of the synthetic work, decarboxylation attempts with silver salts 
of the carboxylic acid with I2 (Hunsdiecker conditions) or with Pb(IV) and halide salts 
such as LiCl and LiBr (Kochi conditions) were carried out. None of them gave 
satisfying results. Instead, decomposition of the starting material was observed. 
 
The classic Hunsdiecker reaction
[12, 13]
 and its Kochi variant,
[14]
 particularly in its metal-
free version introduced by Barton,
[16, 22]
 is well established for the conversion of 
carboxylic acids into halides via a radical mechanism. The protected shikimic acid was 
thus converted to 1-iodo-(3R,4S,5R)-tri-acetoxy-1-cyclohexene 6 using a modified 
Barton-Hunsdiecker halodecarboxylation reaction,
[25]
 specifically here an iodinative 
decarboxylation.
[23, 24]
 
 
The decarboxylative halogenation has been well described by Barton and co-workers 
for both aliphatic and aromatic acids via a radical decomposition of the thiohydroxamic 
ester (derived from the reaction between the acid chloride and  N-hydroxypyridine-2-
thione) in the presence of a halogen source.
[16, 21, 23]
 Interestingly, a thorough search of 
the literature revealed that very little has been reported on its application to vinyl 
carboxylic acids,
[11, 29, 89]
 particularly when considering that vinyl halides and mainly 
iodides are very useful substrates in a variety of organic reactions, namely C-C coupling 
reactions.  
 
The Barton procedure is a one pot conversion of carboxylic acid functionalized 
compounds to their halogenated analogues, which requires a two step methodology:  
(a) the conversion of the carboxylic acid to the acid chloride with oxalyl chloride in the 
presence of a catalytic amount of dimethyl formamide in anhydrous dichloromethane; 
COOHOH
OH
OH
COOHAcO
AcO
OAc
IAcO
AcO
OAc
i ii
(a),(b)
Iododecarboxylation
64%
86%
Shikimic acid 5 6
Scheme 17. Reagents & conditions: (i) pyridine/acetic anhydride; (ii) (a) oxalyl 
chloride, DMFcat, anhydrous CH2Cl2; (b) sodium salt of N-hydroxypyridine-2-thione, 
DMAPcat, CF3CH2I, anhydrous CH2Cl2, irradiation by a 250W floodlamp. 
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(b) the decarboxylation step via the formation of the thiohydroxamic ester. (Scheme 18). 
The acid chloride is added to a mixture of the sodium salt of N-hydroxypyridine-2-
thione, the halogen donor 2-iodo-1,1,1-trifluoroethane (CF3CH2I), with a catalytic 
amount of 4-dimethylaminopyridine in anhydrous DCM, the solution then being 
irradiated with a 250W UV electric flood lamp. 
 
The reaction proceeds by a radical chain mechanism
[16]
 involving a carbon radical 
intermediate which reacts with the halogen donor to form the desired halogen derivative 
(Scheme 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A study on suitable conditions for the halodecarboxylation of acetylated shikimic acid 5 
was carried out. Different conditions were applied to the system in order to optimize the 
reaction. It was assumed that the acid chloride was always formed quantitatively, 
therefore the second step of the procedure became the main focus and was investigated 
by varying certain reaction parameters. The reactions containing different equivalents of 
halogen donors were irradiated with different UV sources for various reaction times.  
The Table 1 below summarizes the conditions used. 
 
 
 
 
Scheme 18. Iododecarboxylation mechanism. 
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Clearly from the table above, it can be concluded that 5 or 6 equivalents of CF3CH2I are 
enough for the iododecarboxylation reaction to proceed, along with irradiation of the 
mixture by a 250W electric flood lamp for at least one hour. These became the standard 
conditions for the iododecarboxylation reaction of protected shikimic acid. Use of the 
common iodine source diiodoethane or irradiation with specific UV-sources did not 
result in improved yields. Chloro- and bromo-decarboxylation proved to be less 
efficient as trial experiments afforded the 1-chloro-(3R,4S,5R)-tri-acetoxy-1-
cyclohexene 21 and 1-bromo-(3R,4S,5R)-tri-acetoxy-1-cyclohexene 22 in low yields of 
23% and 36% respectively. (Scheme 19). 
 
 
 
 
 
 
 
 
Entry 
Halogen 
donor 
Equivalent Light 
Time 
(min) 
Yield 
(%) 
Compound 
1 CF3CH2I 11 
250W electric 
flood lamp 
60 57 6 
2 CF3CH2I 11 
250W electric 
flood lamp 
240 28 6 
3 
CF3CH2I/ 
ICH2CH2I 
2/3.5 
250W electric 
flood lamp 
90 20 6 
4 ICH2CH2I 11 
250W electric 
flood lamp 
120 5 6 
5 CF3CH2I 5 
250W electric 
flood lamp 
90 64 6 
6 CF3CH2I 6 
250W electric 
flood lamp 
75 57 6 
7 CF3CH2I 11 
125W UV (365-
366 nm) 
60 27 6 
8 CF3CH2I 5 
400W UV (365-
366 nm) 
60 17 6 
9 CCl4 11 
250W electric 
flood lamp 
60 23 7 
10 CCl4 11 
125W UV (365-
366 nm)  
60 8 7 
11 CBr4 11 
250W electric 
flood lamp 
75 36 8 
Scheme 19. Reagents & conditions: (a) oxalyl chloride, DMFcat, anhydrous 
CH2Cl2; (b) sodium salt of N-hydroxypyridine-2-thione, DMAPcat, halogen 
donor (see Table 1), anhydrous CH2Cl2, irradiation by UV light. 
Table 1. Halodecarboxylation reaction optimization table. The starting material is the acetylated 
shikimic acid. 
COOHOH
OH
OH
XAcO
AcO
OAc
(a),(b)
Halodecarboxylation
Shikimic acid
6 : X = I
7 : X = Cl
8 : X = Br
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I.2.2.2. Introduction of the phosphonate group: Synthesis of Dimethyl (3R,4S,5R)-tri-
acetoxy-1-cyclohexene-1-phosphonate 9 and deprotection. 
Initially it was thought that phosphonylation would occur under radical conditions, 
following Bentrude’s conditons for the synthesis of vinyl and arylphosphonates,[40] 
using AIBN and n-Bu3SnH at 80°C in the presence of an excess of trimethylphosphite. 
This reaction was not successful. Purification and subsequent NMR analysis of what 
was thought to be the product indicated that acetyl groups had been removed and that no 
vinylphosphonate proton, usually characterized as a doublet around 6.5 ppm, could be 
detected. 
 
 
 
 
 
 
 
 
 
It was therefore decided to synthesize the vinylphosphonate using a palladium(0) 
catalyzed step.
[47]
 Utilizing the experimental conditions employed by Hirao,
[41, 42]
 this 
coupling step involves the reaction of vinyl-iodide 6 with dimethylphosphite and 
triethylamine in the presence of a catalytic amount of tetrakis(triphenylphosphine) 
palladium. Phosphonylation occurred but only with poor yields. The low yield of this 
reaction was contributed to the base labile acetyl groups which display instability to the 
conditions utilizing triethylamine with heating.
[90]
 
Another peculiarity of this reaction is the formation of a side product 10 which is 
obtained in a non-negligible amount (18% yield) compared to compound 9 (28% yield). 
At present, the mechanism of this deiodination remains to be established. 
Hydrodehalogenation as a side reaction has already been observed using the same 
experimental conditions of Hirao’s reaction.[45] Such products have also been mentioned 
in the literature.
[39]
 
 
Scheme 20. Reagents & conditions: (i) HP(O)(OMe)2, Pd(PPh3)4, anhydrous 
NEt3, anhydrous Toluene, 80°C. 
PAcO
AcO
OAc
O
OMe
OMe
IAcO
AcO
OAc
HAcO
AcO
OAc
i
28%
96
+
Side product 10
33 
 
The crystal structure of dimethyl (3R,4S,5R)-tri-acetoxy-1-cyclohexene-1-phosphonate 
9 was determined and is shown in Figure 8 below. As expected for the cyclohexene 
ring, the crystal structure displays a half-chair conformation with C-5 and C-4 
respectively above and below the plane formed by the four atoms H, C-3, C-6 and P 
which are bonded to the two sp
2
 carbons C-2 and C-1. Acetoxy groups on C-4 and C-5 
are pseudo axial and the acetoxy group on C-3 is pseudo equatorial.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Following the phosphonate introduction, the first target compounds 1 and 2 were 
obtained by saponification of the acetyl esters and total (using TMSBr) or partial 
cleavage (using NaI) of the methyl phosphonates (Scheme 21). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 21. Reagents & conditions: (i) bromotrimethylsilane, lutidine, 
anhydrous CH2Cl2; (ii) aqueous ammonia (10%); (iii) gel permeation 
chromatography (gpc); (iv) NaI, anhydrous acetone, reflux; (v) aqueous ammonia 
(10%); (vi) gpc. 
Figure 8. ORTEP-generated structure of acetylated 
‘phospha’-shikimic acid dimethyl ester 9. 
PAcO
AcO
OAc
O
OMe
OMe
OH
OH
OH
P
OMe
O
O
NH
4
+
OH
OH
OH
P
O
O
O
NH
4
+
NH
4
+
9
1
2
i, ii, iii
iv, v, vi
34 
 
Protected ‘phospha’-shikimic acid 9 was subjected to cleavage of the methyl 
phosphonates using TMSBr and lutidine in anhydrous CH2Cl2 for 4 hours, giving the 
free phosphonic acid which was carried to the next step without further purification. 
Analysis by NMR of the crude product revealed that the phosphonate was deprotected. 
Deacetylation of the latter compound was carried out in aqueous ammonia leading to 
‘Phospha’-shikimic acid 1 which was directly purified by gel permeation 
chromatography on a Biogel P4 column. 
Mono-demethylation of compound 9 was achieved using sodium iodide in dry acetone 
under reflux conditions to afford the sodium salt.
[91]
 Deprotection of the hydroxyl 
groups was achieved with aqueous ammonia affording the mono-methyl ‘Phospha’-
shikimic acid 2 which was purified by gel permeation chromatography on a Biogel P4 
column. 
 
In only three steps starting from the shikimic acid, the overall yield of this synthesis of 
‘phospha’-shikimic acid dimethyl ester 9 is 14%. In order to improve the yield of the 
phosphonylation step and to access the 3-dehydro ‘phospha’-shikimic acid, a novel and 
more efficient synthesis of protected ‘phospha’-shikimic acid was thus required 
involving a new protecting group strategy. 
 
I.2.3. A alternate protecting group strategy towards shikimic acid 
derivatives. 
I.2.3.1. A new protecting group strategy. 
We noted previously that the difficulties encountered during formation of phosphonate 
9 could be due to its protecting group pattern that is the acetyl groups which were labile 
under the conditions used (triethylamine with heating). As a consequence, protecting 
groups unaffected under nucleophilic and basic conditions, such as ketals or silyl ethers, 
were used in an attempt to introduce the dialkyl phosphonate in better yields.  
Moreover, protection of the hydroxyl groups of the shikimic acid had to be done in a 
manner to access specifically the hydroxyl group belonging to C-3 and alter it in a 
chemoselective manner to afford the dialkyl (4S,5R)-dihydroxy-3-oxo-1-cyclohexene-
1-phosphonate. 
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To begin with, a regioselective protection was needed and specifically a trans-vicinal 
protection of the hydroxyl groups belonging to C-4 and C-5 of the shikimic acid
[92, 93]
 in 
order to protect independently the hydroxyl group belonging to the C-3.  
We therefore started the synthesis with esterification and protection of shikimic acid as 
the methyl ester-4,5-trans diketal 11 in one step according to a published procedure
[92]
 
(Scheme 22). 
 
 
 
 
 
 
 
 
 
The regioselective protection of the trans-vicinal diol was achieved in presence of 
butane-2,3-dione, a catalytic amount of (+)-camphorsulfonic acid (CSA), and trimethyl 
orthoformate in methanol under reflux (90°C) for 72h to give compound 11 in 62% 
yield after purification. The protected cis-vicinal diol is also obtained but not 
characterized and used to recycle compound 11. Unfortunately, even using the same 
conditions, the yields were not fully comparable to the literature yields of 80 and 
87%.
[92, 93]
  
Silylation of the 3-OH was carried out reacting compound 11 with tert-
butyldimethylsilyl chloride in anhydrous CH2Cl2, in presence of imidazole and a 
catalytic amount of DMAP for 24h at room temperature to give silylated compound 12 
in 76% yield.
[93]
  
  
Scheme 22. Reagents & conditions: (i) CH(OMe)3, 2,3-butanedione, CSAcat, MeOH; (ii) 
TBDMSCl, imidazole , CH2Cl2. 
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I.2.3.2. Iododecarboxylation and phosphonate introduction: key steps towards 3-
dehydro-‘phospha’-shikimic acid derivatives. 
 
 
 
 
 
 
 
 
 
 
Saponification of protected shikimic acid 12, followed by the two key steps 
iododecarboxylation and phosphonate introduction afforded protected ‘phospha’-
shikimic acid 15 (Scheme 23). 
 
Demethylation of compound 12 was carried out in a 1:1 mixture of aqueous NaOH 
(0.5M) and MeOH to give free acid 13 in 80% yield after purification. The latter 
compound was iododecarboxylated as described earlier to furnish the iodo derivative 14 
which was obtained in 39% yield. However, 25% of the starting material 13 was 
recovered. This could be due to the quality of the oxalyl chloride used and/or the length 
of time the sample was irradiated. Based on the recovered starting material, the yield of 
this iododecarboxylation step is 52%. 
Introduction of the phosphonate group was achieved under the same conditions as 
described earlier to obtain phosphonate derivative 15. As expected, the new desired 
phosphonate derivative 15 was obtained in an increased 70% yield thus making this 
protecting group pattern a superior choice for the palladium coupling step. 
 
At this stage of the synthesis, five steps from the shikimic acid, the overall yield of the 
synthesis of intermediate 15 was 14% which unfortunately would mean no 
improvement overall in the generation of ‘phospha’-shikimic acids 1 and 2. However, 
this new protecting group strategy allowed for a significant improvement in the yield of 
the phosphonate introduction step.  
Scheme 23. Reagents & conditions: (i) NaOH 0.5M, MeOH; (ii) (a) oxalyl chloride, DMFcat, 
anhydrous CH2Cl2; (b) sodium salt of N-hydroxypyridine-2-thione, DMAPcat, CF3CH2I, 
anhydrous CH2Cl2, irradiation by a 250W floodlamp; (iii) dimethylphosphite, Pd(PPh3)4, 
anhydrous NEt3, anhydrous toluene. 
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Cleavage of the silyl ether was achieved under anhydrous conditions with 
tetrabutylammonium fluoride in THF to afford the deprotected alcohol 16 in 96% yield 
(Scheme 24). The crystal structure of dimethyl (3R,4S,5R)- 3-hydroxy-4,5-(2,3-
dimethoxy-butan-2,3-dioxy)-cyclohex-1-ene-1-phosphonate 16 was determined and is 
shown in Figure 9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oxidation of 16 was carried out by a simple and efficient procedure
[94]
, using IBX a 
mild oxidant, and proceeded in high yields affording the protected 3-dehydro-
‘phospha’-shikimic acid derivative 17. Following this procedure, alcohol 16 was 
dissolved in acetone, IBX was added to the solution which was heated to 65°C for 2 to 3 
hours to give the ketone 17 in 94% yield. 
Scheme 24. Reagents & conditions: (i) TBAF, THF; (ii) IBX, anhydrous 
acetone, reflux. 
Figure 9. ORTEP-generated structure of alcohol 16. 
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The first deprotection step (Scheme 25) was the acidic hydrolysis of the 4,5-trans 
diketal derivative 17 with aqueous trifluoroacetic acid which afforded after flash 
chromatography the trans-diol 18 in 80% yield. The following deprotection step to 
achieve was the partial cleavage of the dimethylphosphonate 18. Three attempts were 
carried out without giving any results (aqueous ammonia (10% w/w), sodium hydroxide 
(0.05 M) and thiophenol (7 eq)/NEt3 (14 eq). Finally, monomethyl ester 4 was 
successfully generated by iodide-mediated O-alkyl cleavage
[91]
 and purification by gel 
permeation chromatography. 
 
The total cleavage of the dimethylphosphonate was regrettably not achieved from 
compound 18. Indeed the usual conditions, bromotrimethyl silane and lutidine in 
anhydrous DCM, were thought not to be adequate conditions for the deprotection of this 
compound bearing an enolisable carbonyl group. Protection of the carbonyl group was 
thus a necessity. 
 
I.2.4. Route B. 
Route B involved oxidation and protection of the ketone before the iododecarboxylation 
and phosphonylation steps (Scheme 26). Route B gave access to target compounds 3 
and 4 as it allowed the total cleavage of the methyl phosphonate esters (Scheme 27). 
 
 
 
Scheme 25. Reagents & conditions: (i) TFA/H2O : 9/1; (ii) NaI, anhydrous 
acetone, reflux; (iii) gpc; (iv) TMSBr, lutidine, anhydrous CH2Cl2. 
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IBX-oxidation of the protected shikimic acid 11 possessing the free hydroxyl group at 
C-3 afforded the keto-derivative 19 in 88% yield, which was then protected by 
acetalization of the carbonyl group with 2-bromoethanol under basic conditions
[95]
 to 
afford the dioxolane 20 in 65% yield. The carboxylic methyl ester 20 was saponified 
under basic conditions to yield the free acid 21 in 80% yield. The Hunsdiecker-Barton 
iododecarboxylation of compound 21 into its iododerivative 22 was carried out and 
afforded a slightly better yield than those obtained previously (60% yield, based on 
consumed starting material). The phosphonate coupling of compound 22 with 
dimethylphosphite under usual conditions afforded compound 23 in an increased yield 
of 82%.  
 
After six steps, using the shikimic acid as a starting material, the overall yield for the 
formation of the protected 3-dehydro-‘phospha’-shikimic acid 23 was 14%. Again, the 
overall yield of this synthesis was not improved. This is because the necessary 
protecting group steps proved not to be quantitative and time restrictions prevented their 
optimization in this project. It may be conceivable that optimized conditions may 
improve the overall yield significantly. However, this protecting group pattern offered a 
superior route to carry out the iododecarboxylation and the phosphonylation reactions in 
better yields. 
 
 
 
Scheme 26. Reagents & conditions: (i) IBX, anhydrous acetone, reflux; (ii) 2-bromoethanol, t-
BuOK, DMF; (iii) NaOH 0.5M, MeOH; (iv) (a) Oxalyl chloride, DMFcat, anhydrous CH2Cl2; 
(b) sodium salt of N-hydroxypyridine-2-thione, DMAPcat, CF3CH2I, anhydrous CH2Cl2, 
irradiation by a 250W floodlamp; (v) dimethylphosphite, Pd(PPh3)4, anhydrous NEt3, 
anhydrous toluene. 
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Compound 23 was first reacted with TMSBr and lutidine in anhydrous CH2Cl2 to give 
the intermediate phosphonic acid which was subjected to acidic deprotection (aqueous 
TFA) of the ketals and was then purified by gel permeation chromatography to afford 
target compound 3. 
To obtain target compound 4, deprotection of the carbonyl and hydroxyl groups was 
first achieved with aqueous TFA. Then, mono-demethylation of the crude intermediate 
18 was carried out using sodium iodide in dry acetone under reflux conditions to afford 
the sodium salt of compound 4. Purification by gel permeation chromatography 
afforded the ammonium salt of compound 4.  
 
I.2.5. Dehydroquinase assay 
Dehydroquinase, which catalyses the reversible dehydration of 3-dehydro-quinate into 
3-dehydroshikimate, is involved in the biosynthetic shikimate pathway and in the 
catabolic quinate pathway (as shown in Figure 2).  
Inhibitory activities of target compounds 1, 2, 3 and 4 in a dehydroquinase assay
[96]
 
could not be assessed due to time constraints but will be shortly investigated in the 
laboratory. Type I and type II dehydroquinase enzymes will be assayed by monitoring 
the increase in absorbance at 234 nm in the UV spectrum due to the absorbance of the 
enone-carboxylate chromophore of 3-dehydroshikimate. 
 
Scheme 27. Reagents & conditions: (i) TMSBr, lutidine, anhydrous 
CH2Cl2; (ii) TFA/H2O : 9/1; (iii) gpc; (iv) TFA/H2O : 9/1; (v) NaI, 
anhydrous acetone, reflux; (vi) gpc. 
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I.3. Conclusion. 
 
We achieved a novel extension of the Hunsdiecker-Barton iododecarboxylation to 
vinyl-, in particular trihydroxy- and dihydroxyketo-cyclohexenylcarboxylic acids with 
different protecting groups. Our application of the iododecarboxylation in combination 
with the phosphonylation represents a short and effective route to ‘phospha’-shikimic 
acid and its derivatives. As a consequence, our approach could be used for the synthesis 
of phospha-isosteres of various bioactive molecules. We therefore decided to apply our 
strategy to the synthesis of phospha-isosteres of the influenza neuraminidase inhibitor 
Oseltamivir as described in the following chapter.  
 
Efficient synthesis of novel, highly active phospha-
isosteres of the Influenza neuraminidase inhibitor 
Oseltamivir. 
I.4. Theoretical part. 
I.4.1. Influenza. 
I.4.1.1. Introduction to influenza viruses 
Influenza is an infectious disease caused by enveloped RNA viruses of the 
Orthomyxoviridae family, the Influenza viruses (A, B and C). Influenza A viruses are 
the cause of all flu pandemics and are known to infect birds, mammals and humans. The 
natural host for these viruses are wild birds. Influenza B viruses are known to infect 
humans and seals and influenza C viruses are known to infect humans and pigs. In 
humans, the site of infection by influenza A virus is the respiratory epithelium lining the 
trachea. Thus influenza is a respiratory tract infection and the common symptoms in 
humans are fever, headache, sore throat, coughing, muscle pain and fatigue. In certain 
cases, influenza can cause pneumonia which can be fatal. Influenza viruses that infect 
birds are generally described as avian influenza viruses. 
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Influenza A viruses are divided into subtypes based on the two main viral surface 
glycoproteins Hemagglutinin (H or HA) and Neuraminidase (N or NA) on the basis of 
which they are classified. There are 16 known hemagglutinin subtypes (H1-H16) and 9 
known neuraminidase subtypes (N1-N9) and many different combinations of these 
proteins are possible.
[97]
 For example, some subtypes of influenza A, like H1N1 (1918), 
H2N2 (1957) and H3N2 (1968) viruses have caused illness in people worldwide during 
the twentieth century.
[98, 99]
 
 
Three prominent subtypes of the avian flu are known to infect both birds and people. 
These subtypes are influenza A H5, influenza A H7 and influenza A H9. All known 
subtypes of influenza A viruses are circulating among wild birds which do not usually 
fall ill when infected with avian influenza A viruses, while domestic poultry fall ill and 
usually die from avian influenza. 
Influenza A and B viruses are further classified into strains. Avian influenza A virus 
strains are classified as low pathogenic or highly pathogenic on the basis of genetic 
features of the virus and the severity of the illness they can cause. Low pathogenic avian 
influenza A viruses are usually associated with mild disease in poultry whereas highly 
pathogenic viruses can cause severe illness and high mortality in poultry.
[97]
 
 
I.4.1.2. Influenza A virus H5N1 
More specifically, avian influenza A (H5N1) virus is considered to be highly 
pathogenic. This virus can cause rapid and fatal illness in many bird populations. Its 
spread in poultry and wild birds in many countries has raised concerns about the 
increased risk of transmission of H5N1 to humans, although it seems that avian 
influenza A viruses do not easily infect humans. They may be transmitted from animals 
to humans directly from intimate contact with birds, from avian virus-contaminated 
environments or through an intermediate host. The possibility of human to human 
transmission is being intensively investigated.
[100, 101]
 
 
Since the pathogenic virus has been isolated from a farmed goose in 1996 in China and 
fatal human infection cases have been reported in 1997 in Hong Kong, the avian 
influenza A H5N1 virus is considered by health authorities as a potential threat to 
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human beings and has therefore been studied intensively worldwide. Indeed, the 
influenza A H5N1 virus meets two of the three criteria for a new pandemic influenza 
virus, it is able to replicate in human beings and a major part of the human population 
does not have antibodies to the virus. The third criterium is the potential spread of the 
virus from man to man which has so far not been observed.
[102]
 Since then, outbreaks in 
many types of poultry, domestic animals and humans have been reported westwards 
across Asia, Europe, the Middle East and North Africa.  
 
The WHO (World Health Organization), on the 2nd June 2009,  confirmed 433 cases of 
H5N1 in humans in Azerbaijan, Bangladesh, Cambodia, China, Djibouti, Egypt, 
Indonesia, Iraq, Myanmar, Lao People's Democratic Republic, Nigeria, Pakistan, 
Thailand, Turkey and Vietnam, leading to 262 deaths.
[103]
 
 
As mitigation measures, vaccines and antivirals are options. Definitive vaccines have 
not yet been made but prototypes against the H5N1 strain are being studied and 
produced. Vaccines against influenza always need to be updated due to the antigenic 
drift of these viruses and, in case of a pandemic, vaccines would not be manufactured in 
time, so stockpiles of antiviral drugs are necessary to combat the avian flu.
[99, 104]
 There 
are 5 different classes of compounds active against influenza A virus, with some being 
currently available and some being developed:
[105]
 
 Neuraminidase inhibitors such as Oseltamivir, Zanamivir and Peramivir (which 
is still being studied), 
 
 
 
 
 
 
 
 
 
 
 M2 ion channel blockers such like amandatine and rimandatine, which were the 
first antiviral treatments for influenza (Figure 11), 
Figure 10. Neuraminidase inhibitors. 
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 IMP dehydrogenase inhibitors such as ribarivin and viramidine (Figure 11), 
 
 
 
 
 
 
 
 
 
 
 Interferones (which are natural proteins produced by the cells of the immune 
system) and siRNAs, 
 RNA polymerase inhibitors such as T705 and flutimide (Figure 12). 
 
 
 
 
 
 
 
 
I.4.1.3. The role of neuraminidase and hemagglutinin in influenza virus replication 
The influenza virus membrane contains two surface glycoproteins (hemagglutinin and 
neuraminidase) which give the virus the ability to cause the disease, as illustrated below 
in Figure 13. The hemagglutinin binds to the terminal sialic acid found on the host cell’s 
surface glyco-proteins allowing the influenza virus to attach and penetrate the host cell. 
Following cell entry, the M2 protein, located in the viral envelope, allows acid to enter 
the virus, thus enabling the release of the virus genetic material (the RNAs and 
polymerase enzymes) into the host cell. Then the ribonucleic acid strands are replicated 
in the nucleus of the infected host cell and packaged into new virions which migrate to 
the cell membrane as they are produced. The neuraminidase proteins intervene at this 
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stage. They cleave the terminal sialic acids from the cell surface proteins in order to 
release the new virus which will thus propagate the infection by invading other host 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The M2 protein inhibitors, the amandatines which interfere with viral uncoating inside 
the cell, are associated with some toxic effects and with rapid emergence of drug-
resistance. In consequence, much work has been focused on the design of 
neuraminidase inhibitors for which the mechanism of action is illustrated in Figure 
14
[104]
. Designed to be analogues of sialic acid, the natural neuraminidase substrate, or 
structurally mimicking the oxocarbenium cation intermediate during sialic acid 
hydrolysis by influenza virus neuraminidase, NA inhibitors are, in contrast to the 
amandatines, less likely to promote the development of drug-resistant influenza and less 
toxic.
[104-106]
 
 
 
 
 
Figure 13. Influenza virus life cycle. 
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I.4.1.4. The influenza virus haemagglutinin membrane glycoprotein 
As described previously, the haemagglutinin glycoprotein (HA) of the influenza virus 
membrane is responsible for binding of the virus to cell-surface receptors to initiate 
virus infection. The structure of the influenza virus HA complexed with its receptor 
(sialic acid) was reported in the late 1980’s by Wiley and co-workers.[107] 
 
The haemagglutinin glycoprotein of influenza virus is a trimer, shaped as an elongated 
cylinder of 135 Å in length with a triangular cross-section varying in radius from 15 to 
40 Å. As an illustration, the structures of H5 (A/Dk/Sing/97) avian and H9 (A/Sw/9/98) 
swine HA are shown below.
[109]
 
 
 
 
Figure 14. Mechanism of action of Neuraminidase Inhibitors: Panel A shows the action of 
neuraminidase in the continued replication of virions in influenza infection. The replication is 
blocked by neuraminidase inhibitors (Panel B), which prevent virions from being released from 
the surface of infected cells (Figure taken with permission from the New England Journal of 
Medicine 2005, 353, 1363). 
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Each of the identical subunits consists of two disulfide-linked glycopolypeptides, 
categorized as HA1 and HA2. The HA structure is divided into two distinct regions:
[108]
 
 a long fibrous region, containing residues from both HA1 and HA2, consisting of 
a triple-stranded coiled-coil of α-helices anchored in the membrane by HA2. 
 a globular region of antiparallel β-sheets which sits on the top of the fibrous 
region and contains residues only from HA1. It contains the host-receptor 
binding site and the variable antigenic determinants. Due to the presence of 
these antibody binding sites, HA is a key target for the human host immune 
system. During antigenic drift, mutations in HA structure preventing antibodies 
to bind, allow the virus to cause news epidemics. As a consequence these 
antibody-binding sites are important targets for vaccine development.  
 
Figure 15. Ribbon diagram of the trimer of H5 (A/Dk/Sing/97) avian HA colored by 
subdomains: receptor subdomain R (blue), vestigial enzyme subdomain E’ (yellow), HA2 
stem F subdomain (red), F’ subdomain HA1 1-52 (pink), F’ subdomain HA1 275-307 
(purple). Oligosaccharides are coloured by atom type. (B) Trimer of H9 swine 
(A/Sw/9/98) HA. (Figure taken with permission from the Embo Journal 2002, 21, 865).  
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There are two different linkages between sialic acid and the penultimate galactose 
residues of carbohydrate side chains found in nature, the Neu5Ac α(2,3)-Gal and 
Neu5Ac α(2,6)-Gal glycosidic linkages.  
 
 
 
 
 
 
 
 
 
 
Extensive surveys of influenza viruses isolated from a variety of species have shown 
that linkage recognition specificity correlates with species specificity for infection. HAs 
show differences in the specificity of receptor binding based on the recognition of sialic 
acids, either α(2,3)- or α(2,6)-linked to galactose. HAs of avian viruses prefer sialic acid 
(2,3)-linked, which is predominant in avian enteric tracts where these viruses replicate. 
By contrast, the major linkage found in the human respiratory tract is a α(2,6)-linkage 
and perhaps consequently HAs of human viruses preferentially recognize sialic acid in 
α(2,6)-linkage. Swine viruses recognize sialic acid in either linkage.[110-116] Significant 
differences have been observed between the conformations of α(2,3)- and α(2,6)-linked 
sialosides when binding to HAs.
[117, 118]
  
This receptor-binding specificity suggests that HAs of avian influenza viruses need to 
adapt to infect and replicate in different species. Consequently, the conversion of avian 
HA to one that preferentially recognize sialic acid in an α(2,6)-linkage to terminal 
galactose residues of glycoconjugates is an important step in the generation of pandemic 
strains. The HA mutations responsible for the binding of H5N1 influenza A viruses to 
human-type sialoglycoconjugate receptors have been addressed by various methods, 
which showed that few amino acid changes would allow the avian virus HA to switch 
from recognizing preferentially a α(2,3)-linkage to a α(2,6)-linkage.[119-121] 
 
Figure 16. Naturally occurring α(2,3)- and α(2,6)-sialoglycoconjugates. 
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I.4.1.5. The influenza virus neuraminidase membrane glycoprotein 
As described previously, neuraminidase removes sialic acid from cell-surface receptors 
to facilitate virus release and propagation to uninfected cells. There are nine subtypes 
for neuraminidase (N1-N9) which belong to two phylogenetically distinct groups.
[122]
 
Group-1 contains N1, N4, N5 and N8 subtypes and group-2 contains N2, N3, N6, N7 
and N9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The structure of the influenza virus glycoprotein neuraminidase was resolved by X-ray 
crystallography for the group-2 neuraminidases N2 and N9 subtypes in the 1980’s,[123, 
124]
 and more recently (within the last decade), the crystal structures of three group-1 
neuraminidases from the N1, N4 and N8 subtypes have been determined.
[122, 125]
  
Figure 17. a, Ribbons representation of the 
group-1 (N1) neuraminidase tetramer. One 
monomer is colored to emphasize the 
molecules’ canonical six-bladed β-propeller 
structure. The active site region at the center 
of the six-balded β-propeller structure is 
highlighted and then shown in larger scale in 
b and c. b, Superposition of the active sites of 
three NAs from group-1, showing how similar 
they are: N1, green, N4, gold, and N8, blue. c, 
Superposition of the active site of N1 (green) 
and N9 (yellow) NAs, demonstrating that N9 is different to N1 in the 150-loop region. 
Conserved residues such as Glu 119, Asp 151 and Glu 276 and the hydrophobic residue at 
position 149 are shown in stick representation (Figure taken with permission from Nature 
2006, 443, 45). 
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The neuraminidase structure is a tetramer with a box-shaped head (100x100x60 Å). 
Each monomer is composed of six topological antiparallel β-sheets arranged in a 
propeller formation. The N1 neuraminidase tetramer is shown in Figure 17a.
[122]
  
The recent structural comparison of group-1 and group-2 neuraminidases, in complex 
with and without their inhibitors (oseltamivir, zanamivir, DANA and peramivir), 
illustrates that their active sites are almost identical (Figure 17c
[122]
).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, some specific conformational differences can be observed between the two 
groups centred around the ‘150-loop’ (residues 147-152) which opens a cavity adjacent 
to the active site in the crystal structures of group-1 NAs (Figure 18).
[122]
 This open 
form of the ‘150-loop’ implicates the potential of new opportunities for antiviral drug 
design.
[122, 125, 126]
 
In contrast to the receptor-binding specificity observed for HAs towards α(2,3)- and 
α(2,6)-linked sialylgalactosides depending on infected species, it is less clear what NAs’ 
preferences are towards α(2,3)- or α(2,6)-linked sialylgalactosides during hydrolysis of 
Figure 18. Molecular surfaces of group-1 and group-2 NAs with 
bound oseltamivir showing the 150-cavity in the group-1 structure 
that arises because of the distinct configuration of the 150-loop. a, b, 
N1 (a, green) and N9 (b, yellow) shown in surface representation 
with the protein main shown in ‘worm’ representation (Figure taken 
with permission from Nature 2006, 443, 45). 
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the ketosidic linkage. It has been shown that avian influenza virus NAs have a 
pronounced preference for α(2,3)-linked sialylgalactosides. Regarding human influenza 
virus NAs, they act on both linkages but still with a preference for α(2,3)-linked 
sialylgalactosides.
[127-129]
 These data are generally obtained by analyzing the reaction 
kinetics for the hydrolysis of the two substrates by a given neuraminidase or whole 
virus. 
By synthesizing sialoglycoconjugate mimetics (compounds 46 and 54), we suggest 
inhibitor-based tools for the characterization of influenza virus NAs. Structural 
comparaison of group-1 and group-2 neuraminidases in complex with our 
sialoglycoconjugate mimetics 46 and 54 could give precious information on receptor 
binding specificity of the neuraminidase active site. 
 
I.4.2. Oseltamivir. 
I.4.2.1. A neuraminidase inhibitor. 
Oseltamivir was developed by Gilead Sciences
[84, 130, 131]
 and is currently marketed by 
Hoffmann-La Roche under the trade name TamifluTM.
[85, 132]
 It is used in the treatment 
and prophylaxis of both Influenza A and B viruses which includes the H5N1 virus. 
Oseltamivir is the first commercially developed orally active neuraminidase inhibitor. It 
is an ethyl ester prodrug, which is enzymatically hydrolysed to the free carboxylate 
which is the active metabolite. 
 
 
 
 
 
 
 
 
Oseltamivir is the successful result of structure-based inhibitor design using the 
crystallographic data of two of the group-2 neuraminidases N2 and N9.
[123, 124]
 
Oseltamivir (like DANA (Figure 19) and zanamivir (Figure 10)) mimics the 
Figure 19. Oseltamivir, DANA. 
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oxocarbenium-ion transition state occurring during sialoside hydrolysis by influenza 
virus neuraminidase.  
 
 
 
 
 
 
Studies of the mechanism of sialoside hydrolysis by influenza virus neuraminidase 
demonstrated that to allow hydrolysis, the 
2
C5 chair conformation of the sialoside pyran 
ring is distorted towards a boat conformation through complexation of the carboxylate 
in equatorial position with three arginine residues in the enzyme’s active site (the 
arginine triad conserved in sialidases). Following protonation of the glycosidic oxygen 
in axial position, the glycosidic bond breaks and the system is proposed to run through 
an oxocarbenium-ion type intermediate with half chair conformation before being 
trapped by a water molecule to release the sialic acid, product of the hydrolysis.
[133, 134]
 
The oseltamivir carboxylate and its interaction with neuraminidase residues are shown 
in Figure 20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Neuraminidase active site designations and important 
interactions of Oseltamivir carboxylate (Figure drawn using Visual 
Molecular Dynamics (VMD) with the pdb 2ht7, crystal structure of N8 
neuraminidase in open complex with oseltamivir). 
Scheme 28. Sialoside hydrolysis by influenza virus neuraminidase. 
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Different types of interactions are occurring between the ligand and the active site. Two 
are charge-charge interactions. The first one is the carboxylate group acting as a 
negatively ionisable group (at the C1 position) in interaction with three positive charges 
belonging to Arg 118, Arg 292 and Arg 371 (the arginine triad). The second interaction 
results from the positive ionisable amino group (at the C5 position) facing three 
negative charges belonging to Glu 119, Glu 227 and Asp 151. The pentyl chain of the 
ether group at the C3 position undergoes hydrophobic interactions in the active site, the 
residues Ile 222, Arg 224, Ala 246 and Glu 276 surround it. The other interactions are 
hydrogen-bond interactions. Two are hydrogen-bond donors, the cation NH3
+
 (at the C5 
position) and the N-H of the acetamide group (at the C4 position) and one is a 
hydrogen-bond acceptor, the carbonyl of the acetamide group. 
The success of structure-based neuraminidase inhibitor design has been attributed to 
proposals that the active sites of the neuraminidases are highly conserved across all 
influenza A and B virus strains. Mutations are thus unlikely to happen, in fact they 
would compromise the neuraminidase activity. However, a few mutations are known to 
occur in resistant subtypes of influenza virus, taking place in the sites of Arg 292, His 
274 and Glu 119.
[98]
 
 
I.4.2.2. Oseltamivir syntheses. 
Tamiflu (Oseltamivir phosphate) has acquired importance due to its activity against 
both influenza A and B viruses. Indeed, Tamiflu has been stockpiled by governments 
worldwide in order to protect humans against a potential future pandemic. Considering 
the amount of Tamiflu required worldwide in the event of a pandemic, a lot of effort has 
been put into finding an efficient synthetic route to produce it in large quantities.  
 
The first discovery and synthesis of Oseltamivir were made by Gilead Sciences.
[84]
 
Using (-)-shikimic acid as starting material, Oseltamivir was synthesized using a set of 
SN2 reactions to obtain the required L-xylo ring configuration and the late introduction 
of the pentyloxy sidechain by opening of a tritylaziridine, allowing for introduction of 
sidechain group diversity which is critical in the drug discovery process (Scheme 
29).
[130]
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The first investigated routes to synthesize Oseltamivir used (-)-shikimic acid and (-)-
quinic acid as starting materials. However, (-)-shikimic acid, with its 1,2-double bond 
already in place and a synthesis of oseltamivir which had a higher overall yield, led it to 
become the starting material of choice.
[131]
 Extensive development by Gilead Sciences 
and by Roche led to the current industrial synthesis of Oseltamivir phosphate from (-)-
shikimic acid in a sequence of 10 steps with a 35% overall yield. The synthesis 
proceeds through a 3,4-pentylidene 5-mesylshikimate intermediate which is 
regioselectively reduced to an epoxide intermediate. The azide based stereoselective 
opening of the latter leads to the formation of an aziridine intermediate which is then 
converted to the acetamidoazide (starting material used in our synthesis of ‘phospha’-
Tamiflu and derivatives). Oseltamivir phosphate is then obtained by reduction of the 
azide and formation of the phosphate salt (Scheme 30).
[85, 131, 132, 135]
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To address initial uncertainties regarding supply of (-)-shikimic acid and the hazards 
involved with large scale use of azides, the Roche group developed alternate 
approaches. An azide-free approach closely related to the industrial synthesis, a Diels-
Alder approach (reaction of furan with ethyl acrylate) and an enzymatic 
desymmetrization approach using 2,6-dimethoxyphenol as starting material were 
investigated.
[85, 132, 136, 137]
  
 
Nonetheless, the increasing significance of Tamiflu has prompted several renowned 
academic laboratories to compete in the search for an effective and elegant synthesis. As 
a result, a considerable number of novel syntheses of Tamiflu has been reported in 
recent years.
[138, 139]
 The following section gives a short overview of these attempts to 
find new synthetic routes to Tamiflu. 
 Fang et al. have developed synthetic routes leading to Tamiflu and its 
phosphonate congener ‘Tamiphosphor’.[140, 141] Following Streicher and co-
workers’ synthetic approach to L-xylo cyclohexenephosphonates,[1-5] their first 
synthesis used D-xylose as chiral precursor and an intramolecular Horner-
Wadsworth-Emmons reaction as key step to form the cyclohexene core of the 
Tamiflu. Their second synthesis (11 steps, 21% overall yield) used bromoarene 
cis-1,2-dihydrodiol as starting material and an organometallic coupling reaction 
as key step. 
 Corey and co-workers reported a synthesis using a catalytic and enantioselective 
Diels-Alder reaction developed in his group, employing butadiene and 
trifluoroethyl acrylate as starting materials. Oseltamivir phosphate was 
synthesized in 11 steps and about 30% overall yield.
[142, 143]
 
 Shibasaki and co-workers reported enantioselective approaches using a catalytic 
desymmetrization of meso-aziridines synthesized from 1,4-cyclobutadiene.
[144, 
145]
 These initial synthetic routes are relatively long with very low overall yields, 
prompting them to develop a completely different synthetic route using a Diels-
Alder reaction between siloxy diene and fumaroyl chloride and a Curtius 
rearrangement as key steps.
[146]
 This route required less steps than their first and 
second generation syntheses. Recently, they reported a synthesis of Tamiflu (in 
12 steps, 16% overall yield) using a barium-catalyzed asymmetric Diels-Alder 
type reaction.
[147]
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 Fukuyama and co-workers used an asymmetric Diels-Alder reaction between 
dihydropyridine and acroleine as the first step, followed by a bromolactonization 
and a Hofmann rearrangement as key transformations in the synthesis of 
Tamiflu in 11 steps and about 6% overall yield.
[148, 149]
 
 Cong and Yao reported a ring-closing metathesis-based synthetic route to 
synthesize Tamiflu from L-serine as starting chiral material, in 18 steps and 16% 
overall yield.
[150]
 
 Trost and Zhang reported a concise synthesis of Oseltamivir by 
desymmetrization of a racemic bicyclic lactone using their own Pd-ligand 
system, in 8 steps and an overall yield of 30%.
[151]
 
 Kann and co-workers’ route to Oseltamivir relied on the synthesis of an 
enantiomerically pure iron carbonyl complex. The synthesis contains 12 steps 
with an overall yield of 4%.
[152]
 
 Banwell and co-workers reported a longer synthesis of Tamiflu from 
enantiomerically pure cis-1,2-catechol (16 steps) compared to Fang’s second 
synthesis (11 steps).
[153]
 
 Hayashi and co-workers reported a high yielding synthesis by three ‘one-pot’ 
operations, affording Oseltamivir in an overall yield of 57% in only 9 
reactions.
[154]
 
 Mandai and Oshitari reported an asymmetric synthesis of Oseltamivir from D-
mannitol without any chromatographic purification (18 steps, 7% overall 
yield).
[155]
 They reported another enantioselective synthesis from L-methionine 
in 18 steps and 8%.
[156]
  
 Nie and Shi reported two different syntheses from (-)-shikimic acid very similar 
to Roche’s industrial synthesis.[157, 158] 
 
I.4.3. ‘Phospha’-Tamiflu syntheses. 
During our work on the synthesis of ‘phospha’-Tamiflu, Fang et al. achieved the 
syntheses of Oseltamivir, its phosphonate congener (‘phospha’-Tamiflu or 
‘Tamiphosphor’) and the guanidine analogues.[140] These syntheses were inspired by the 
synthetic strategy of Streicher et al. towards cyclohexenephosphonates using D- and L-
xylose as chiral precursors.
[1-4, 6]
 In brief, after appropriate protection and modification 
of xylose, an intramolecular Horner-Wadsworth-Emmons reaction was carried out to 
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furnish the cyclohexene scaffold of the target compounds. Substitution of the hydroxyl 
group belonging to carbon 5 by an azido group with inversion of configuration, 
followed by inversion of configuration of the hydroxyl group at carbon 3, introduction 
of the ether side chain, azide reduction and saponification afforded ‘Tamiphosphor’ 
(Scheme 31).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to shorten this synthesis and improve the overall yield, Fang et al. designed 
another synthesis of Oseltamivir and ‘Tamiphosphor’.[141] An azide-free synthesis was 
developed utilizing the readily available starting material bromoarene cis-1,2-
dihydrodiol which allows a late-stage functionalization by transformation of the 
bromine atom into a carboxylate or a phosphonate by the use of organometallic 
coupling reactions. It must be noted that like us, they used a modified Hirao’s 
procedure
[50]
 to introduce the phosphonate moiety. The palladium-promoted coupling 
reaction of vinyl halides with dialkyl phosphites to furnish vinyl phosphonates is the 
obvious reaction of choice due to its convenience and effectiveness.
[41, 42]
 
  
Scheme 31. Fang et al. synthesis of ‘phospha’-Tamiflu using D-xylose as starting material. 
Reagents & conditions: (i) H2, Pd/C, EtOH, 25°C, 24h; NaOEt, EtOH, 25°C, 5h, 80%; (ii) 
(PhO)2PON3, (i-Pr)N=C=N(i-Pr), PPh3, THF, 25°C, 48h; (iii) HCl, EtOH, reflux, 1h, 74%; (iv) 
Tf2O, pyridine, CH2Cl2, -15 to -10°C, 2h ; KNO2, 18-crown-6, DMF, 40°C, 24h, 71%; (v) 
Cl3CC(=NH)OCHEt2, CF3SO3H, CH2Cl2, 25°C, 16h, 82%; (vi) H2, Lindlar catalyst, EtOH, 
25°C, 16h, 85%; (vii) TMSBr, CHCl3, 25°C, 24h, aqueous NH4HCO3, lyophilization, 85%. 
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I.5. Results and discussion. 
I.5.1. Strategy towards ‘phospha’-Tamiflu and its derivatives. 
 
The first objective was to apply the strategy developed for the synthesis of ‘phospha’-
shikimic acid to the synthesis of the ‘phospha’-Tamiflu. Taking advantage of the 
availability of the industrial precursor of Tamiflu, the acetamido-azide precursor could 
be used as a starting material. Our Hunsdiecker-Barton iododecarboxylation 
methodology and the subsequent palladium-mediated phosphonylation step should 
afford the ‘phospha’-Tamiflu in yields high enough to allow for derivatisation as well. 
 
 
 
 
 
 
 
 
 
 
 
I.5.2. Key steps towards the key intermediate 34. 
I.5.2.1. A first approach. 
In order to allow the halodecarboxylation step, Tamiflu’s precursor was saponified to 
give the free acid 24 in 97% yield. Our tried and tested conditions for the 
iododecarboxylation were applied to the latter compound. Unfortunately, this step 
always resulted in low yields. The iodo-derivative compound 25 was difficult to purify 
due to the formation of many side-products with similar TLC behaviour (the side 
products have not been characterized). Moreover, no starting material was recovered 
from the reaction. 
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Scheme 32. Strategy towards ‘phospha’-Tamiflu and its derivatives. 
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With compound 25 in hand, a few phosphonylation attempts were then carried out 
leading to the unexpected and undesired compound 26 in moderate yields (see Scheme 
34). The use of tetrakis(triphenylphosphine)palladium(0) for the coupling of the iodo-
azide 25 with dimethyl phosphonate was not the best choice for the reaction as it 
allowed the triphenylphosphine to convert the azide into the iminophosphorane 
derivative. 
 
 
 
 
 
 
 
 
 
 
Scheme 33. Reagents & conditions: (i) NaOH 0.5M, dioxane; (ii) (a) oxalyl chloride, 
DMFcat, anhydrous CH2Cl2; (b) N-hydroxypyridine-2-thione, DMAPcat, CF3CH2I, 
anhydrous CH2Cl2, irradiation by a 250W floodlamp. 
Scheme 34. Reagents & conditions: (i) Dimethylphosphite, 
Pd(PPh3)4, anhydrous NEt3, anhydrous THF. 
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In order to avoid this unwelcome conversion of the azide into the iminophosphorane, 
phosphonylation was attempted using an alternative palladium catalyst. The use of 
bis(dibenzylideneacetone)palladium(0) (Pd2(dba)3) did not bring any improvement to 
the reaction. The iodo compound was not activated by the catalyst and showed no sign 
of reaction even after five hours refluxing in anhydrous THF. 
 
Consequently, reduction of the azide to the amine followed by protection of the amine 
was a necessary step prior to the palladium-mediated coupling with dimethyl 
phosphonate. However the Hunsdiecker-Barton iododecarboxylation step needed to be 
optimized as well in order to gain access to a suitably amino-protected phosphonate key 
compound. From that, the synthesis of ‘phospha’-Tamiflu and its derivatives would 
only require standard deprotection and alkylation steps. 
 
I.5.2.2. Protected amino derivatives of Tamiflu’s precursor. 
The initial idea was to synthesize protected amino compounds to study their effect on 
the decarboxylation step. Unfortunately, due to time restriction and the project moving 
on, this study was not fully completed. The next paragraphs show the synthesis of three 
different carbamates (Boc, Fmoc and benzyl) and one acetamide (trifluoroacetamide). 
The azide group of the industrial Tamiflu precursor was first reduced to the amine 
which was then protected as its carbamate. Azides may be converted to amines using 
the Staudinger reaction
[159-161]
 (with the use of a trialkyl phosphine) or by hydrogenation 
(using in our case the Lindlar catalyst
[162]
 due to the required presence of the alkene on 
the cyclohexene ring). Tamiflu’s precursor was thus subjected independently to both 
reactions giving the free amine in quantitative yields, the hydrogenation being a much 
more convenient and easier procedure compared to the Staudinger reaction. 
 
 
 
 
 
 
 
Scheme 35. Reagents & conditions: (i) Pd, Lindlar’s catalyst, H2, 
EtOH; (ii) (a) PMe3, anhydrous THF, (b) H2O. 
O
AcHN
COOEt
N
3
O
AcHN
COOEt
NH
2
i or ii
quantitative
27
61 
 
Three different carbamates have been used as protecting groups
[90]
, the t-butyl (Boc) 
carbamate cleaved by acidic hydrolysis, the benzyl (Cbz or Z) carbamate cleaved by 
catalytic hydrogenolysis and the 9-fluorenylmethyl (Fmoc) carbamate cleaved by β-
elimination with base. 
Since Sato et al.
[163]
 showed that reduction of azides by hydrogenation followed by 
addition of di-t-butyl dicarbonate (Boc2O) provided the Boc-protected amines, 
reduction and protection steps are frequently performed in a one-pot two stage 
procedure to transform azides into protected amines. 
This way, the Boc-protected compound 28 was first synthesized following Afonso’s 
procedure,
[164]
 using the Staudinger reaction with PMe3 and reacting the 
iminophosphorane formed with Boc2O, in a moderate yield of 41%. 
 
 
 
 
 
 
 
 
 
 
An improved procedure
[165]
 using 2-(t-butoxycarbonyloxyimino)-2-phenylacetonitrile 
(Boc-ON) as an activated Boc-transferring agent instead of Boc-anhydride led to the 
Boc-protected compound 28 in an improved yield of 74 %. 
 
 
 
 
 
 
 
 
 
 
Scheme 36. Reagents & conditions: (i) (a) PMe3, anhydrous THF, (b) 
Boc2O, (c) H2O; (ii) (a) PMe3, anhydrous THF, (b) Boc-ON, (c) H2O. 
Scheme 37. Reagents & conditions: (i) (a) PMe3, anhydrous THF, (b) benzyl 
chloroformate, (c) NaHCO3. 
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Benzyl carbamate 29 was obtained in 53% yield using a similar one-pot transformation 
involving reduction of the azide by PMe3 followed by addition of benzyl chloroformate. 
 
 
 
 
 
 
 
 
 
 
Following the same procedure, reduction of the azide by PMe3 and addition of 9-
fluorenylmethyl chloroformate afforded 9-fluorenyl carbamate 30 in 33% yield. 
 
Compounds 28 and 29 were saponified under basic conditions (NaOH 0.5M) and 
purified by flash chromatography to give the free acid derivatives which were not 
characterized as they were used to ascertain the effect of the carbamate protecting 
groups on the iododecarboxylation. Unfortunately this reaction failed in both cases as 
shown below in Scheme 39. 
 
 
 
 
 
 
 
 
 
 
Attempts were made to synthesize the amino protected compound as the trifluoro 
acetamide. The trifluoro acetamide derivative was synthesized from the free carboxylic 
acid 24 as it would be impossible to saponify the ester in presence of the trifluoro 
acetamide due to its lability under basic conditions. The azide was reduced with PMe3 
Scheme 38. Reagents & conditions: (i) (a) PMe3, anhydrous THF, (b) FmocCl, 
(c) NH4Cl. 
Scheme 39. Reagents & conditions: (i) (a) oxalyl chloride, DMFcat, anhydrous 
CH2Cl2; (b) N-hydroxypyridine-2-thione, DMAPcat, CF3CH2I, anhydrous CH2Cl2, 
irradiation by a 250W floodlamp. 
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and the iminophosphorane thus formed was reacted with trifluoroacetic anhydride to 
give the trifluoro acetamide 31 in 22 % yield. Unfortunately, due to time restriction 31 
was not subjected to the iododecarboxylation. 
 
 
 
 
 
 
 
 
 
I.5.2.3. Optimised route leading to key monoalkyl phosphonate intermediate 34. 
As shown previously, the iododecarboxylation of compound 24 always resulted in low 
yields. It was thought that the formation of the acyl chloride was certainly the major 
issue causing the halodecarboxylation step to be unsuccessful. A new experimental 
route was thus needed to convert the carboxylic acid into the acyl chloride. The use of 
oxalyl chloride with a catalytic amount of DMF leads to the formation of the highly 
electrophilic and cationic Vilsmeier reagent, which reacts rapidly with the carboxylic 
acid to form the acyl chloride and regenerates DMF. 
 
Therefore, the alternative route utilizes a stoichiometric amount of Vilsmeier reagent to 
react with the carboxylic acid, instead of different chlorinating agents (such as SOCl2 
and PCl5), to generate the acyl chloride in situ. The Vilsmeier reagent can be formed by 
reaction between DMF and activated chlorinated compounds such as thionyl chloride 
(SOCl2),
[166]
 POCl3,
[167]
 COCl2 or oxalyl chloride.
[168]
  
 
 
 
chloride, and its reaction with DMF only provides the Vilsmeier reagent and a gaseous 
by-product SO2. The Vilsmeier reagent is obtained as a white powder after evaporation 
of SO2 under high vacuum. 
Scheme 40. Reagents & conditions: (i) (a) PMe3, anhydrous THF, 
(b) (CF3CO)2O, (c) NH4Cl. 
Formation of the Vilsmeier reagent was achieved using thionyl 
chloride and DMF in stoichiometric amounts. Thionyl chloride is 
the reagent of choice because of its lower cost, compared to oxalyl  
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The Hunsdiecker-Barton iododecarboxylation of compound 24 was carried out 
following the same procedure as used previously except that in the first step oxalyl 
chloride in presence of a catalytic amount of DMF was replaced by a stoichiometric 
amount of the Vilsmeier reagent with the carboxylic acid 24. 
 
 
 
 
 
 
 
 
 
This modified procedure proved to be a success, the vinyl iodide 25 was obtained in a 
very good yield of 77% based on consumed starting material. It is important to note that 
for the second step of the halodecarboxylation procedure, the addition of the acyl 
chloride to the mixture of N-hydroxypyridine-2-thione, 2-iodo-1,1,1-trifluoroethane and 
a catalytic amount of DMAP in anhydrous CH2Cl2 must be done without further 
evaporation and dilution of the mixture containing the acyl chloride (as it was done 
when using oxalyl chloride). 
In order to avoid the formation of the iminophosphorane during the palladium-mediated 
phosphonylation step, the azide 25 needed first to be reduced and protected. The tert-
butyl carbamate protecting group introduced in an efficient way as described in a 
procedure by Ariza et al. 
[165]
 with the use of Boc-ON was the protecting group of 
choice due to its stability under basic conditions and its effective introduction. 
 
 
 
 
 
 
 
 
 
Scheme 42. Reagents & conditions: (i) (a) PMe3, anhydrous THF, (b) Boc-ON, 
anhydrous THF, (c) H2O; (ii) dimethylphosphite, Pd(PPh3)4, anhydrous NEt3, 
anhydrous toluene. 
Scheme 41. Reagents & conditions: (i) (a) Vilsmeier 
reagent, anhydrous CH2Cl2; (b) N-hydroxypyridine-2-
thione, DMAPcat, CF3CH2I, anhydrous CH2Cl2, irradiation 
by a 250W floodlamp. 
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The Boc protected amine 32 was obtained in 72% yield. The palladium coupling step of 
compound 32 with dimethylphosphite furnished cyclohexenephosphonate 33 in 80% 
yield with no traceable by-products. The mono-saponification was achieved under basic 
conditions (NaOH 0.25M) to afford monoester 34 in 96% yield. 
 
 
 
 
 
 
 
 
The key cyclohexenephosphonate monomethyl ester intermediate 34 was synthesized in 
a moderate overall yield of 41% in five steps from the industrial Tamiflu precursor. 
Monoester 34 is the key precursor in the following syntheses of all phosphonate 
monoesters, employing a previously established mixed diester strategy:
[4, 5, 169, 170]
 
Esterification via condensation under Mitsunobu conditions or via alkylation with 
triflates, followed by selective cleavage of the methyl ester group. 
  
Scheme 43. Reagents & conditions: (i) NaOH 0.25M, dioxane, 
then Amberlite IR-120 (H
+
). 
O
AcHN
P
NHBoc
O
OMe
OMe
PO
AcHN
NHBoc
O
OH
OMe
33 34
i
96%
Figure 22. ORTEP-generated structure of iodo compound 32. 
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I.5.3. Synthesis of ‘phospha’-Tamiflu derivatives 
To demonstrate the versatility of the approach and to obtain a structurally diverse set of 
exemplary inhibitors, we chose to synthesize: 
 the phospha-isostere 35 of Tamiflu and its methyl ester 36 as proof of 
principle,
[171]
 
 the hexyl ester 40 having a hydrophobic aglycone mimetic,[171] 
 the two galactosyl esters 46 and 54 with the natural sialic acid aglycone 
galactose mimicking the 2-6- and 2-3-sialoglycoconjuguates respectively,[172]  
 the hexyl thioacetate ester 60, allowing access to multimeric inhibitors and 
immobilization. 
 
Compounds 35, 36, 40, 46 and 54 should be then tested for inhibition of the 
neuraminidase activity of an H1N1 virus (A/Norway/1758/07) in collaboration with the 
National Institute for Medical Research (NIMR, London, UK). 
 
I.5.3.1. Synthesis of ‘phospha’-Tamiflu 35 and its methyl ester 36 
‘Phospha’-Tamiflu was synthesized from dimethylphosphonate 33 (Scheme 44). 
 
 
 
 
 
 
 
 
 
Complete demethylation of 33 by stirring at room temperature with TMSBr and lutidine 
for 9 hours and removal of the Boc protecting group under standard acidic conditions 
(TFA/H2O : 1/1) afforded Phospha-Tamiflu 35 in 88% yield after gpc. Cleavage of the 
pentyl ether was observed when compound 33 was left for considerably longer time 
with TMSBr and lutidine. 
 
Scheme 44. Reagents & conditions: (i) TMSBr, lutidine, anhydrous 
CH2Cl2; (ii) TFA/H2O : 1/1; (iii) gel permeation chromatography 
(gpc) (0.1M NH4HCO3). 
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The monomethyl ester 36 was obtained by a simple deprotection step from compound 
34 in 40% yield after gel permeation chromatography. 
 
 
 
 
 
 
 
 
I.5.3.2. Introduction of an hydrophobic moiety by alkylation: synthesis of the hexyl ester 
40 of ‘phospha’-Tamiflu 
A convenient approach to synthesize mixed diesters of cyclohexenephosphonates has 
already been reported by our group, based on esterification by alkylation of 
cyclohexenephosphonate monoester with suitable alkyl triflates or by condensation 
using Mitsunobu conditions
[4, 5]
 We could also show that, alkylation of 
cyclohexenephosphonate monobenzyl esters with octyl triflate can be achieved in good 
yield.
[4]
 The same methodology was thus applied to the synthesis of the hexyl methyl 
‘phospha’-Tamiflu derivative from cyclohexenephosphonate monomethyl ester 34 and 
hexyl triflate 37. 
 
In order to achieve the alkylation step, formation of the triethyl ammonium salt of 
compound 34 and synthesis of hexyl triflate 37 were first required.  
 
 
 
 
 
 
 
Scheme 45. Reagents & conditions: (i) TFA/H2O : 1/1 ; (ii) gpc. 
Scheme 46. Reagents & conditions: (i) NEt3, dioxane. 
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The triethyl ammonium phosphonate salt of 34 was obtained by stirring the free acid 
with a few drops of triethyl amine in dioxane. After lyophilisation triethyl ammonium 
salt 34 was obtained as a white powder. 
 
 
 
 
 
Hexyl triflate 37 was synthesized from commercially available hexanol by reacting the 
latter with triflic anhydride in presence of NEt3 in anhydrous toluene. A simple 
extraction was sufficient to obtain hexyl triflate 37 as a colourless oil which was only 
characterized by 
1
H NMR spectroscopy and used without further purification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alkylation of the triethyl ammonium salt of compound 34 with hexyl triflate 37 gave an 
inseparable mixture of diastereomeric hexyl methyl phosphonates 38 in a moderate 50% 
yield, unreacted starting material could be recovered. Selective demethylation of 
diastereoisomers 38 using thiophenol and NEt3 afforded hexyl phosphonate 39 in 72% 
yield. Boc-cleavage under acidic conditions (TFA/H2O : 1/1) followed by purification 
by gpc furnished target ‘phospha’-Tamiflu monohexyl ester 40 in 68% yield. 
 
Scheme 48. Reagents & conditions: (i) hexyl-triflate 37, anhydrous DMF; (ii) 
thiophenol, anhydrous NEt3, anhydrous THF; (iii) TFA/H2O : 1/1; (iv) gpc. 
Scheme 47. Reagents & conditions: (i) Triflic anhydride, NEt3, anhydrous toluene. 
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I.5.3.3. Introduction of a sugar moiety by alkylation: Synthesis of α(2-6)-
sialoglycoconjugate mimetic 46 
It has been shown by us that esterification of substituted cyclohexenephosphonate 
monoalkyl esters with carbohydrates could be achieved in moderate yields via 
alkylation with a triflated sugar or via condensation using Mitsunobu conditions.
[4]
 The 
same methodologies were thus applied to the synthesis of α(2,6)-sialoglycoconjugate 
mimetic 46. 
The first attempt to esterify the methyl phosphonic acid 34 under Mitsunobu 
conditions
[169, 173, 174]
 with a suitable but not fully protected galactopyranoside 
derivative
[175]
 is shown in Scheme 49. It was thought that the unprotected secondary 
alcohol would not be an issue and interfere in the reaction as the primary alcohol is 
more reactive. Unfortunately the reaction did not proceed even after days of stirring and 
heating. The starting material was however recovered.  
We thus decided to try modified Mitsunobu conditions
[176]
 including the use of the more 
electron-deficient tri-(4-chlorophenyl)phosphine to increase the electrophilicity of the 
phosphorus and a base such as triethyl amine which would act as a catalyst. As this 
failed as well, we then synthesized the 6-O-galactosyl triflate to undergo alkylation of 
the triethyl ammonium phosphonate salt 34, but unfortunately alkylation was not 
observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 Scheme 49. Esterification trials under Mitsunobu’s conditions and by alkylation. 
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We thus concluded that complete protection of the sugar was thus required for the 
alkylation to proceed. The synthesis of fully protected sugar triflate 43 is shown below 
(Scheme 50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The first two protection steps of β-D-galactopyranoside were achieved following 
literature procedures.
[177]
 Silylation of the primary alcohol with TBDPSCl in anhydrous 
DMF in the presence of imidazole followed by isopropylidenation with 2,2-
dimethoxypropane in dry acetone in the presence of a catalytic amount of para-
toluenesulfonic acid, which are standard protection steps in carbohydrate chemistry, 
afforded Methyl 6-O-(tert-butyldiphenylsilyl)-3,4-O-isoprolylidene-β-D-
galactopyranoside in good yields. Methoxymethylation
[178]
 of the latter compound was 
carried out using NaH and MOMCl in anhydrous THF to afford the fully protected 
sugar 41 in 94% yield., which was then desilylated using TBAF in anhydrous THF to 
obtain the desired hydroxyl derivative 42 in 94% yield. Triflation of primary alcohol 42 
with triflic anhydride and lutidine, gave sugar triflate 43 in 92% yield. 
 
 
 
 
 
 
Scheme 50. Reagents & conditions: (i) TBDPSCl, imidazole, anhydrous DMF; (ii) DMP, p-
TsOHcat, acetone; (iii) NaH, MOMCl, anhydrous THF; (iv) TBAF, anhydrous THF; (v) 
lutidine, triflic anhydride, -30°C. 
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Triflated sugar 43 was used to alkylate the triethylammonium salt of monomethyl ester 
34 to give mixed diester 44 in 28% yield (scheme 51). The unreacted starting material 
34 was recovered during purification. Cleavage of the methyl ester of diastereoisomers 
44 with thiophenol and triethylamine afforded monoester 45 in 70% yield. Final 
deprotection was achieved in aqueous trifluoroacetic acid to furnish α(2,6)-sialoside 
mimetic 46 in 64% yield after purification by gel-permeation chromatography. 
 
I.5.4. An alternative approach to mixed diesters of ‘phospha’-Tamiflu 
I.5.4.1. Introduction of a sugar moiety by phosphonate coupling: Synthesis of α(2,3)-
sialoglycoconjugate mimetic 54 
As it has been reported previously,
[5]
 attempts to esterify cyclohexenephosphonate-
monobenzyl esters and cyclohexephosphonate-monomethyl esters via alkylation with 
secondary sugar triflates or condensation under Mitsunobu conditions with secondary 
sugar alcohols failed. As expected, these attempts also failed with the ‘phospha’-
Tamiflu derivative 34. 
 
 
 
Scheme 51. Reagents & conditions: (i) Galactose-triflate 43, anhydrous DMF; (ii) 
thiophenol, anhydrous NEt3, anhydrous THF; (iii) TFA/H2O : 1/1; (iv) gpc. 
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To overcome this issue which was probably due to steric hindrance, a direct Pd(0)-
mediated coupling with a respective sugar-modified phosphonic acid was envisaged. 
The synthesis of this protected methyl galactosyl phosphonic acid 50 is summarized in 
Scheme 53. 
 
Methyl 2-O-methoxymethyl-4,6-O-benzylidene-β-D-galactopyranoside 48 was 
synthesized by selective protection and deprotection steps starting with methyl-β-D-
galactopyranoside. The first two protecting steps were carried out as described in 
literature. Benzylidenation
[179]
 with benzaldehyde dimethyl acetal and p-TsOH in 
acetonitrile gave methyl 4,6-O-benzylidene-β-D-galactopyranoside in 98% yield. 
Selective allylation
[180-183]
 occurred in two steps, activation of the 2,3-diol with 
dibutyltin oxide
[184]
 in dry toluene under reflux to give the cyclic dibutylstannylidene 
derivative which was reacted with allyl bromide and TBAI under reflux to give a 3.2 : 1 
mixture of the 3-O- and 2-O- allyl ethers, which were easily separated by flash 
chromatography, in 56% and 17% yield respectively. Methyl 3-O-allyl-4,6-O-
benzylidene-β-D-galactopyranoside was then momylated[178] to provide the fully 
protected sugar 47 in 55% yield. Direct palladium mediated allylic cleavage 
[183, 185]
 of 
47 was achieved with PdCl2 in aqueous acetic acid in the presence of sodium acetate to 
furnish 3-O- deprotected sugar 48 in 69% yield. 
 
 
 
 
Scheme 52. Attempted esterification with secondary sugar alcohol. 
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Dimethyl chlorophosphonate 49 was obtained by reaction of a 2 to 1 mixture of 
trimethylphosphite and phosphorus trichloride respectively, and further purification by 
distillation under reduced pressure (34°C, 42 Torr).
[186]
 
 
 
 
 
The desired mixed diester 50 was synthesized in 62% yield by phosphonylation of the 
secondary alcohol 48 with dimethyl chlorophosphonate 49 to give the triester which 
immediately hydrolyzed on silica during purification by flash chromatography to give 
50 (Scheme 53).  
 
 
 
 
 
 
 
 
Scheme 53. Reagents & conditions: (i) benzaldehyde dimethyl acetal, p-TsOHcat, 
acetonitrile; (ii) (a) dibutyltin oxide, anhydrous toluene, reflux, (b) TBAI, allylbromide, 
anhydrous toluene, reflux; (iii) NaH, MOMCl, dry THF; (iv) NaOAc, PdCl2, AcOH/H2O : 
10/1; (v) chloro(dimethyl)phosphine 49, N,N-diisopropylethyl amine, anhydrous CH2Cl2. 
Scheme 54. Dimethyl chlorophosphonate formation. 
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Coupling of H-phosphonate 50 with vinyl iodide 32 using Pd(PPh3)4 furnished protected 
diastereomeric mixed diesters 51 in a moderate 29% yield. However, no dehalogenation  
 
 
 
 
 
 
and is slowly hydrolysed
[187]
 during work-up and purification by flash chromatography 
to form phosphine oxide 52 (Scheme 56). 
The modified procedure, introduced by Hayes and co-workers
[57]
 (Scheme 10) using 
propylene oxide as an alternative HI scavenger and using palladium acetate and 1,1’-
bis(diphenylphosphino)ferrocene (dppf) instead of Pd(PPh3)4, would be an interesting 
alternative to investigate for this coupling step. 
 
 
 
 
 
 
Scheme 55. Reagents & conditions: (i) anhydrous NEt3, Pd(PPh3)4; (ii) thiophenol, 
anhydrous NEt3, anhydrous THF; (iii) TFA/H2O : 1/1; (iv) gpc. 
product (as observed previously) had formed but instead 
the phosphine oxide 52 was obtained as a side-product 
in 9% yield. A coupling reaction between PPh3 and 
vinyl iodide 32 seems to occur but no formal mechanism 
has been elucidated. It is thought that substituted 
cyclohexene triphenylphosphonium iodide is formed 
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The mixed diester 51 was then subjected to final deprotection steps. Selective 
phosphonate demethylation converted the mixture of diastereoisomers 51 into the 
monoester 53 in 74% yield which was deprotected in aqueous acetic acid to furnish 
α(2,3)-sialoside mimetic 54 in 61% yield after purification by gel-permeation 
chromatography. A selective observation of phosphonate ester protons by 
1
H spin-echo 
difference (SED) spectroscopy
[188]
 of compound 54 confirmed the ‘phospha’-Tamiflu 
moiety linkage to the 3-position of the galactose (see Appendix 2 : NMR spectrum of 
compound 54). 
 
I.5.4.2. Introduction of a variable ω-thioacetyl linker for immobilisation and 
oligomerisation of the ‘phospha’-Tamiflu motif 
 
 
 
 
 
 
 
 
 
 
Scheme 57. Reagents & conditions: (i) imidazole, TIPSCl; (ii) TsCl, DMAP, anhydrous 
pyridine, 0°C; (iii) KSAc, pyridine; (iv) TBAF, AcOH, THF; (v) chloro(dimethyl)phosphine 49, 
N,N-diisopropylethyl amine, anhydrous CH2Cl2. 
Scheme 56. Supposed mechanism of side-product phosphine oxide 52. 
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Hexane-1,6-diol was mono-protected as the triisopropylsilyl ether
[189]
 in a moderate 
45% yield due to the inevitable formation of the disilyl ether. The remaining free 
alcohol was then tosylated
[190]
 to furnish 55 in 80% yield. The tosylate was substituted 
by KSAc in pyridine to give 56 in a good 86% yield, which was desilylated with TBAF 
in presence of acetic acid in THF to afford ω-thioacetyl hexanol 57 in 72% yield. 
Phosphonylation of 57 with dimethyl chlorophosphonate 49 gave the phosphite which 
was directly hydrolyzed on silica during purification by flash chromatography to furnish 
the desired mixed diester hydrogen phosphite 58 in 41% yield. By-product 59 was 
isolated in 11% yield and 
fully characterized. 
Finally, O-methyl O-(ω-thioacetyl hexyl) phosphonic acid 58 was coupled to vinyl 
iodide 32 to give the diastereoisomers of methyl (ω-thioacetoxy hexyl)-‘phospha’-
tamiflu 60 in 36% yield. 
 
 
 
 
 
 
 
  
Scheme 58. Reagents & conditions: (i) anhydrous NEt3, Pd(PPh3)4. 
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I.5.5. Inhibition of neuraminidase activity 
In collaboration with the National Institute for Medical Research (NIMR, London, UK), 
phosphonates 35, 36, 40, 46 and 54 were investigated for inhibitory activity in a whole-
virus assay using allantoic fluid from infected eggs (Table 2).
[171, 172]
 In this standard 
assay, which is widely used in the influenza field, the inhibition constant Ki is obtained 
by measuring the effect of the inhibitor on the rate of MUNANA hydrolysis.
[191-196]
 
 
35 36 40 46 54 Oseltamivir 
0.17 ± 0.08 0.30 ± 0.04 0.22 ± 0.03 0.74 ± 0.08 0.29 ± 0.02 0.14 ± 0.02 
 
 
 
 
 
‘Phospha’-Tamiflu and its monoesters display an inhibitory activity against influenza 
virus neuraminidase very much in the same range as Oseltamivir itself. This was further 
confirmed by inhibition of neuraminidase from Oseltamivir-resistant virus 
(A/Norway/1735/07, KM for MUNANA = 11.1 ± 0.6 µM) by ‘phospha’-Tamiflu 35 
with a Ki of 48 ± 8 nM compared with 36 nM for Oseltamivir.
[171]
 These findings are 
important as they allow the conclusion that the inhibitory properties of Oseltamivir are 
fully retained when the carboxylate is substituted by a monoalkyl phosphonate which 
retains a negative charge under physiological conditions. 
Regarding sialylgalactoside mimetics 46 (α(2,6)-sialogalactoside mimetic) and 54 
(α(2,3)-sialogalactoside mimetic), a significant difference in their respective inhibitory 
activity against influenza virus neuraminidase was observed.
[172]
 α(2,3)-sialylgalactoside 
mimetic 54 inhibits somewhat more strongly than the isomeric α(2,6)-sialylgalactoside 
mimetic 46. In the absence of detailed structural data, this finding cannot be directly 
correlated with the substrate specificity of the virus but it does demonstrate that the set 
of the two compounds is useful to establish a fingerprint for the neuraminidase which is, 
at least partly, governed by its substrate specificity. In other words, the ratio of the 
inhibition constants of 46 and 54 should show some proportionality to the ratio of the 
binding constants of the respective α(2,3)- and α(2,6)-sialylgalactoside substrates.  
 
Table 2. Inhibition constants (Ki [nM]) for target phosphonates. 
(Inhibition of Munana hydrolysis catalysed by neuraminidase from influenza virus 
A/Norway/1758/07; Inhibition constants (Ki) were determined as described in III.2.3 Inhibition of 
neuraminidase activity of influenza viruses from allantoic fluid from infected eggs; KM for 
MUNANA = 6.4 ± 0.6 µM) 
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I.5.6. Future scope 
Compound 60 will be used as a precursor to the synthesis of the ‘Phospha’-Tamiflu 
dimmer which will then be tested for inhibitory activity against influenza virus 
neuraminidase. The synthesis of a multivalent inhibitor will as well be investigated. 
Immobilization of Tamiflu on nanoparticles (gold nanoparticles or CdSe-nanodots) or 
on resin is in the pipeline of the group’s work as illustrated in Scheme 59. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immobilization of Tamiflu has already been reported by Shibasaki,
[197]
 replacing the 
pentyl ether pharmacophore of Oseltamivir by a linker. Our ‘phospha’-Tamiflu 
approach would allow immobilization without impairing the Oseltamivir 
pharmacophore.  
 
To further investigate the binding specificity of neuraminidase towards α(2,6)- or 
α(2,3)-linked sialylgalactosides and to probe the cavity adjacent to the active site, the 
‘150-loop’ (representing residues 147 to 152) observed in the crystal structures of 
group-1 neuraminidases, it could be of interest to synthetise α(2,6)- and α(2,3)-
sialyloligosaccharide mimetics possessing a longer carbohydrate chain. Inhibition data 
and structural data of such mimetics could lead to a better understanding of 
neuraminidase activity. 
  
Scheme 59. From compound 60 to ‘Phospha’-Tamiflu dimer to ‘Phospha’-Tamiflu nano-
gold.particules. 
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I.6. Conclusion 
We have achieved the novel extension of the Hunsdiecker-Barton decarboxylation to 1-
cyclohexenecarboxylic acids and successfully applied it to the synthesis of ‘phospha’-
shikimic acid and derivatives as well as to the synthesis of ‘phospha’-Tamiflu and 
derivatives. We thus provide access not only to the potent inhibitor ‘phospha’-Tamiflu 
35 but also to its monoesters. This approach allows for adding functionality to the 
Oseltamivir pharmacophore, without compromising the inhibitory activity and allowing 
for the presentation of the Tamiflu motif on an unlimited variety of carrier structures. 
 
  
80 
 
Experimental section 
I.7. General procedures 
All reactions were carried out in oven dried glassware with magnetic stirrers. All 
reagents were purchased from commercial suppliers and used without further 
purification. Methanol and DMF were purchased anhydrous and used as received. 
Methylene chloride was distilled twice before use and solvents for chromatography 
(toluene and ethyl acetate) were distilled before use. All other solvents used in the 
reactions were distilled from appropriate drying agents prior to use. Fine chemicals 
were purchased from Aldrich-, Sigma- or Acros-Chemicals and were of the highest 
purity available. Reactions were monitored by TLC (Thin Layer Chromatography) 
using pre-coated silica gel 60 F254 plates (pre-coated plastic sheets with a 0.20 mm layer 
of silica gel with fluorescent indicator UV254) (POLYGRAM SIL G/UV254, Macherey-
Nagel). Compounds were detected by UV absorption and/or by staining with a 
molybdenum phosphate reagent (20g ammonium molybdate and 0.4g cerium(IV) 
sulfate in 400mL of 10% aqueous sulfuric acid) or with a basic KMnO4 solution and 
subsequent heating at 120°C for a few minutes. Chromatography purification was 
performed using silica gel 60Å ‘Davisil’ (particle size 35-70μm) from Fisher Scientific, 
UK. Silica-based MPLC chromatography was carried out on the Büchi Sepacore system 
equipped with glass columns packed with LiChroprep Si 60 (15-25 µm) from Merck, 
Darmstadt, Germany. Gel permeation chromatography was carried out in the 1-10 mg 
scale on a XK 16/70 column (bed volume 130 mL), from Amersham packed with 
Sefadex G-10 (particle size 40-120 µm) and 0.1M NH4HCO3 as buffer. Detection was 
achieved with a differential refractometer from Knauer, Berlin, Germany. 
1
H NMR, 
13
C 
NMR, 
31
P NMR and all multidimensional spectra were recorded on Varian VNMRS 
spectrometers (600 MHz, 500 MHz or 400 MHz, see compound characterisation for 
individual experiments). Chemical shifts in 
1
H and 
13
C NMR spectra were referenced to 
the residual proton resonance of the respective deuterated solvents, CDCl3 (7.24 ppm), 
D2O (4.80 ppm) and D2O in CD3OD (4.88 ppm). For 
31
P NMR spectra H3PO4 was used 
as external standard (0 ppm). In some cases, 
13
C chemical shifts were deduced from 
heteronuclear multiple spin correlation (HSQC) spectra. The H6ax and H6eq assignments 
refer to the pseudoaxial and pseudoequatorial protons in the cyclohexene systems, 
respectively, obtained by ROESY spectroscopy. In pseudo-disaccharidic systems the 
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cyclohexene ring is indicated by the suffix ‘a’, the sugar by the suffix ‘b’. Diastereomic 
mixtures of mixed diesters were indicated by the suffix ‘h’ (higher moving) and ‘l’ 
(lower moving) but in most cases no attemps of separation were made. 
HR-ESI-MS (High Resolution Electro-Spray Ionisation Mass Spectrometry) was 
ascertained for all compounds on a Brucker Daltonics Apex III in positive mode with 
MeOH and/or H2O as solvents.  
Fluorescence was measured in a JASCO FP-6300 fluorimeter. 
 
I.8. Synthetic procedures and compound characterization 
I.8.1. ‘Phospha’-shikimic derivatives 
 
Di(diisopropyl)ammonium [(3R,4S,5R)-trihydroxy-1-cyclohexene-1-phosphonate] 
(1) 
 
 
 
Compound 9 (10 mg, 0.027 mmol) was dissolved in dichloromethane (1 mL) and 
trimethylsilyl bromide (36 µL, 0.27 mmol) and lutidine (38 µL, 0.324 mmol) were 
added to the solution. After 4 hours stirring, the solvent was evaporated and aqueous 
ammonia 10% (1.5 mL) was added. After 2 hours stirring, the mixture was frozen and 
lyophilized. The residue was purified on a Biogel P4 column to afford, after 
lyophilization, compound 1 as the ammonium salt. 1 was dissolved in H2O (2mL), a 
drop of diisopropyl amine was added, the mixture was stirred for 5 min, then frozen and 
lyophilized to afford the diisopropyl ammonium salt of compound 1.  
1
H NMR (600 MHz, D2O) δH 6.18 (d, 1H, JP-2 = 17.9 Hz, H-2), 4.34-4.31 (m, 1H, H-3), 
3.96-3.90 (m, 1H, H-5), 3.66 (dd, 1H, J = 9.7, 4.4 Hz, H-4), 3.52 (sept, J = 6.6 Hz, 4H, 
NCH), 2.77 (ddd, J = 17.4, 6.3, 6.3 Hz, 1H, H-6’), 2.19 (dd, J = 17.6, 8.3 Hz, 1H, H-6), 
1.31 (d, J = 6.6 Hz, 24H). 
13
C NMR (600 MHz, D2O) δC 139.42 (d, J = 165 Hz, C-1), 128.59 (m, C-2), 72.78 (C-
4), 67.11, 66.99, 66.92 (1s, 1d, C-3, C-5), 47.15 (NCH), 33.59 (d, J = 8.9 Hz, C-6), 
18.20. 
31
P NMR (161.9 MHz, D2O) δP 10.80. 
OH
OH
PO
3
OH [+H2N(CH(CH3)2)2]2
2-
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Ammonium [methyl (3R,4S,
 
5R)-trihydroxy-1-cyclohexene-1-phosphonate] (2) 
 
 
 
 
Compound 9 (11 mg, 0.030 mmol) was dissolved in dry acetone (2 mL) and NaI (20 
mg, 0.133 mmol) was added to the solution under nitrogen atmosphere. The mixture 
was heated to reflux for 8 hours and then the solvent was evaporated. Aqueous 
ammonia 10% was added to the residue, and the mixture was stirred for 3 hours, was 
then frozen and lyophilized. The residue was purified on a Biogel P4 column to afford 
compound 2. 
1
H NMR (500 MHz, D2O) δH 6.42 (d, JP-2 = 19.3 Hz, 1H, H-2), 4.45 (s, 1H, H-3), 4.05-
3.99 (m, 1H, H-5), 3.81-3.74 (m, 1H, H-4), 3.57 (d, J = 10.7 Hz, 3H, POCH3), 2.77-2.57 
(m, 1H, H-6’), 2.25-2.15 (m, 1H, H-6). 
13
C NMR (500 MHz, D2O) δC 135.48 (d, J = 7.3 Hz, C-2), 132.29 (d, J = 170.6 Hz, C-
1), 71.98 (C-4), 66.49/66.33 (C-3/C-5), 51.61 (m, POMe), 32.37 (d, J = 9.1 Hz, C-6). 
31
P NMR (121.4 MHz, D2O) δP 16.49. 
HR-ESI-MS calculated for C7H12O6P (M+H+Na)
+
 247.0342200, found 247.0341957. 
 
Diammonium [(4S,
 
5R)-dihydroxy-3-oxo-1-cyclohexene-1-phosphonate] (3) 
 
 
 
 
Compound 23 (10 mg, 0.025 mmol) was dissolved in dichloromethane (1 mL) and 
trimethylsilyl bromide (36 µL, 0.25 mmol) and lutidine (38 µL, 0.3 mmol) were added 
to the solution. After 12 hours stirring, TMSBr (36 µL, 0.25 mmol) and lutidine (38 µL, 
0.3 mmol) were added to the mixture. After few hours, the solvent was evaporated and 
the residue was dissolved in 2 mL of aqueous trifluoroacetic acid (TFA:H2O ; 9:1). 
After overnight stirring, the mixture was frozen and lyophilized. Gel permeation 
chromatography on a Biogel P4 column afforded compound 3. 
1
H NMR (500 MHz, D2O) δH 6.48 (d, J 2,P = 16.5 Hz, 1H, H-2), 4.31 (d, J = 11.3 Hz, 
1H, H-4), 4.07-3.98 (m, 1H, H-5), 3.18-3.08 (m, 1H, H-6’), 2.73-2.63 (m, 1H, H-6). 
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13
C NMR (400 MHz, D2O) δC 128.72 (d, J = 7.3 Hz, C-2), 127.24 (d, J = 181.6 Hz, C-
1), 78.34 (C-4), 71.53 (d, J =12.0 Hz, C-5), 34.93 (d, J = 7.4 Hz, C-6). 
31
P NMR (121.4 MHz, D2O) δP 8.16. 
 
Ammonium [methyl (4S,
 
5R)-dihydroxy-3-oxo-1-cyclohexene-1-phosphonate] (4) 
 
 
 
 
From 18: Compound 18 (8 mg, 0.034 mmol) was dissolved in dried acetone (1 mL) and 
NaI (15 mg, 0.10 mmol) was added to the solution under nitrogen atmosphere. The 
mixture was heated to reflux for 8 hours and then the solvent was evaporated. The 
residue was purified on a Biogel P4 column to afford compound 4. 
From 23: Aqueous trifluoroacetic acid (TFA:H2O ; 9:1) (2 mL) was added to compound 
23 (30 mg, 0.076 mmol) and the mixture was stirred overnight. More aqueous TFA (2 
mL) was added and the mixture stirred for 24 hours. After evaporation under vacuum, 
the deprotected "dimethylphosphonate" compound was purified by flash 
chromatography on a Pasteur pipette (EA:MeOH ; 10:1). The pure intermediate (13.5 
mg, 0.057 mmol) was dissolved in dried acetone. NaI (25 mg, 0.17 mmol) was added 
under nitrogen atmosphere. The mixture was heated to reflux, stirred for 6 hours, then 
frozen and lyophilized. Gel permeation chromatography on a Biogel P4 column 
afforded compound 4. 
1
H NMR (400 MHz, D2O) δH 6.55 (dd, J 2,P = 17.9, 3.0 Hz, 1H, H-2), 4.36 (d, J = 11.2 
Hz, 1H, H-4), 4.07 (ddd, J = 10.5, 10.5, 5.2 Hz, 1H, H-5), 3.64 (d, J = 10.9 Hz, 3H, 
POCH3), 3.05 (ddd, J = 17.9, 9.7, 5.2, 1H, H-6’), 2.68 (dddd, J = 17.9, 10.1, 3.0, 3.0 Hz, 
1H, H-6).  
13
C NMR (400 MHz, D2O) δC 131.89 (d, J = 7.3 Hz, C-2), 78.38 (C-4), 71.10 (d, J = 
13.2 Hz, C-5), 52.18 (d, J = 5.5 Hz, POMe), 34.25 (d, J = 7.6 Hz, C-6). 
31
P NMR (121.4 MHz, D2O) δP 12.84. 
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(3R,4S,5R)-tri-acetoxy-1-cyclohexene-1-carboxylic acid (5) 
 
 
 
 
Shikimic acid (0.4 g, 2.3 mmol) was dissolved in pyridine/acetic anhydride (2/1 ; 9 
mL).After 5 hours stirring, the solution was concentrated under vacuum. Toluene was 
added to the mixture to help remove pyridine by co-evaporation. The residue was 
dissolved in ethyl acetate and washed with HCl 1M (10 mL x 3) and then with brine (5 
mL x 3). The organic phase was dried with MgSO4, evaporated and the residue was 
purified by flash chromatography (Tol:EA:Acetic acid; 3:1:0.5%) to furnish compound 
5 (0.635 g, 2.1 mmol) in 88% yield. Rf = 0.27 (Tol:EA ; 2:1). 
1
H NMR  (300 MHz, CDCl3) δH 10.72 (bs, 1H, COOH), 6.82 (s, 1H, H-2), 5.71 (s, 1H, 
H-3), 5.24 (m, 2H, H-4, H-5), 2.85 (d, J = 17.5 Hz, 1H, H-6’), 2.39 (d, J = 18.1 Hz, 1H, 
H-6), 2.05, 2.04, 2.02 (3s, 9H, 3 OC(O)CH3).  
13
C NMR (300 MHz, CDCl3) δC 170.32, 170.16, 170.08 (COOH, 3 OCOCH3), 135.04 
(C-2), 130.73 (C-1), 67.55, 66.83 (C-4, C-5), 66.10 (C-3), 28.10 (C-6), 21.05, 20.81 (3 
OCOCH3). 
HR-ESI-MS calculated for C13H16O8 (M+Na)
+
 323.0735470, found 323.0737386. 
 
1-iodo-(3R,4S,5R)-tri-acetoxy-1-cyclohexene (6) 
 
 
 
 
Triacetoxyshikimic acid 5 (50 mg, 0.166 mmol) was dissolved in dry CH2Cl2 (0.5 mL) 
in which DMF (0.12 μL) had been added. To the solution was added, under dinitrogen, 
oxalyl chloride (0.11 mL, 1.24 mmol). The mixture was stirred at room temperature 
under dinitrogen for 45 min and then concentrated under vacuum. The residue was 
taken up in CH2Cl2 (0.5 mL). 
Meanwhile a mixture of the sodium salt of N-hydroxypyridine-2-thione (27 mg, 0.18 
mmol), DMAP (1.8 mg, 0.015 mmol), 2-iodo-1,1,1-trifluoroethane 5eq (CF3CH2I) (0.08 
mL, 0.83 mmol) was mixed by stirring in dry CH2Cl2 (1 mL) under nitrogen in a quartz 
tube.  
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5 min before adding the residue of the first step, the quartz tube, still under nitrogen, 
was brought to reflux by irradiation with a 250W floodlamp. The solution of acid 
chloride was then added to this second mixture which was irradiated for 45 min. 
After removal of the solvent, the mixture was purified directly by flash chromatography 
(Tol:EA ; 5:1) to give compound 6 in 58%. Rf = 0.42 (Tol:EA ; 5:1). 
1
H NMR (300 MHz, CDCl3) δH 6.31-6.24 (m, 1H,  H-2), 5.43-5.36 (m, 1H, H-3), 5.24-
5.11 (m, 2H, H-4, H-5), 3.13 (dd, J = 17.9, 4.8 Hz, 1H, H-6’), 2.58 (dd, J = 17.5, 5.3 
Hz, 1H, H-6), 2.02, 2.01, 1.99 (3s, 9H, 3 OC(O)CH3). 
13
C NMR (300 MHz, CDCl3) δC 170.09, 170.01, 169.97 (3 OCOCH3), 133.22 (C-2), 
98.19 (C-1), 68.07, 67.80, 67.68 (C-3, C-4, C-5), 43.78 (C-6), 21.01, 20.92, 20.85 (3 
OCOCH3). 
HR-ESI-MS calculated for C12H15IO6 (M+Na)
+
 404.9806440, found 404.9805523. 
 
1-chloro-(3R,4S,5R)-tri-acetoxy-1-cyclohexene (7) 
 
 
 
 
Synthesis of 7: see synthesis of compound 6, CCl4 (11 eq) was used as the halogen 
donor. Yield: 24%. 
1
H NMR (300 MHz, CDCl3) δH 5.83 (d, 1H, H-2), 5.57 (dd, J3,4 = 4.4, J3,2 = 4.4 Hz, 1H, 
H-3), 5.32-5.24 (m, 1H, H-5), 5.17 (dd, J4,5 or 3 = 9.4, J4, 3 or 5 = 4.0 Hz, 1H, H-4), 2.98 
(dd, J6’,6 = 18.1, J6’,5 = 6.2 Hz, 1H, H-6’), 2.45 (dd, J6,6’ = 18.2, J6,5 = 7.1 Hz, 1H, H-6), 
2.06, 2.05, 2.03 (3s, 9H, 3 OAc); 
HR-ESI-MS calculated for C12H15ClO6Na (M+Na)
+
 313.0446680, found 313.0449370. 
 
1-bromo-(3R,4S,5R)-tri-acetoxy-1-cyclohexene (8) 
 
 
 
 
Synthesis of 8: see synthesis of compound 6, CBr4 (11 eq) was used as the halogen 
donor. Yield: 36%. 
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1
H NMR (300 MHz, CDCl3) δH 6.05 (d, J2,3 = 5.09 Hz, 1H, H-2), 5.51 (dd, J3,4 = 4.5, 
J3,2 = 4.5 Hz, 1H, H-3), 5.31-5.22 (m, 1H, H-5), 5.18 (dd, J4,5 or 3 = 9.4, J4,3 or 5 = 4.0 Hz, 
1H, H-4), 3.10 (dd, J6’,6 = 18.3, J6’,5 = 5.9 Hz, 1H, H-6’), 2.56 (dd, J6,6’ = 18.3, J6,5 = 6.3 
Hz, 1H, H-6), 2.06, 2.05, 2.03 (3s, 9H, 3 OAc); 
13
C NMR (300 MHz, CDCl3) δC 125.48 (C-2), 70.15 (C-4), 67.47 (C-5), 67,28 (C-3), 
39.93 (C-6), 21.15, 21.24, 21.32 (3 COCH3);  
HR-ESI-MS calculated for C12H15BrO6Na (M+Na)
+
 356.9935390 found 356.9944219. 
 
Dimethyl (3R,4S,5R)-tri-acetoxy-1-cyclohexene-1-phosphonate (9) 
 
 
 
 
Anhydrous toluene was degassed in dinitrogen. Compound 6 (48 mg, 0.13 mmol) in dry 
toluene (0.5 mL) was added to a solution of tetrakis triphenylphosphine palladium (0.2 
equiv, 30 mg) in dry toluene (0.5 mL), under a dinitrogen atmosphere. To that mixture 
was added a solution of triethylamine (4 equiv, 96 µL) and dimethylphosphite (4 equiv, 
52 µL) in dry toluene (0.5 mL), under dinitrogen. The mixture was heated to 80°C and 
maintained at this temperature for 3 hours. After cooling down at room temperature, the 
reaction was quenched by addition of saturated aqueous NH4Cl (1 mL).The mixture was 
extracted with toluene, washed with brine and the solvent evaporated. Purification by 
flash chromatography (Tol:EA ; 5:1 -> 2:1) gave the desired compound 9 in 28% yield. 
Rf = 0.02 (Tol:EA ; 5:1). 
1
H NMR (300 MHz, CDCl3) δH 6.52 (d, J 2,P = 21.1 Hz, 1H, H-2), 5.67 (s, 1H, H-3), 
5.29-5.18 (m, 2H, H-4, H-5), 3.74, 3.70 (2d, J = 3.8 Hz, 6H, 2 OCH3), 2.78 (d, J = 18.5 
Hz, 1H, H-6’), 2.28 (d, J = 17.9 Hz, 1H, H-6), 2.05, 2.04, 2.02 (3s, 9H, 3 OC(O)CH3). 
13
C NMR (300 MHz, CDCl3) δC 170.11, 170.08, 170.02 (OCOCH3), 136.91 (d, J = 8.9 
Hz, C-2), 129.48 (d, J =184.0 Hz, C-1), 67.95, 66.73 (d, J = 13.7 Hz, C-4, C-5), 66.02 
(d, J = 21.6 Hz, C-3), 52.97, 52.93 (d, J = 5.9 Hz, 2 POMe), 29.10 (d, J = 9.3 Hz, C-6), 
21.16, 20.93, 20.91 (3 OCOCH3). 
31
P NMR (121.4 MHz, CDCl3) δP 19.15. 
HR-ESI-MS calculated for C14H21O9P (M+Na)
+
 387.0812160, found 387.0815399. 
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(3R,4S,5R)-tri-acetoxy-cyclohex-1-ene (10)  
 
 
 
 
Side product from the reaction above formed in 18% yield. Rf = 0.41 (Tol:EA ; 5:1). 
1
H NMR (300 MHz, CDCl3) δ 5.90-5.81 (m, 1H, H-2), 5.72-5.64 (m, 1H, H-1), 5.57 
(dd, J3,4 = 4.3, J3,2 = 4.3 Hz, 1H, H-3), 5.32-5.22 (m, 1H, H-5), 5.15 (dd, J4,5 or 3 = 10.2, 
J4,3 or 5 = 4.0 Hz, 1H, H-4), 2.74 (ddd, J6’,6 = 18.5, J6’,5 = 4.9, J6’,1 = 4.9 Hz, 1H, H-6’), 
2.22-2.09 (m, 1H, H-6), 2.06, 2.04, 2.01 (3s, 9H, 3 OAc); 
HR-ESI-MS calculated for C12H16O6Na (M+Na)
+
 279.0832730 found 279.0839093. 
 
Methyl (3R,4S,5R)-3-hydroxy-4,5-(2,3-dimethoxy-butan-2,3-dioxy)-cyclohex-1-ene-
1-carboxylate (11) 
 
 
 
To a mixture of shikimic acid (0.5 g, 2.87 mmol), butane-2,3-dione (0.5 mL, 2 equiv), a 
catalytic amount of (+)-camforsulfonic acid (CSAcat) in methanol (10 mL) was added 
trimethylorthoformate (1.57 mL, 5 equiv). The mixture was refluxed under nitrogen for 
72h. After being cooled to room temperature, saturated aqueous NaHCO3 (5 mL) was 
added to the mixture and stirred for 5 to 10 min. Removal of the solvent and purification 
by flash chromatography (Tol:EA ; 5:1 -> 1:1) yields compound 11 in 62%. Rf = 0.67 
(EA:MeOH ; 100:1). 
1
H NMR  (300 MHz, CDCl3) δH 6.88 (dd, J =4.9, 2,6 Hz, 1H, H-2), 4.36 (dd, J = 4.7 
Hz, 4.7 Hz, 1H, H-3), 4.07 (ddd, J =10.7 Hz, 10.7, 5.8 Hz, 1H, H-5), 3,72 (s, 3H, 
COOCH3), 3.60 (dd, J = 10.7 Hz, 4.3 Hz, 1H, H-4), 3.25, 3.23 (2s, 6H, 2 OCH3), 2.81 
(dd, J =17.5, 5.6 Hz, 1H, H-6’), 2.22 (ddd, J =17.5, 10.3, 2.4 Hz, 1H, H-6), 1.31, 1.28 
(2s, 6H, 2 CH3). 
13
C NMR (300 MHz, CDCl3) δC 166.71 (COOCH3), 135.24 (C-2), 131.76 (C-1), 
100.11, 99.32, 70.64 (C-4), 65.13 (C-3), 62.50 (C-5), 52.16 (COCH3), 48.17, 48.05 (2 
OCH3), 30.22 (C-6), 17.97, 17.78 (2 CH3). 
HR-ESI-MS calculated for C14H22O7 (M+Na)
+
 325.1252420, found 325.1257742. 
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Methyl (3R,4S,5R)-3-[(tert-butyldimethylsilyl)oxy]-4,5-(2,3-dimethoxy-butan-2,3-
dioxy)-cyclohex-1-ene-1-carboxylate (12) 
 
 
 
 
To a solution of compound 11 (0.309 mg, 1.02 mmol), imidazole (167 mg, 2.45 mmol), 
and a catalytic amount of dimethylaminopyridine (DMAPCat ; 0.05 eq) in anhydrous 
DCM (5 mL) was added tert-butyldimethylsilyl chloride (185 mg, 1.23 mmol). The 
mixture was stirred at room temperature for 24h. Saturated aqueous NaHCO3 (5 mL) 
was added to the reaction mixture which was then extracted with DCM (15 mL x 3), 
washed with brine (10 mL x 2) and dried over MgSO4. The solvent was removed and 
the product was purified by flash chromatography (Tol:EA ; 10:1 then 5:1) to yield 
compound 12 in 76%. Rf = 0.59 (Tol:EA ; 5:1). 
1
H NMR  (300 MHz, CDCl3) δH 6.75 (dd, J =5.3, 2,6 Hz, 1H, H-2), 4.29 (dd, J = 4.5,
 
J 
= 4.5 Hz, 1H, H-3), 4.09 (ddd, J =10.6, 10.60, 6.0 Hz, 1H, H-5), 3.72 (s, 3H, COOCH3), 
3.45 (dd,  J = 10.7, 4.4 Hz, 1H, H-4), 3.22,3.20 (2s, 6H, 2 OCH3), 2.78 (dd, J = 17.5, 6.0 
Hz, 1H, H-6’), 2.19 (ddd, J = 17.5, 10.6, 2.6 Hz, 1H, H-6), 1.27, 1.26 (2s, 6H, 2 CH3), 
0.86 (s, 9H, t-Bu), 0.10, 0.08 (2s, 6H, 2 SiCH3). 
13
C NMR (300 MHz, CDCl3) δC 167.26 (COOMe), 136.92 (C-2), 129.91 (C-1), 99.68, 
98.90, 70.97 (C-4), 66.14 (C-3), 62.55 (C-5), 52.18 (COCH3), 47.96, 47.80 (2 OCH3), 
30.54 (C-6), 25.91 (C(CH3)3), 18.55 (SiC(CH3)3), 18.05, 17.87 (2 CH3), –4.49, -4.62 (2 
SiCH3). 
HR-ESI-MS calculated for C20H36O7Si (M+Na)
+
 439.2124900, found 439.2122511. 
 
(3R,4S,5R)-3-[(tert-butyldimethylsilyl)oxy]-4,5-(2,3-dimethoxy-butan-2,3-dioxy)-
cyclohex-1-ene-1-carboxylic acid (13) 
 
 
 
 
To compound 12 (300 mg, 0.72 mmol) diluted in MeOH (1 mL), was added a solution 
of aqueous NaOH 0.5M (2 mL). The mixture was stirred for 16h. Amberlite IR-120 H
+
 
was added until the pH=7 to neutralize the solution which was then filtered, evaporated, 
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diluted in DCM, washed with brine, and evaporated. The product was purified by flash 
chromatography (Tol:EA:Acetic acid ; 5:1:0.2% and then 3:1:0.2%) to afford 
compound 13 in 80% yield. Rf = 0.12 (Tol:EA ; 5:1). 
1
H NMR  (300 MHz, CDCl3) δH 6.87 (dd, J = 5.4, 2,3 Hz, 1H, H-2), 4.31 (dd, J = 4.6, 
4.6 Hz, 1H, H-3), 4.11 (ddd, J =10.6, 10.6, 6.0 Hz, 1H, H-5), 3.47 (dd, J = 10.8, 3.9 Hz, 
1H, H-4), 3.23, 3.21 (2s, 6H, 2 OCH3), 2.77 (dd, J = 17.5, 6.0 Hz, 1H, H-6’), 2.20 (ddd, 
J = 17.3, 10.3, 2.3 Hz, 1H, H-6), 1.27, 1.26 (2s, 6H, 2 CH3), 0.86 (s, 9H, t-Bu), 0.10, 
0.08 (2s, 6H, 2 SiCH3). 
13
C NMR (300 MHz, CDCl3) δC 171.83 (COOH), 139.19 (C-2), 129.41 (C-1), 99.74, 
98.99, 70.95 (C-4), 66.10 (C-3), 62.52 (C-5), 48.04, 47.90 (2 OCH3), 30.27 (C-6), 25.97 
(C(CH3)3), 18.57 (SiC(CH3)3), 18.07, 17.90 (2 CH3), –4.49, -4.61 (2 SiCH3). 
HR-ESI-MS calculated for C19H34O7Si (M+Na)
+
 425.1972650, found 425.1966011. 
 
1-iodo-(3R,4S,5R)-3-[(tert-butyldimethylsilyl)oxy]-4,5-(2,3-dimethoxy-butan-2,3-
dioxy)-cyclohex-1-ene (14) 
 
 
 
 
Compound 13 (124 mg, 0.308 mmol) was dissolved in dry CH2Cl2 (1 mL) in which 
DMF (0.3 μL) had been added. To the solution was added, under dinitrogen, oxalyl 
chloride (0.13 mL, 1.54 mmol). The mixture was allowed to stay at room temperature 
stirring under dinitrogen for 45 min (until there is no more bubbling) and then 
concentrated under vacuum. The residue was taken up in dry CH2Cl2 (1 mL). 
Meanwhile, a mixture of N-hydroxypyridine-2-thione (47 mg, 0.37 mmol), DMAP (4 
mg, 0.1 equiv), 2-iodo-1,1,1-trifluoroethane (0.12 mL, 1.23 mmol) was mixed by 
stirring in dry DCM (1 mL) under nitrogen in a quartz tube.  
5 min before adding the residue of the first step, the quartz tube, still under nitrogen, is 
brought to reflux by irradiation with a 250W floodlamp. The solution of acid chloride 
was then added to this second mixture, and irradiation was continued for a further 30 
min. 
After removal of the solvent, the mixture was purified directly by flash chromatography 
(Tol:EA, 10:1 and then 5:1) to give compound 14 in 39% of yield. 25% of starting 
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material 13 was recovered. The yield based on recovered starting material is 52%. Rf = 
0.80 (Tol:EA ; 5:1). 
1
H NMR (500 MHz, CDCl3) δH 6.28 (dd, J = 5.7, 2.3 Hz, 1H, H-2), 4.18 (ddd, J = 10.5, 
10.5, 6.3 Hz, 1H, H-5), 4.07-4.0 (m, 1H, H-3), 3.46 (dd, J = 10.7, 3.6 Hz, 1H, H-4), 
3.21, 3.19 (2s, 6H, 2 OCH3), 2.85 (dd, J = 17.6,
 
6.3 Hz, 1H, H-6’), 2.58 (ddd, J = 17.6, 
10.0, 2.5 Hz, 1H, H-6), 1.25, 1.23 (2s, 6H, 2 CH3), 0.86 (s, 9H, t-Bu), 0.07, 0.05 (2s, 
6H, 2 SiCH3). 
13
C NMR (500 MHz, CDCl3) δC 138.3 (C-2), 99.72, 99.0, 97.17 (C-1), 70.23 (C-4), 
68.86 (C-3), 63.53 (C-5), 48.02,47.91 (2 OCH3), 45.51 (C-6), 26.02 (t-Bu), 18.60 
(SiC(CH3)3), 18.03, 17.90 (2 CH3), –4.43,-4.59 (2 SiCH3) 
HR-ESI-MS calculated for C18H33IO5Si (M+Na)
+
 507.1030910, found 507.1034148. 
 
Dimethyl (3R,4S,5R)-3-[(tert-butyldimethylsilyl)oxy]-4,5-(2,3-dimethoxy-butan-2,3-
dioxy)-cyclohex-1-ene-1-phosphonate (15) 
 
 
 
 
 
Anhydrous toluene was degassed in dinitrogen. Compound 14 (169 mg, 0.35 mmol) 
dissolved in dry toluene (1 mL) was added to a solution of tetrakis triphenylphosphine 
palladium (40 mg, 0.1 equiv) in dry toluene (1 mL) saturated under a dinitrogen 
atmosphere. To that mixture was added a solution of triethylamine (147 µL, 1.05 mmol) 
and dimethylphosphite (65 µL, 0.7 mmol) in dry toluene (1 mL), under nitrogen. The 
mixture was heated to 80°C and maintained at this temperature for 4 hours. After 
cooling down at room temperature, the reaction was quenched by addition of saturated 
aqueous NH4Cl (3 mL). The mixture was then extracted with toluene, washed with brine 
and the solvent evaporated. Purification by flash chromatography (Tol:EA ; 5:1 -> 1:1) 
gave the desired compound 15 in 70% yield. Rf = 0.10 (Tol:EA ; 3:1). 
1
H NMR (300 MHz, CDCl3) δH 6.59 (ddd, J2,P = 20.8, 4.6, 2,3 Hz, 1H, H-2), 4.25 (dd, J 
= 4.5,
 
4.5 Hz, 1H, H-3), 4.12 (ddd, J = 10.4, 10.4, 6.1 Hz, 1H, H-5), 3.47 (dd, J = 10.8, 
3.9 Hz, 1H, H-4), 3.22, 3.20 (2s, 6H, 2 OCH3), 2.54 (ddd, J = 16.8, 8.2, 6.4 Hz, 1H, H-
6’), 2.23-2.09 (m, 1H, H-6), 1.27, 1.25 (2s, 6H, 2 CH3), 0.85 (s, 9H, t-Bu), 0.09, 0.06 
(2s, 6H, 2 SiCH3). 
TBDMSO
O
O
OMe
MeO
P
O
OMe
OMe
91 
 
13
C NMR (500 MHz, CDCl3) δC 141.79 (d, J = 7.6 Hz, C-2), 126.96 (d, J = 181.9 Hz, 
C-1), 99.81, 99.12, 70.99 (d, J = 2.4 Hz, C-4), 66.41 (d, J = 21.7 Hz, C-3), 62.48 (d, J = 
14.4 Hz, C-5), 52.75, 52.73 (2d, J = 5.7 Hz, P(OCH3)2), 48.07, 47.94 (2 OCH3), 31.03 
(d, J = 9.4 Hz, C-6), 25.94 (t-Bu), 18.08/17.89 (2 CH3), –4.44, -4.63 (2 SiCH3). 
31
P NMR (161.9 MHz, CDCl3) δP 20.70. 
HR-ESI-MS calculated for C20H39O8PSi (M+Na)
+
 489.2011710, found 489.2044024. 
 
Dimethyl (3R,4S,5R)-3-hydroxy-4,5-(2,3-dimethoxy-butan-2,3-dioxy)-cyclohex-1-
ene-1-phosphonate (16) 
 
 
 
Compound 15 (0.122 g, 0.26 mmol) was dissolved in anhydrous THF (2 mL) and TBAF 
(0.1 g, 0.31 mmol) was added to the solution. The mixture was stirred at room 
temperature for 3h, then quenched by addition of saturated aqueous NH4Cl and 
extracted with diethyl ether. Purification by flash chromatography (Tol:EA ; 3:1 to 1:1) 
gave compound 16 in 96% of yield. Rf  0.49 (EA:MeOH ; 5:1). 
1
H NMR (300 MHz, CDCl3) δH 6.68 (ddd, J2,P = 21.0, J = 4.6, 2.4 Hz, 1H, H-2), 4.33 
(dd, J = 4.5,
 
4.5 Hz, 1H, H-3), 4.09 (ddd, J = 10.6, 10.6, 5.7 Hz, 1H, H-5), 3.72, 3.68 
(2d, J = 3.9 Hz, 6H, P(OCH3)2), 3.60 (dd, J = 10.8, 4.2 Hz, 1H, H-4), 3.24, 3.23 (2s, 6H, 
2 OCH3), 2.75 (bs, 1H, OH), 2.58 (ddd, J = 16.9, 8.7, 5.7 Hz, 1H, H-6’), 2.29-2.14 (m, 
1H, H-6), 1.31, 1.27 (2s, 6H, 2 CH3). 
13
C NMR (300 MHz, CDCl3) δC 139.55 (d, J = 8.5 Hz, C-2), 129.50 (d, J = 181.3 Hz, 
C-1), 100.27, 99.54, 70.62 (d, J = 2.3 Hz, C-4), 65.51 (d, J = 21.7 Hz, C-3), 62.42 (d, J 
= 14.4 Hz, C-5), 52.96, 52.96 (2d, J = 5.8 Hz, P(OCH3)2), 48.32, 48.25 (2 OCH3), 30.72 
(d, J = 9.6 Hz, C-6), 18.06, 17.88 (2 CH3). 
31
P NMR (161.9 MHz, CDCl3) δP 19.69. 
HR-ESI-MS calculated for C14H25O8P (M+Na)
+
 375.1176890, found 375.1179254. 
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Dimethyl (4S,5R)-4,5-(2,3-dimethoxy-butan-2,3-dioxy)-3-oxo-cyclohex-1-ene-1-
phosphonate (17) 
 
 
 
 
Compound 16 (42 mg, 0.125 mmol) was dissolved in acetone (2 ml). IBX (105 mg, 3 
eq) was added to the solution. The mixture was stirred for 2h 30min at 65°C. The 
mixture was then filtered through celite and the filtrate was evaporated under vacuum. 
Purification by flash chromatography (EA) gave the ketone 17 in 94% yield. Rf = 0.39 
(EA). 
1
H NMR (300 MHz, CDCl3) δH 6.58 (dd, J2,P = 20.6, J = 2.9 Hz, 1H, H-2), 4.31 (d, J = 
11.7 Hz, 1H, H-4), 4.08 (ddd, J = 11.2, 11.2, 5.2 Hz, 1H, H-5), 3.80, 3.76 (2d, J = 2.6 
Hz, 6H, P(OCH3)2), 3.27, 3.23 (2s, 6H, 2 OCH3), 2.86 (ddd, J = 17.9, 10.3, 5.3 Hz, 1H, 
H-6’), 2.61 (dddd, J = 17.8, 10.6, 3.2, 3.2 Hz, 1H, H-6), 1.39, 1.29 (2s, 6H, 2 CH3). 
13
C NMR (300 MHz, CDCl3) δC 136.5 (C-2), 75.6 (C-4), 48.9, 48.6 (2 OCH3), 31.26 
(C-6), 18.0, 17.9 (2 CH3). 
31
P NMR (121.4 MHz, CDCl3) δ 17.69. 
 
Dimethyl (4S,5R)-dihydroxy-3-oxo-1-cyclohexene-1-phosphonate (18) 
 
 
 
 
Compound 17 (0.030 g, 0.0856 mmol) was dissolved in aqueous trifluoroacetic acid 
(TFA:H2O ; 9:1 ; 3 mL). The solution was stirred overnight then frozen and lyophilized. 
Purification by flash chromatography (EA:MeOH:Et3N ; 5:1:0.2% -> 1:1:0.2%) gave 
compound 18 in 79% yield. Rf = 0.20 (EA:MeOH ; 5:1). 
1
H NMR (600 MHz, CDCl3) δH 6.70 (dd, J2,P = 20.2, J = 3.1 Hz, 1H, H-2), 4.11 (d, J = 
10.9 Hz, 1H, H-4), 3.93 (ddd, J = 10.6, 10.6, 5.3 Hz, 1H, H-5), 3.81, 3.79 (2d, J = 6.5 
Hz, 6H, P(OCH3)2), 3.00 (ddd, J = 18.3, 10.4, 5.3 Hz, 1H, H-6’), 2.56 (dddd, J = 18.3, 
10.1, 3.2, 3.2 Hz, 1H, H-6). 
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13
C NMR (600 MHz, CDCl3) δC 197.69 (d, J = 25.4 Hz, C-3), 147.34 (d, J = 178.4 Hz, 
C-1), 134.55 (d, J = 8.0 Hz, C-2), 79.46 (C-4), 72.37 (d, J = 14.85 Hz, C-5), 53.62, 
53.58 (POCH3), 32.95 (d, J = 7.5 Hz, C-6). 
31
P NMR (121.4 MHz, CDCl3) δP 17.14. 
HR-ESI-MS calculated for C8H13O6P (M+Na)
+
 259.0342940, found 259.0341957. 
 
Methyl (4S,5R)-4,5-(2,3-dimethoxy-butan-2,3-dioxy)-3-oxo-cyclohex-1-ene-1-
carboxylate (19) 
 
 
 
Compound 11 (120 mg, 0.40 mmol) was dissolved in acetone (4 ml). IBX (331 mg, 
1.20 mmol) was added to the solution. The mixture was stirred for 3 hours at reflux 
under nitrogen. The mixture was then filtered through celite and the filtrate was 
evaporated under vacuum. Purification by flash chromatography (Tol:EA ; 3:1) gave the 
ketone 19 in 88% yield. 
1
H NMR (300 MHz, CDCl3) δH 6.78 (d, J = 3.1 Hz, 1H, H-2), 4.29 (d, J = 11.5, 1H, H-
4), 4.07 (ddd, J = 10.7, 10.7, 5.3 Hz, 1H, H-5), 3.81 (s, 3H, COOCH3), 3.27, 3.22 (2s, 
6H, 2 OCH3), 3.05 (dd, J = 18.5, 5.3 Hz, 1H, H-6’), 2.61 (ddd, J = 18.3, 10.6, 3.1 Hz, 
1H, H-6), 1.39, 1.30 (2s, 6H, 2 CH3). 
13
C NMR (300 MHz, CDCl3) δC 194.66 (C-3), 166.00 (COOCH3), 144.81 (C-1), 132.86 
(C-2), 100.50, 99.48, 75.26 (C-4), 67.22 (C-5), 53.14 (COOCH3), 48.64, 48.28 (2 
OCH3), 30.65 (C-6), 17.81, 17.73 (2 CH3). 
HR-ESI-MS calculated for C14H20O7 (M+Na)
+
 323.1100290, found 323.1101241. 
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Methyl (4S,5R)-3,3-(ethan-1,2-dioxy)-4,5-(2,3-dimethoxy-butan-2,3-dioxy)-
cyclohex-1-ene-1-carboxylate (20). 
 
 
 
 
To a stirred solution of compound 19 (177 mg ; 0.59 mmol) and 2-bromoethanol (250 
μL ; 6 eq) in anhydrous DMF (2 mL) at –60°C under nitrogen was added dropwise a 
solution of t-BuOK (397 mg ; 3.54 mmol) in anhydrous DMF (2 mL) for 10 min. Then 
the mixture was stirred until ambient temperature was reached. Then aqueous NH4Cl 
was added and the mixture was extracted with EA (4 x 10 mL). Combined organic 
phases were washed with brine (2 x 5 mL) and dried with MgSO4. After filtration, the 
solvent was removed under vacuum and the residue was purified by flash 
chromatography (Tol:EA ; 5:1) to afford compound 20 in 65%. 
1
H NMR (300 MHz, CDCl3) δH 6.50 (d, J = 2.5 Hz, 1H, H-2), 4.22, 4.10 (m, 2H, -
OCH2CH2O-), 4.07-3.93 (m, 3H, -OCH2CH2O-, H-5), 3.78 (d, J = 11.1 Hz, 1H, H-4), 
3.72 (s, 3H, COOCH3), 3.25 (s, 6H, 2 OCH3), 2.77 (dd, J = 17.5, 6.0 Hz, 1H, H-6’), 
2.25 (ddd, J = 17.5, 10.4, 2.8 Hz, 1H, H-6), 1.30, 1.28 (2s, 6H, 2 CH3). 
13
C NMR (300 MHz, CDCl3) δC 166.57 (COOCH3), 136.37 (C-2), 130.53 (C-1), 105.19 
(C-3), 99.60, 99.13, 73.58 (C-4), 67.33, 66.43 (-OCH2CH2O-), 65.37 (C-5), 52.36 
(COOCH3), 48.18, 48.00 (2 OCH3), 29.59 (C-6), 18.01, 17.99 (2 CH3). 
HR-ESI-MS calculated for C16H24O8 (M+Na)
+
 367.1363780, found 367.1363388. 
 
(4S,5R)-3,3-(ethan-1,2-dioxy)-4,5-(2,3-dimethoxy-butan-2,3-dioxy)-cyclohex-1-ene-
1-carboxylic acid (21) 
 
 
 
 
To compound 20 (220 mg, 0.64 mmol) dissolved in MeOH (1 mL), was added NaOH(aq) 
0.5M (3 mL). The mixture was stirred overnight. Amberlite IR-120 H
+
 was added until 
the pH=7 to neutralize the solution which was then filtered (rinsing the Amberlite with 
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MeOH), evaporated, diluted in DCM, washed with brine, and evaporated. The product 
was purified by flash chromatography (Tol:EA ; 3:1) to afford acid 21 in 82% yield. 
1
H NMR (300 MHz, CDCl3) δH 6.60 (d, J = 2.3 Hz, 1H, H-2), 4.21-4.11 (m, 2H, -
OCH2CH2O-), 4.07-3.94 (m, 3H, -OCH2CH2O-, H-5), 3.79 (d, J = 11.3 Hz, 1H, H-4), 
3.25 (s, 6H, 2 OCH3), 2.75 (dd, J = 17.5, 5.8 Hz, 1H, H-6’), 2.25 (ddd, J = 17.6, 10.4, 
2.6 Hz, 1H, H-6), 1.30, 1.28 (2s, 6H, 2 CH3). 
13
C NMR (300 MHz, CDCl3) δC 170.99 (COOH), 138.42 (C-2), 129.98 (C-1), 105.02 
(C-3), 99.64, 99.17, 73.42 (C-4), 67.36, 66.47 (-OCH2CH2O-), 65.30 (C-5), 48,21, 
48,02 (2 OCH3), 29.27 (C-6), 18.01, 17.98 (2 CH3). 
HR-ESI-MS calculated for C15H22O8 (M+Na)
+
 353.1207980, found 353.1206888. 
 
1-iodo-(4S,5R)-3,3-(ethan-1,2-dioxy)-4,5-(2,3-dimethoxy-butan-2,3-dioxy)-
cyclohex-1-ene (22) 
 
 
 
Compound 21 (80 mg, 0.24 mmol) was dissolved in dry CH2Cl2 (1 ml) in which DMF 
(0.3 μL) had been added. To the solution was added, under dinitrogen, oxalyl chloride 
(0.11 mL, 1.29 mmol). The mixture was allowed to stay at room temperature stirring 
under dinitrogen for 45 min and then concentrated under vacuum. The residue was 
taken up in dry CH2Cl2 (1 ml). 
Meanwhile, a mixture of N-hydroxypyridine-2-thione (46 mg, 0.31 mmol), DMAP (3 
mg, 0.1 equiv), 2-iodo-1,1,1-trifluoroethane (0.10 mL, 1.03 mmol) was mixed by 
stirring in dry DCM (2 mL) under nitrogen in a quartz tube.  
5 min before adding the residue of the first step, the quartz tube, still under nitrogen, is 
brought to reflux by irradiation with a 250W floodlamp. The solution of acid chloride 
was then added to this second mixture which was irradiated for a further 30 min. 
After removal of the solvent, the mixture was purified directly by flash chromatography 
(Tol:EA, 10:1 and then 7:1) to give compound 22 in 60% yield.  
1
H NMR (300 MHz, CDCl3) δH 6.09 (d, J = 2.1 Hz, 1H, H-2), 4.24-3.85 (m, 5H, -
OCH2CH2O-, H-5), 3.75 (d, J = 11.1 Hz, 1H, H-4), 3.24, 3.23 (2s, 6H, 2 OCH3), 2.84 
(dd, J = 17.4, 6.3 Hz, 1H, H-6’), 2.63 (ddd, J = 17.4, 10.0, 2.5 Hz, 1H, H-6), 1.27, 1.24 
(2s, 6H, 2 CH3). 
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13
C NMR (300 MHz, CDCl3) δC 138.35 (C-2), 106.33 (C-3), 99.54, 99.22, 97.40 (C-1), 
73.29 (C-4), 67.09, 66.24 (-OCH2CH2O-), 65.81 (C-5), 48.22, 47.99 (2 OCH3), 44.32 
(C-6), 18.00, 17.93 (2 CH3). 
HR-ESI-MS calculated for C14H21IO6 (M+Na)
+
 435.0279560, found 435.0275025. 
 
Dimethyl (4S,5R)-3,3-(ethan-1,2-dioxy)-4,5-(2,3-dimethoxy-butan-2,3-dioxy)-
cyclohex-1-ene-1-phosphonate (23) 
 
 
 
 
 
Anhydrous toluene was degassed in dinitrogen. Compound 22 (160 mg, 0.39 mmol) in 
dry toluene (2 mL) was added to a solution of tetrakis triphenylphosphine palladium (67 
mg, 0.15 equiv) in dry toluene (1 mL) saturated under a dinitrogen atmosphere. To that 
mixture was added a solution of triethylamine (165 µL, 1.16 mmol) and 
dimethylphosphite (106 µL, 1.16 mmol) in dry toluene (1 mL), under nitrogen. The 
mixture was heated to 80°C and maintained at this temperature for 3 hours. After 
cooling down at room temperature, the reaction was quenched by addition of saturated 
aqueous NH4Cl (3 mL). The mixture was then extracted with toluene, washed with brine 
and the solvent evaporated. Purification by flash chromatography (Tol:EA ; 1:1 -> 0:1) 
gave dimethyl phosphonate 23 in 81% yield. 
1
H NMR (300 MHz, CDCl3) δH 6.32 (dd, J2,P = 21.5, J = 2.2 Hz, 1H, H-2), 4.17-4.07 
(m, 2H, -OCH2CH2O-), 4.06-3.90 (m, 3H, -OCH2CH2O-, H-5), 3.76 (d, J = 10.9 Hz, 
1H, H-4), 3.70, 3.67 (2d, J = 5.4 Hz, 6H, P(OCH3)2), 3.23 (s, 6H, 2 OCH3), 2.61-2.47 
(m, 1H, H-6’), 2.25-2.11 (m, 1H, H-6), 1.28, 1.25 (2s, 6H, 2 CH3). 
13
C NMR (300 MHz, CDCl3) δC 141.25 (d, J = 7.5 Hz, C-2), 127.93 (d, J = 180.8 Hz, 
C-1), 105.08 (d, J = 25.0 Hz, C-3), 99.82, 99.37, 73.54 (d, J = 2.2 Hz, C-4), 67.46, 
66.57 (-OCH2CH2O-), 65.49 (d, J = 15.1 Hz, C-5), 53.10, 53.10 (2d, J = 5.7 Hz, 
P(OCH3)2), 48.42, 48.22 (2 OCH3), 30.09 (d, J = 8.8 Hz, C-6), 18.16, 18.14 (2s, 2 CH3). 
31
P NMR (121.4 MHz, CDCl3) δP 20.16. 
HR-ESI-MS calculated for C16H27O9P (M+Na)
+
 417.1281860, found 417.1284901. 
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I.8.2. ‘Phospha’-Tamiflu derivatives 
Ethyl (3R,4R,5S)-4-acetamido-5-azido-3-(1-ethylpropoxy)-1-cyclohexene-1-
carboxylate. 
 
 
 
 
Tamiflu’s precursor was obtained from F. Hoffman-La Roche Ltd. Analytical purity 
was confirmed by NMR. 
 
(3R,4R,5S)-4-acetylamino-5-azido-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic 
acid (24). 
 
 
 
 
Oseltamivir precursor (1 g, 2.95 mmol) was dissolved in dioxane (6 mL), a NaOH-
solution (0.5 M, 6 mL) was added and the mixture was stirred overnight. The mixture 
was neutralized with Amberlite IR-120 (H
+
), filtered and lyophilized. The residue was 
purified by flash chromatography (Tol:EA:AcOH ; 1:1:0.5%) to afford the free acid 24 
(889 mg, 97% yield) as a colorless solid. Rf = 0.27 (Tol:EA, 1:1). 
1
H NMR (500 MHz, CD3OD) δH 6.85 (s, 1H, H-2), 4.27 (s, 1H, H-3), 3.90-3.80 (m, 2H, 
H-4, H-5), 3.48-3.42 (m, 1H, pentyl-CH), 2.89 (d, J = 18.6 Hz, 1H, H-6), 2.31-2.22 (m, 
1H, H-6’), 2.07 (s, 3H, COCH3), 1.63-1.53 (m, 4H, 2 pentyl-CH2), 1.01-0.93 (m, 6H, 2 
pentyl-CH3). 
HR-ESI-MS calculated for C14H22N4O4 (M+Na)
+
 333.1534270, found 333.1533263. 
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(3R,4R,5S)-4-acetylamino-5-azido-3-(1-ethylpropoxy)-1-iodocyclohexene (25) 
 
 
 
 
Under an atmosphere of dry nitrogen, the free acid 24 (250 mg, 0.81 mmol) and 
(chloromethylene)dimethyliminium chloride (Vilsmeier reagent, 124 mg, 0.97 mmol) 
were dissolved in dry CH2Cl2 (2 mL) and the mixture was stirred for 40 min at room 
temperature. Simultaneously, using a quartz tube, N-hydroxypyridine-2-thione (144 mg, 
0.97 mmol), DMAP (50 mg, 0.4 mmol) and 2-iodo-1,1,1-trifluoroethane (0.317 mL, 
3.22 mmol) were dissolved in dry CH2Cl2 (2 mL) under an atmosphere of dry nitrogen 
by help of an ultrasonic bath. The mixture was irradiated and heated to reflux with a 
250W floodlamp for 5 minutes, followed by addition of the acyl chloride mixture. 
Irradiation and refluxing was then continued for a further 30 min. After evaporation of 
the solvent, the mixture was purified by flash chromatography (Tol:EA; 5:1 -> 2:1) to 
give the iodo derivative 25 (129 mg, 0.33 mmol) as a pale yellow crystalline solid and 
starting material 24 (117 mg, 0.38 mmol). Yield: 41% (77% based on consumed starting 
material). Rf = 0.53 (Tol:EA; 1:1). 
1
H NMR (500 MHz, CDCl3) δH 6.26 (s, 1H, H-2), 5.74 (bd, J = 6.4 Hz, 1H, NH), 4.38-
4.31 (m, 2H, H-3, H-5), 3.29-3.19 (m, 2H, H-4, pentyl-CH), 2.89 (dd, J = 17.5 Hz, 1H, 
H-6), 2.57-2.48 (m, 1H, H-6’), 1.99 (s, 3H, COCH3), 1.50-1.39 (m, 4H, 2 pentyl-CH2), 
0.88-0.83 (m, 6H, 2 pentyl-CH3). 
13
C NMR (125.8 MHz, CDCl3) δC 171.2, 139.1 (C-2), 92.3 (C-1), 82.2 (pentyl-CH), 
75.6 (C-3), 57.94 (C-4 or C-5), 57.92 (C-5 or C-4), 44.9 (C-6), 26.5, 25.9 (2 pentyl-
CH2), 23.8, 9.8, 9.5 (2 pentyl-CH3).  
HR-ESI-MS calculated for C13H21IN4O2 (M+Na)
+
 415.0606840, found 415.0601400. 
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Dimethyl (3R,4R,5S)-4-acetylamino-5-(triphenylphosphoranylidene)amino-3-(1-
ethylpropoxy)-1-cyclohexene-1-phosphonate (26). 
 
 
 
 
 
 
 
Under an atmosphere of dry nitrogen, tetrakis triphenylphosphine palladium (142 mg, 
0.12 mmol) and azo-vinyl iodide 32 (161 mg, 0.41 mmol) were dissolved in anhydrous 
toluene (3 mL). Triethylamine (229 µL, 1.64 mmol) and dimethylphosphite (150 µL, 
1.64 mmol) were added to the solution and the mixture was stirred at 65 °C for 2 hours. 
PPh3 (108 mg, 0.41 mmol) was added to the mixture which was stirred for one more 
hour at the same temperature. After cooling to room temperature, the reaction was 
quenched by addition of saturated aqueous NH4Cl (3 mL). CH2Cl2 (30 mL) was added 
and the organic phase was extracted with NH4Cl (10 mL), washed with brine (2x10 
mL), dried over MgSO4 and evaporated. Purification by flash chromatography 
(EA:MeOH; 10:1 -> 2:1) gave the vinyl phosphonate 26 (72 mg, 0.12 mmol, 29%). Rf = 
0.28 (EA:MeOH; 3:1). 
1
H NMR (300 MHz, CD3OD) δH 7.93-7.83 (m, 3H), 7.80-7.68 (m, 12H), 7.47 (d, J = 
21.9 Hz, 1H, H-2), 4.17 (bd, J = 7.8 Hz, 1H), 3.89-3.79 (m, 1H), 3.66 (d, J = 11.4 Hz, 
3H, OCH3), 3.59 (d, J = 11.4 Hz, 3H, OCH3), 3.52-3.44 (m, 1H), 3.37-3.30 (m, 1H), 
2.60-2.38 (m, 1H, H-6), 2.34-2.20 (m, 1H, H-6’), 1.72 (s, 3H, COCH3), 1.51-1.37 (m, 
4H, 2 pentyl-CH2), 1.51-1.37 (m, 6H, 2 pentyl-CH3). 
HR-ESI-MS calculated for C33H42N2O5P (M+H)
+
 609.2669270, found 609.2673651. 
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Ethyl (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-
carboxylate (27). 
 
 
 
 
Under an atmosphere of dry nitrogen, the Lindlar catalyst (151,4 mg) was added to 
Tamiflu’s precursor (400 mg, 1.19 mmol) and the mixture was dissolved in EtOH (6 
mL). The mixture was stirred overnight and then filtered through celite. Removal of the 
solvent under vacuum afforded compound 27 (366 mg, 1.17 mmol) in 98% yield. 
HR-ESI-MS calculated for C24H32N2O7 (M+Na)
+
 335.1943750, found 335.1941285. 
 
Ethyl (3R,4R,5S)-4-acetylamino-5-N-(tert-Butoxycarbonyl)-amino-3-(1-
ethylpropoxy)-1-cyclohexene-1-carboxylate (28). 
 
 
 
 
 
 
Under an atmosphere of dry nitrogen, Tamiflu’s precursor (200 mg, 0.59 mmol) was 
dissolved in dry THF, PMe3 was added (0.65 mL of 1M solution in THF, 0.65 mmol) 
and the mixture was stirred at room temperature for 2 hours. When TLC indicated the 
absence of starting material, the mixture was cooled to -16°C and a solution of 2-(tert-
Butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON, 160 mg, 0.65 mmol) in THF 
(1 mL) was added via cannula. The mixture was then stirred for 3.5 hours, during which 
it was allowed to come to room temperature. Water (6 mL) was added and the solution 
was stirred for additional few minutes. The solution was extracted with EA (30 mL) and 
then washed with saturated aqueous NaCl (2x20 mL), the organic phase was dried over 
MgSO4, concentrated and the residue was purified by flash chromatography (Tol:EA; 
5:1 -> 1:1) to afford compound 28 (175 mg, 0.42 mmol, 72%). Rf = 0.32 (Tol:EA; 1:1). 
HR-ESI-MS calculated for C21H36N2O6 (M+Na)
+
 435.2471280, found 435.2465580. 
  
O
AcHN
NH
2
O
OEt
O
AcHN
NH
O
OEt
O
O
101 
 
Ethyl (3R,4R,5S)-4-acetylamino-5-N-(benzyloxycarbonyl)-amino-3-(1-
ethylpropoxy)-1-cyclohexene-1-carboxylate (29). 
 
 
 
 
 
 
Under an atmosphere of dry nitrogen, Tamiflu’s precursor (50 mg, 0.15 mmol) was 
dissolved in dry THF, PMe3 was added (0.16 mL of 1M solution in THF, 0.16 mmol) 
and the mixture was stirred at room temperature for 2 hours. When TLC indicated the 
absence of starting material, the mixture was cooled to -16°C and a solution of benzyl 
chloroformate (420 µL, 2.95 mmol) in THF (1 mL) was added via cannula. The mixture 
was then stirred for 3.5 hours, during which it was allowed to come to room 
temperature. A few milliliters (5 mL) of semi-saturated NaHCO3 were added and the 
solution was stirred for additional few minutes. The solution was extracted with CH2Cl2 
(20 mL) and then washed with saturated aqueous NaCl (2x10 mL). The organic phase 
was dried over MgSO4, concentrated and the residue was purified by flash 
chromatography (Tol:EA; 5:1 -> 1:1) to afford compound 29 (35 mg, 0.08 mmol, 35%). 
Rf = 0.29 (Tol:EA; 1:1). 
HR-ESI-MS calculated for C24H34N2O6 (M+Na)
+
 469.2315650, found 469.2309079. 
 
Ethyl (3R,4R,5S)-4-acetylamino-5-N-(9-fluorenylmethoxycarbonyl)-amino-3-(1-
ethylpropoxy)-1-cyclohexene-1-carboxylate (30). 
 
 
 
 
 
 
Under an atmosphere of dry nitrogen, Tamiflu’s precursor (50 mg, 0.15 mmol) was 
dissolved in dry THF, PMe3 was added (0.22 mL of 1M solution in THF, 0.22 mmol) 
and the mixture was stirred at room temperature for 2 hours. When TLC indicated the 
absence of starting material, the mixture was cooled to -16°C and a solution of 
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FMOCCl (191 mg, 0.74 mmol) in THF (1 mL) was added via cannula. The mixture was 
then stirred overnight, during which it was allowed to come to room temperature. A few 
milliliters (5 mL) of semi-saturated NaHCO3 were added and the solution was stirred 
for additional few minutes. The solution was extracted with EA (15 mL) and 
subsequently washed with saturated aqueous NaCl (2x10 mL). The organic phase was 
dried over MgSO4, concentrated and the residue was purified by flash chromatography 
(Tol:EA; 5:1 -> 1:1) to afford compound 30 (21 mg, 0.05 mmol, 27%). 
HR-ESI-MS calculated for C31H38N2O6 (M+Na)
+
 557.2622300, found 557.2622081. 
 
(3R,4R,5S)-4-acetylamino-5-trifluoroacetylamino-3-(1-ethylpropoxy)-1-
cyclohexene-1-carboxylic acid (31). 
 
 
 
 
 
 
Under an atmosphere of dry nitrogen, (3R,4R,5S)-4-acetylamino-5-azido-3-(1-
ethylpropoxy)-1-cyclohexene-1-carboxylic acid (50 mg, 0.15 mmol) was dissolved in 
dry THF, PMe3 was added (0.18 mL of 1M solution in THF, 0.177 mmol) and the 
mixture was stirred at room temperature for 2 hours. When TLC indicated the absence 
of starting material, the mixture was cooled to -16°C and a solution of trifluoroacetic 
anhydride (103 µL, 0.74 mmol) in THF (1 mL) was added via cannula. The mixture was 
then stirred for 3.5 hours, during which it was allowed to come to room temperature. A 
few milliliters (5 mL) of semi-saturated NH4Cl were added and the solution was stirred 
for additional few minutes. EA (15 mL) was added and the solution was extracted with 
saturated aqueous NaCl (2x10 mL), the organic phase was dried over MgSO4, 
concentrated and the residue was purified by flash chromatography (Tol:EA; 5:1 -> 1:1) 
to afford compound 30 (26 mg, 0.05 mmol, 33%). Rf = 0.09 (Tol:EA; 3:1). 
HR-ESI-MS calculated for C16H23F3N2O5 (M+Na)
+
 403.1454850, found 403.1451275. 
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(3R,4R,5S)-4-acetylamino-5-N-tert-Butoxycarbonyl-amino-3-(1-ethylpropoxy)-1-
iodocyclohexene (32) 
 
 
 
 
Under an atmosphere of dry nitrogen, the azido compound 25 (236 mg, 0.6 mmol) was 
dissolved in dry THF, PMe3 was added (0.661 mL of 1M solution in THF, 0.66 mmol) 
and the mixture was stirred at room temperature for 1 hour. When TLC indicated the 
absence of starting material, the mixture was cooled to -16°C and a solution of 2-(tert-
Butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON, 222 mg, 0.9 mmol) in THF (1 
mL) was added via cannula. The mixture was then stirred for 3.5 hours, during which it 
was allowed to come to room temperature. Water (2 mL) was added and the solution 
was stirred for additional few minutes. The solution was extracted with CH2Cl2 (30 mL) 
and then washed with saturated aqueous NaCl (2x20 mL). The organic phase was dried 
over MgSO4, concentrated and the residue was purified by flash chromatography 
(Tol:EA; 5:1 -> 1:1) to afford compound 32 (202 mg, 0.43 mmol, 72%) as a pale yellow 
crystalline solid. Rf = 0.39 (Tol:EA; 1:1). 
1
H NMR (600 MHz, CDCl3) δH 6.31 (s, 1H, H-2), 5.51 (bd, J = 8.1 Hz, 1H, NHAc), 
5.25 (bd, J = 8.1 Hz, 1H, NHBoc), 4.10-4.05 (m, 1H, H-4), 3.85-3.79 (m, 1H, H-5), 
3.76 (bs, 1H, H-3), 3.28 (bs, 1H, pentyl-CH), 2.85 (bd, J = 17.9, 1H, H-6), 2.60 (dd, J = 
17.4, 7.5 Hz, 1H, H-6’), 1.96 (s, 3H), 1.51-1.43 (m, 4H, 2 pentyl-CH2), 1.40 (s, 9H), 
0.86 (m, 6H, 2 pentyl-CH3). 
13
C NMR (150.9 MHz, CDCl3) δC 170.9, 156.2, 138.2 (C-2), 95.1 (C-1), 82.2 (pentyl-
CH), 79.9, 77.8, (C-3), 53.3 (C-4), 50.6 (C-5), 45.2 (C-6), 28.6, 26.3, 26.0 (2 pentyl-
CH2), 23.5, 9.7, 9.5 (2 pentyl-CH3).  
HR-ESI-MS calculated for C18H31IN2O4 (M+Na)
+
 489.1238250, found 489.1220716. 
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Dimethyl (3R,4R,5S)-4-acetylamino-5-N-tert-Butoxycarbonyl-amino-3-(1-
ethylpropoxy)-1-cyclohexene-1-phosphonate (33) 
 
 
 
 
 
Under an atmosphere of dry nitrogen, tetrakistriphenylphosphine palladium (230 mg, 
0.2 mmol) and vinyl iodide 32 (620 mg, 1.33 mmol) were dissolved in anhydrous 
toluene (10 mL). Triethylamine (0.74 mL, 5.32 mmol) and dimethylphosphite (0.49 mL, 
5.32 mmol) were added to the solution and the mixture was stirred at 75 °C for 90 
minutes. After cooling to room temperature, the reaction was quenched by addition of 
saturated aqueous NH4Cl (10 mL). CH2Cl2 (50 mL) was added and the organic phase 
was extracted with NH4Cl (10 mL), washed with brine (2x10 mL), dried over MgSO4 
and evaporated. Purification by flash chromatography (EA:MeOH; 1:0 -> 6:1) gave the 
desired vinyl phosphonate 33 in 80% yield as a white glassy solid. Rf = 0.42 
(EA:MeOH; 6:1). 
1
H NMR (600 MHz, CDCl3) δH 6.58 (d, JP-2 = 22.1 Hz, 1H, H-2), 5.88 (d, J = 9.4 Hz, 
1H, NHAc), 5.12 (d, J = 9.2 Hz, 1H, NHBoc), 4.07-4.00 (m, 1H, H-4), 3.90 (bs, 1H, H-
3), 3.80-3.72 (m, 1H, H-5), 3.69 (d, J = 10.8 Hz, 3H, OCH3), 3.68 (d, 3H, J = 10.8 Hz, 
OCH3), 3.32 (m, 1H, pentyl-CH), 2.57 (m, 1H, H-6), 2.18 (m, 1H, H-6’), 1.95 (s, 3H, 
COCH3), 1.51-1.42 (m, 4H, 2 pentyl-CH2), 1.38 (s, 9H, C(CH3)3), 0.85-0.84 (m, 6H, 2 
pentyl-CH3). 
13
C NMR (150.9 MHz, CDCl3) δC 171.0, 156.4, 142.6 (d, JP-2 = 8.1 Hz, C-2), 126.6 (d, 
JP-1 = 182.9 Hz, C-1), 82.4 (pentyl-CH), 79.9, 76.3 (d, JP-3 = 22.2 Hz, C-3), 54.5 (C-4), 
52.8, (d, J = 6.4 Hz, OCH3), 52.7 (d, J = 6.1 Hz, OCH3), 49.4 (d, JP-5 = 14.2 Hz, C-5), 
31.4 (d, JP-6 = 9.5 Hz, C-6), 28.5, 26.3, 25.8 (2 pentyl-CH2), 23.5, 9.7, 9.3 (2 pentyl-
CH3). 
31
P NMR (161.9 MHz, CDCl3) δP 19.58.  
HR-ESI-MS calculated for C20H37N2O7P (M+Na)
+
 471.2260180, found 471.2230592. 
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Methyl [(3R,4R,5S)-4-acetylamino-5-N-tert-Butoxycarbonyl-amino-3-(1-
ethylpropoxy)-1-cyclohexene]-1-phosphonic acid (34) 
 
 
 
 
Phosphonate 33 (100 mg, 0.22 mmol) was dissolved in dioxane (2 mL), NaOH-solution 
(0.25M, 2 mL) was added and the mixture was stirred overnight at room temperature, 
neutralised with Amberlite IR-120 (H+) and lyophilised. Purification by flash 
chromatography (EA:MeOH; 6:1 -> 1:2) yielded phosphonic acid 34 (93 mg, 0.21 
mmol) in 96% yield as a white solid. Rf = 0.21 (CH2Cl2:MeOH, 2:1). The product can 
be converted to the ammonium salt by lyophilisation from 0.1 M (NH4HCO3-solution). 
1
H NMR (500 MHz, D2O) δH 6.38 (d, JP-2 = 19.8 Hz, 1H, H-2), 4.30 (bd, J = 6.8 Hz, 
1H, H-3), 3.89 (dd, J = 10.1 Hz, 1H, H-4), 3.80 (m, 1H, H-5), 3.64-3.54 (m, 1H, pentyl-
CH), 3.58 (d, J = 10.6 Hz, 3H, OCH3), 2.61 (m, 1H, H-6), 2.30 (m, 1H, H-6’), 2.09 (s, 
3H, COCH3), 1.69-1.46 (m, 4H, 2 pentyl-CH2), 1.49 (s, 9H, C(CH3)3), 0.97 (t, J = 7.3 
Hz, 3H, pentyl-CH3), 0.91 (t, J = 7.3 Hz, 3H, pentyl-CH3). 
13
C NMR (125.8 MHz, D2O) δC 174.2, 157.6, 136.9 (m, C-2), 131.1 (d, JP-1 = 171.7 Hz, 
C-1), 84.1 (pentyl-CH), 81.0, 76.8 (C-3), 55.6 (C-4), 51.7 (d, J = 5.1 Hz, OCH3), 49.3 
(d, JP-5 = 14.3 Hz, C-5), 31.2 (d, JP-6 = 9.8 Hz, C-6), 27.6, 25.7, 25.3 (2 pentyl-CH2), 
22.2, 8.7, 8.6 (2 pentyl-CH3). 
31
P NMR (161.9 MHz, D2O) δP 15.3.  
HR-ESI-MS calculated for C19H35N2O7P (M+Na)
+
 457.2104680, found 457.2074091. 
 
Diammonium [(3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethylpropoxy)-1-
cyclohexene-1-phosphonate] (35) 
 
 
 
 
Under an atmosphere of dry nitrogen, compound 33 (11 mg, 0.025 mmol) was dissolved 
in dry CH2Cl2 (1 mL). Lutidine (34 μL, 0.294 mmol) and trimethylsilyl bromide (33 μL, 
0.245 mmol) were added and the mixture was stirred at room temperature for 9h. The 
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solvent was evaporated and TFA (50% in water, 2 mL) was added. After 1 hour of 
stirring at room temperature, the mixture was frozen and lyophilised. The residue was 
purified by gel permeation chromatography to afford compound 35 (7 mg, 88 %) as a 
white solid. 
1
H NMR (600 MHz, D2O) δH 6.34 (d, JP-2 = 19.5 Hz, 1H, H-2), 4.27 (bd, J = 8.9 Hz, 
1H, H-3), 4.09 (dd, J = 11.7, 8.8 Hz, 1H, H-4), 3.61-3.54 (m, 2H), 2.87-2.82 (ddd, J = 
17.0, 7.9, 5.4 Hz ,1H, H-6ax), 2.55-2.49 (ddddd, J = 17.0, 10.7, 5.9, 2.9 Hz, 1H, H-6eq), 
2.11 (s, 3H), 1.63-1.55 (m, 3H), 1.52-1.45 (m, 1H), 0.92 (t, J = 7.5 Hz, 3H), 0.87 (t, J = 
7.5 Hz, 3H). 
13
C NMR (150.9 MHz, D2O) δC 175.1, 134.1 (d, JP-2 = 6.9 Hz, C-2), 132.1 (d, JP-1 = 
173.5 Hz, C-1), 84.3 (pentyl-CH), 75.9 (d, JP-3 = 18.4 Hz, C-3), 52.9 (C-4), 49.7 (d, JP-5 
= 13.2 Hz, C-5), 29.2 (d, JP-6 = 10.8 Hz, C-6), 25.4, 25.1 (2 pentyl-CH2), 22.3, 8.5, 8.4 
(2 pentyl-CH3). 
31
P NMR (161.9 MHz, D2O) δP 10.24.  
HR-ESI-MS calculated for C13H25N2O5P (M+H)
+
 321.1573660, found 321.1573849. 
HR-ESI-MS calculated for C13H25N2O5P (M+Na)+ 343.1398270, found 343.1393295. 
HR-ESI-MS calculated for C13H25N2O5P (2M+Na)+ 663.2897800, found 663.2894380. 
 
Ammonium [methyl (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethylpropoxy)-1-
cyclohexene-1-phosphonate] (36) 
 
 
 
 
Compound 34 (44 mg, 0.101 mmol) was dissolved in aqueous TFA (50%, 4 mL) and 
the mixture was stirred at room temperature for 2 hours. Following lyophilisation, the 
residue was purified by gel permeation chromatography and again lyophilised to afford 
compound 36 (13 mg, 0.04 mmol) as a white solid in 40% yield. 
1
H NMR (500 MHz, D2O) δH 6.44 (d, JP-2 = 19.3 Hz, 1H, H-2), 4.34 (bd, J = 9.7 Hz, 
1H, H-3), 4.11 (dd, J = 10.0 Hz, 1H, H-4), 3.65-3.56 (m, 2H, H-5, pentyl-CH), 3.59 (d, 
J = 10.8 Hz, 3H, OCH3), 2.83 (m, 1H, H-6), 2.50 (m, 1H, H-6’), 2.16 (s, 3H, COCH3), 
1.69-1.49 (m, 4H, 2 pentyl-CH2), 0.97 (t, 3H, pentyl-CH3), 0.93 (t, 3H, pentyl-CH3). 
13
C NMR (500 MHz, D2O) δC 175.1, 137.0-136.8 (m, C-2), 129.4 (d, JP-1 = 173.2 Hz, 
C-1), 84.2 (pentyl-CH), 76.0 (d, JP-3 = 18.9 Hz, C-3), 53.2 (C-4), 51.8-51.7 (m, OMe), 
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49.6 (d, JP-5 = 13.8 Hz, C-5), 29.5 (d, JP-6 = 12.1 Hz, C-6), 25.5, 25.2 (2 pentyl-CH2), 
22.3, 8.6, 8.5 (2 pentyl-CH3). 
31
P NMR (161.9 MHz, D2O) δP 14.17.  
HR-ESI-MS calculated for C14H27N2O5P (M+Na)
+
 357.1562790, found 357.1549796. 
 
Methyl 1-hexyl (3R,4R,5S)-4-acetylamino-5-N-tert-Butoxycarbonyl-amino-3-(1-
ethylpropoxy)-1-cyclohexene-1-phosphonate (38) 
 
 
 
 
 
Synthesis of hexyl triflate 37: Under an atmosphere of dry nitrogen, hexanol (191 μL, 
1.52 mmol) was dissolved in anhydrous toluene (5 mL), NEt3 (274 μL, 1.97 mmol) was 
added with stirring and the mixture was cooled to -20°C. Triflic acid anhydride (305 μL, 
1.82 mmol), dissolved in anhydrous toluene (5 mL) was added in portions to the 
mixture which was stirred for 1 hour and then allowed to warm up to room temperature. 
The colourless upper layer formed was evaporated to give an oil (hexyl triflate) which 
was used without further purification. The purity of 37 was confirmed by NMR. 
Alkylation: 
Compound 34 (26 mg, 0.06 mmol) was converted to its triethyl ammonium salt by 
dilution in distilled water (1 mL), addition of a few drops of NEt3, stirring for 10 min, 
and lyophilisation to give a white solid. The triethyl ammonium salt of compound 34 
was dissolved in anhydrous DMF (1 mL) and hexyl-triflate 37 (50 μL) was added to the 
solution via a syringe. The mixture was stirred for 24 hours at room temperature. 
Following evaporation of the solvent, the residue was purified by flash chromatography 
(Tol:EA; 1:1 -> 0:1) to give compound 38 (15.5 mg, 0.03 mmol) as mixture of 
diastereomers in 50% yield. Rf = 0.13 (EA).  
1
H NMR (600 MHz, CDCl3) δH 6.58 (d, JP-2 = 21.7 Hz, 1H, H-2), 5.65 (bd, J = 8.3 Hz, 
1H, NHAc), 5.00 (m, 1H, NHBoc), 4.13-3.92 (m, 3H, H-4, POCH2-), 3.82-3.75 (m, 1H, 
H-5), 3.69, 3.67 (2d, J = 7.3 Hz, 3H, OCH3), 3.31 (m, 1H, pentyl-CH), 2.58 (m, 1H, H-
6), 2.17 (m, 1H, H-6’), 1.96 (s, 3H, COCH3), 1.67-1.60 (m, 2H), 1.52-1.44 (m, 4H), 
1.40 (s, 9H, C(CH3)3), 1.37-1.21 (m, 6H), 0.89-0.83 (m, 9H). 
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13
C NMR (150.9 MHz, CDCl3, 2 sets of signals) δC 171.0 (2s), 156.5 (2s), 142.1 (2d, JP-
2 = 7.0 Hz, C-2), ~127.1 (2d, JP-1 = 183.7 Hz, C-1), 82.3 (pentyl-CH), 80.0, 76.5 (2d, JP-3 
= 21.7 Hz, C-3), 66.5 (2d, J = 5.9 Hz, -OCH2-), 60.6, 54.7 (2s, C-4), 52.7 (2d, J = 6.0 
Hz, POMe), 49.4 (2d, JP-5 = 6.8 Hz, C-5), 31.5 (2s, C-6), 30.65 (2d, J = 6.1 Hz), 29.9, 
28.5, 26.3, 25.8 (2 pentyl-CH2), 25.4, 23.6, 22.7, 14.2, 9.8, 9.3 (2 pentyl-CH3). 
31
P NMR (242.9 MHz, CDCl3) δP 18.07, 18.05.  
HR-ESI-MS calculated for C25H47N2O7P (M+Na)
+
 541.3032520, found 541.3013095. 
 
1-hexyl [(3R,4R,5S)-4-acetylamino-5-N-tert-Butoxycarbonyl-amino-3-(1-
ethylpropoxy)-1-cyclohexene]-1-phosphonic acid (39) 
 
 
 
 
 
Under atmosphere of dry nitrogen, compound 38 (12 mg, 0.023 mmol) was dissolved in 
anhydrous THF (1 mL) and anhydrous NEt3 (46 μL, 0.32 mmol) and thiophenol (17 μL, 
0.16 mmol) were added to the solution. After 48 hours of stirring at room temperature, 
the same amounts of anhydrous NEt3 (46 μL, 0.32 mmol) and thiophenol (17 μL, 0.16 
mmol) were added and the mixture was stirred for additional 24 h. Following 
evaporation of the solvent, purification by flash chromatography (EA:MeOH, 3:1 -> 
1:2) afforded the monoester 39 (8.5 mg, 0.017 mmol) in 72% yield. Analysis by NMR 
indicated the absence of the methyl ester signal.  
HR-ESI-MS calculated for C24H45N2O7P (M+Na)
+
 527.2860840, found 527.2856594.  
 
Ammonium [1-hexyl (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethylpropoxy)-1-
cyclohexene-1-phosphonate] (40) 
 
 
 
 
 
The monoester 39 (7 mg, 0.0139 mmol) was dissolved in aqueous TFA (50%, 1 mL) 
and the mixture was stirred at room temperature for 2 hours, followed by lyophilisation. 
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The residue was purified by gel permeation chromatography to afford compound 40 in 
68% yield. 
1
H NMR (500 MHz, D2O) δH 6.42 (d, JP-2 = 19.4 Hz, 1H, H-2), 4.33 (bd, J = 9.0 Hz, 
1H, H-3), 4.10 (dd, J = 11.6 Hz, 8.9 Hz, 1H, H-4), 3.92-3.85 (m, 2H, OCH2), 3.64-3.57 
(m, 2H, H-5, pentyl-CH), 2.85 (m, 1H, H-6), 2.52 (m, 1H, H-6’), 2.16 (s, 3H, COCH3), 
1.74-1.48 (m, 6H), 1.48-1.33 (m, 6H), 1.01-0.89 (m, 9H). 
13
C NMR (125.8 MHz, D2O) δC 175.1, 136.1 (d, J = 7.0 Hz, C-2), 130.2 (d, J = 174.0 
Hz, C-1), 84.0 (pentyl-C), 75.9 (d, J = 19.6 Hz, C-3), 65.3 (d, J = 5.5 Hz, OCH2), 53.1 
(C-4), 49.7 (d, J = 14.2 Hz, C-5), 30.7, 29.9 (d, J = 6.6 Hz), 29.5 (d, J = 10.9 Hz, C-6), 
25.5, 25.1, 24.7, 22.3, 21.8, 13.3, 8.6, 8.5 (2 pentyl-CH3). 
31
P NMR (161.9 MHz, D2O) δP 12.55. 
HR-ESI-MS calculated for C19H37N2O5P (M+Na)
+
 427.2327960, found 427.2332299. 
 
Methyl 6-O-(tert-butyldiphenylsilyl)-3,4-O-isopropylidene-2-O-methoxymethyl-β-
D-galactopyranoside (41). 
 
 
 
 
Methyl 6-O-(tert-butyldiphenylsilyl)-3,4-O-isopropylidene-ß-D-galactopyranoside
[177]
 
(516 mg, 1.09 mmol) was dissolved in dry THF (4 mL) and the solution was cooled to -
20°C. Subsequently, NaH (32 mg, 1.31 mmol), suspended in dry THF (3 mL) and 
MOMCl (100 μL, 1.31 mmol) were added dropwise, the mixture was stirred overnight 
and allowed to come up to room temperature. The reaction was quenched by addition of 
saturated aqueous NH4HCO3 (10 mL). CH2Cl2 (40 mL) was added to the solution which 
was then extracted with NH4HCO3 (10 mL), washed with brine (2x10 mL), the organic 
phase was dried over MgSO4 and the solvent evaporated. Purification by flash 
chromatography (Tol:EA, 1:0 -> 10:1) gave compound 41 (531 mg, 1.03 mmol) in 94% 
yield as a colorless oil. Rf = 0.34 (Tol:EA, 10:1).  
1
H NMR (500 MHz, CDCl3) δH 7.71-7.61 (m, 4H, TBDPS), 7.44-7.33 (m, 6H, TBDPS), 
4.84, 4.74 (2d, J = 6.2 Hz, 2H, methoxymethyl-CH2), 4.23 (bd, J = 5.1 Hz, 1H, H-4), 
4.13 (d, J = 8.3 Hz, 1H, H-1), 4.09 (dd, 1H, H-3), 3.99-3.89 (m, 2H, H-6, H-6’), 3.82 
(dd, 1H, H-5), 3.58 (dd, 1H, H-2), 3.47 (s, 3H, methoxymethyl-CH3), 3.41 (s, 3H, 
OCH3), 1.50, 1.33 (2s, C(CH3)2), 1.04 (s, 9H, C(CH3)3). 
O
O
O
TBDPSO
O
O
OMe
110 
 
13
C NMR (125.8 MHz, CDCl3) δC 135.8 (2s), 133.5, 133.4, 129.9, 127.9, 127.8, 109.8, 
103.4 (C-1), 96.2 (methoxymethyl-CH2), 78.8 (C-3), 76.0 (C-2), 73.4 (C-4), 73.3 (C-5), 
62.8 (C-6), 56.5 (OCH3), 55.4 (methoxymethyl-CH3), 27.8, 26.7, 26.4, 19.2.  
HR-ESI-MS calculated for C28H40O7Si (M+Na)
+
 539.2428640, found 539.2435513. 
 
Methyl 3,4-O-isopropylidene-2-O-methoxymethyl-β-D-galactopyranoside (42) 
 
 
 
 
 
Compound 41 (444 mg, 0.883 mmol) and TBAF (334 mg, 1.06 mmol) were dissolved 
in dry THF (10 mL) and the mixture was stirred overnight at room temperature. 
Evaporation of the solvent and purification by flash chromatography (Tol:EA, 5:1 -> 
0:1) gave compound 42 (220 mg, 0.814 mmol) in 92% yield. Rf = 0.45 (EA). 
1
H NMR (500 MHz, CDCl3) δH 4.85, 4.75 (2d, J = 6.4 Hz, 2H, methoxymethyl-CH2), 
4.16 (d, J = 8.0 Hz, 1H, H-1), 4.14-4.09 (m, 2H, H-3, H-4), 3.96 (m, 1H, H-6), 3.81 (m, 
2H, H-5, H-6’), 3.58 (dd, J = 7.8 Hz, 6.4 Hz, 1H, H-2), 3.50 (s, 3H, methoxymethyl-
CH3), 3.39 (s, 3H, OCH3), 2.17 (bdd, J = 8.5, 3.5 Hz, 1H, OH), 1.49, 1.31 (2s, 
C(CH3)2). 
13
C NMR (125.8 MHz, CDCl3) δC 110.5, 103.7 (C-1), 96.4 (methoxymethyl-CH2), 79.1 
(C-3 or C-4), 76.1 (C-2),74.3 (C-3 or C-4), 73.3 (C-5), 62.7 (C-6), 57.0, 55.7, 28.0, 
26.7. 
HR-ESI-MS calculated for C12H22O7 (M+Na)
+
 301.1255650, found 301.1257742. 
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Methyl (methyl 3,4-O-isopropylidene-2-O-methoxymethyl-β-D-galactopyranos-6-
yl) [(3R,4R,5S)-4-acetamido-3-amino-3-(1,1-dimethylethyloxycarbonylamino)-5-(1-
ethylpropoxy)-1-cyclohexene-1-phosphonate] (44). 
 
 
 
 
 
 
Synthesis of Methyl 3,4-O-isopropylidene-2-O-methoxymethyl-6-O-
trifluoromethanesulfonyl-β-D-galactopyranoside (galactose triflate) 43: 
Under an atmosphere of dry nitrogen, alcohol 42 (146 mg, 0.54 mmol) was dissolved in 
dry CH2Cl2 (2 mL), lutidine (125 μL, 1.08 mmol) was added and the mixture was stirred 
for a few minutes before being cooled to -30°C. Triflic anhydride, dissolved in dry 
CH2Cl2 (1 mL) was added to the mixture via syringe and the mixture was stirred for 2 
hours at this temperature. CH2Cl2 (5 mL) was added and the mixture was subsequently 
extracted with NH4HCO3-solution (2x3 mL) and KH2PO4-solution (2x3 mL). The 
organic phase was dried over MgSO4 and the solvent was evaporated. The residue was 
purified on a short pad of silica flushed with CH2Cl2 to give triflate 43 (228 mg, 0.565 
mmol) in 98% yield. The purity of 43 was confirmed by NMR. 
Alkylation:  
Compound 34 (50 mg, 0.115 mmol) was converted to its triethyl ammonium salt by 
dilution in distilled water (1 mL), addition of a few drops of NEt3, stirring for 10 min 
and lyophilization to give a white solid. The salt was dissolved in anhydrous DMF (0.5 
mL) and galactose-triflate 43 (71 mg, 0.173 mmol), dissolved in anhydrous DMF (0.5 
mL) was added. The mixture was stirred for 48 hours at room temperature. Following 
evaporation of the solvent, the residue was purified by flash chromatography ( 
EA:MeOH, 1:0 -> 10:1) to give compound 44 (22 mg, 0.032 mmol) as a white solid in 
28% yield. Rf = 0.41 (EA:MeOH, 10:1). Approximately 50 % of unreacted starting 
material (phosphonate 34) could be recovered.  
1
H NMR (500 MHz, CD3OD) δH 6.70, 6.68 (2d, JP-2 = 22.4 Hz, 1H, H-2a (h,l)), 6.51 (d, 
1H, NH), 4.90, 4.76 (2d, J = 6.3 Hz, 2H, methoxymethyl-CH2), 4.35-4.25, 4.25-4.12 
(2m, 7H, H-3a, H-1b, H-3b, H-4b, H-5b, H-6b, H-6b’), 3.94 (m, 1H, H-4a), 3.85 (d, J = 
11.1 Hz, 3H, POCH3), 3.81 (m, 1H, H-5a), 3.60 (m, 1H, H-2b), 3.57, 3.56 (2s, 3H, 
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methoxymethyl-CH3(h,l)), 3.49 (m, pentyl-CH), 3.46 (s, 3H, OCH3), 2.64 (m, 1H, H-
6a), 2.32 (m, 1H, H-6a’), 2.03 (s, 3H, COCH3), 1.65-1.54 (m, 4H, 2 pentyl-CH2), 1.56, 
1.40 (2s, 6H, C(CH3)2), 1.50 (s, 9H, C(CH3)3), 0.99 (t, 3H, pentyl-CH3), 0.95 (t, 3H, 
pentyl-CH3). 
13
C NMR (125.8 MHz, CD3OD) δC 173.9, 158.1, 144.82 (2d, JP-1 = 6.9 Hz, C-2a), 
111.5, 104.8 (C-1b), 97.2 (d, methoxymethyl-CH2), 83.9 (d, pentyl-CH), 80.5, 80.2, 
77.5 (d, J = 21.0 Hz, C-3a), 77.3 (C-2b), 74.9, 72.9 (2d), 66.4 (2d), 57.3 (d, POCH3), 
56.3 (d, C-4a), 55.9 (-OCH3), 53.7 (methoxymethyl-CH3), 50.6 (C-5a), 32.2 (C-6a), 
28.9, 28.3, 27.4, 26.9, 26.8 (2 pentyl-CH3), 23.1, 10.05, 9.7 (2 pentyl-CH3). 
31
P NMR (161.9, CD3OD) δP 19.11. 
HR-ESI-MS calculated for C31H55N2O13P (M+Na)
+
 717.3359900, found 717.3333975. 
 
(methyl 3,4-O-isopropylidene-2-O-methoxymethyl-β-D-galactopyranos-6-yl) 
[(3R,4R,5S)-4-acetylamino-5-N-tert-Butoxycarbonyl-amino-3-(1-ethylpropoxy)-1-
cyclohexene]-1-phosphonic acid (45) 
 
 
 
 
 
 
Under atmosphere of dry nitrogen, compound 44 (22 mg, 0.032 mmol) was dissolved in 
anhydrous THF (1 mL) and anhydrous NEt3 (14 equiv, 62 μL) and thiophenol (7 equiv, 
23 μL) were added to the solution. After 48 hours of stirring at room temperature, the 
same amounts of anhydrous NEt3 (14 equiv) and thiophenol (7 equiv) were added and 
the mixture was stirred for additional 24 h. After evaporation of the solvent, purification 
by flash chromatography (EA:MeOH, gradient 5:1 -> 1:1) afforded the monoester 45 in 
70% yield. Rf = 0.14 (EA:MeOH, 10:1). Analysis by NMR indicated the absence of the 
methyl ester signal. 
31
P NMR (161.9, CD3OD) δP 11.45. 
HR-ESI-MS calculated for C30H53N2O13P (M+Na)
+
 703.3170980, found 703.3177474. 
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(Methyl -β-D-galactopyranos-6-yl) [(3R,4R,5S)-4-acetamido-3-amino-5-(1-
ethylpropoxy)-1-cyclohexene-1-phosphonate] (46) 
 
 
 
 
 
 
The monoester 45 (12 mg, 0.0176 mmol) was dissolved in aqueous TFA (50%, 2 mL) 
and the mixture was stirred at room temperature for 2 hours, followed by lyophilisation. 
The residue was purified by gel permeation chromatography to afford compound 46 (8 
mg) in 64 % yield. 
1
H NMR (600 MHz, D2O) δH 6.42 (d, JP-2 = 19.5 Hz, 1H, H-2a), 4.36 (d, J = 7.9 Hz, 1H, 
H-1b), 4.29 (bd, J = 8.8 Hz, 1H, H-3a), 4.08 (dd, J = 11.6 Hz, 9.0 Hz, 1H, H-4a), 4.00 
(d, J = 3.4 Hz, 1H, H-4b), 3.95 (dd, J = 6.5 Hz, 6.5 Hz, 1H, H-6b), 3.97-3.93 (1H, H-
5b), 3.86 (dd, 1H, H-6b’), 3.69 (dd, J = 9.9 Hz, 3.5 Hz, 1H, H-3b), 3.60 (s, 3H, OCH3), 
3.57-3.52 (m, 3H, pentyl-CH, H-5a, H-2b), 2.84 (m, 1H, H-6a), 2.52 (m, 1H, H-6a’), 
2.11 (s, 3H, COCH3), 1.63-1.45 (m, 4H, 2 pentyl-CH2), 0.92 (t, 3H, pentyl-CH3), 0.87 
(t, 3H, pentyl-CH3). 
13
C NMR (150.9 MHz, D2O) δC 175.1, 137.1 (d, J = 7.0 Hz, C-2a), 129.5 (d, J = 174.2 
Hz, C-1a), 103.8 (C-1b), 84.2 (pentyl-CH), 75.9 (d, J = 19.7 Hz, C-3a), 73.5 (d, J = 7.8 
Hz, C-6b), 72.6 (C-3b), 70.6 (C-2b), 68.1 (C-4b), 62.6 (d, J = 4.5 Hz, C-5b), 57.2 
(OCH3), 53.1 (C-4a), 49.6 (d, J = 13.9 Hz, C-5a), 29.3 (d, J = 11.5 Hz, C-6a), 25.4, 25.1 
(pentyl-CH2), 22.3 (COCH3), 8.5, 8.4 (pentyl-CH3). 
31
P NMR (161.9 MHz, D2O) δP 13.0. 
HR-ESI-MS calculated for C20H37N2O10P (M+H)
+
 497.2269930, found 497.2258584. 
HR-ESI-MS calculated for C20H37N2O10P (M+Na)
+
 519.2067700, found 519.2078030. 
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Methyl 2-O-methoxymethyl-3-O-allyl-4,6-O-benzylidene-β-D-galactopyranoside 
(47) 
 
 
 
 
To a solution of Methyl 3-O-allyl-4,6-O-benzylidene-β-D-galactopyranoside (0.514 g, 
1.59 mmol) in dry THF (4 mL), cooled to 0°C in an atmosphere of nitrogen, was added 
NaH (57.4 mg, 2.39 mmol) as a suspension in dry THF (3mL). The mixture was stirred 
for 15 min and then cooled to -20°C. MOMCl (157 µL, 2.07 mmol) was added 
dropwise, the mixture was allowed to warm up to room temperature and stirred 
overnight. The reaction was quenched by addition of saturated aqueous NH4HCO3 (5 
mL). CH2Cl2 (40 mL) was added and the mixture was extracted with NH4HCO3 (2x10 
mL), washed with brine (2x10 mL), the organic phase was dried over MgSO4 and 
evaporated. Purification of the residue by flash chromatography (Tol:EA 5:1->1:5) gave 
compound 47 (0.323 g, 0.88 mmol, 55%) as a white solid. Rf = 0.53 (Tol:EA 1:1). 
1
H NMR (500 MHz, CDCl3) δH 7.50 (2H, m), 7.36-7.31 (3H, m), 5.91 (ddd, J = 17.3, 
10.4, 5.7 Hz, 1H, allyl-CHCH2), 5.50 (s, 1H, CHPh), 5.29 (dd, J = 17.2, 1.6 Hz, 1H, 
allyl-CHCH2), 5.16 (dd, J = 10.4, 1.5 Hz, 1H, allyl-CHCH2), 4.82, 4.80 (2d, J = 6.2 Hz, 
2H, methoxymethyl-CH2), 4.29 (dd, J6,6’ = 12.3, J6,5 = 1.4 Hz, 1H, H-6), 4.25 (d, J1,2 = 
7.8 Hz, 1H, H-1), 4.21-4.11 (m, 4-H, 3H, allyl-OCH2), 4.03 (dd, J6’,6 = 12.3, J6’,5 = 1.6 
Hz, 1H, H-6’), 3.84 (dd, J2,3 = 9.7, J2,1 = 7.9 Hz, 1H, H-2), 3.53 (s, 3H, OCH3), 3.44 
(dd, J3,2 = 9.8, J3,4 = 3.6 Hz, 1H, H-3), 3.42 (s, 3H, methoxymethyl-CH3), 3.34 (s, 1H, 
H-5); 
13
C NMR (125.8 MHz, CDCl3) δC 138.01, 135.17, 129.08, 128.24, 126.72, 117.34, 
104.22 (C-1), 101.52 (Ph-CH), 97.65 (methoxymethyl-CH2), 79.21 (C-3), 74.46 (C-2), 
73.72 (C-4), 71.02, 69.40 (C-6), 66.61 (C-5), 56.79 (OCH3), 56.07 (methoxymethyl-
CH3); 
HR-ESI-MS calculated for C19H26O7 (M+Na)
+
 389.1575350, found 389.1570743. 
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Methyl 2-O-methoxymethyl-4,6-O-benzylidene-β-D-galactopyranoside (48) 
 
 
 
 
 
A mixture of compound 47 (0.316 g, 0.86 mmol), NaOAc (0.212 g, 2.59 mmol) and 
PdCl2 (0.168 g, 0.95 mmol) in AcOH (4 mL) and H2O (0.4 mL) was stirred for 5 hours 
at room temperature. The reaction mixture was evaporated in vacuo. The residue was 
dissolved in CH2Cl2 (20 mL) and washed successively with saturated aqueous NaHCO3 
(10 mL) and H2O (10 mL), the organic phase was dried over MgSO4 and evaporated to 
dryness. Purification of the residue by flash chromatography (Tol:EA ; 3:1 -> 1:3) gave 
compound 48 (0.194 g, 0.595 mmol, 69%). Rf = 0.17 (Tol:EA 1:1). 
1
H NMR (500 MHz, CDCl3) δH 7.52-7.46 (m, 2H), 7.37-7.30 (m, 3H), 5.53 (s, 1H, 
CHPh), 4.84, 4.76 (2d, J = 6.5 Hz, 2H, methoxymethyl-CH2), 4.32 (d, J6,6’ = 12.5 Hz, 
1H, H-6), 4.25 (d, J1,2 = 6.5 Hz, 1H, H-1), 4.20 (s, 1H, H-4), 4.05 (d, J6’,6 = 12.5 Hz, 1H, 
H-6’), 3.70-3.62 (m, 2H, H-3, H-2), 3.55-3.52 (m, 3H, OCH3), 3.44-3.41 (m, 4H, H-5, 
methoxymethyl-CH3), 3.01 (bd, J = 5.4 Hz, 1H, OH); 
13
C NMR (125.8 MHz, CDCl3) δC 137.81, 129.36, 128.38, 126.74, 103.77 (C-1), 101.76 
(pentyl-CH), 97.74, 77.92 (C-3), 75.78, 72.48 (C-2, C-4), 69.30 (C-6), 66.71 (C-5), 
57.15 (OCH3), 56.03; 
HR-ESI-MS calculated for C16H22O7 (M+Na)
+
 349.1252960, found 349.1257742. 
 
Chloro(dimethyl)phosphine (49) 
 
 
 
Under an atmosphere of nitrogen, P(OMe)3 (16.2 mL, 137 mmol) was added dropwise 
to PCl3 (6 mL, 68.6 mmol) at 0°C. The colorless solution turned slightly orange as soon 
as the mixture was heated up gradually to 90°C. The mixture was stirred at 90°C for 1 
hour and 30 min. The residue was then distilled under reduced pressure (34°C, 42 Torr). 
1
H NMR (500 MHz, CDCl3) δH 3.68 (d, J = 11.1 Hz). 
31
P NMR (161.9 MHz, CDCl3) δP 169.28. 
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O-Methyl O-(methyl 2-O-methoxymethyl-4,6-O-benzylidene-β-D-galactopyranos-3-
yl) phosphonic acid (50) 
 
 
 
 
Under an atmosphere of nitrogen, compound 48 (31 mg, 0.095 mmol) was dissolved in 
dry CH2Cl2 (1 mL). N,N-diisopropyl ethyl amine (49 µL, 0.285 mmol) was added to the 
solution which was then cooled to 0°C. Chloro(dimethyl)phosphine 49 (40 µL) was 
added dropwise, the reaction mixture was allowed to come to room temperature and 
stirred overnight. Solid NaHCO3 (50 mg) was added to the reaction mixture, followed 
by MeOH (0.5 mL) and silica (50 mg). The mixture was evaporated in vacuo to 
dryness. Purification by flash chromatography (Tol:EA:MeOH 1:1:0 -> 0:10:1) gave 
compound 50 (24 mg, 0.059 mmol, 62%). Upper spot on tlc: Rf = 0.18, lower spot on 
tlc: Rf= 0.16 (EA:MeOH 20:1).  
NMR data of the isomer corresponding to the upper spot: 
1
H NMR (600 MHz, CDCl3) δH 7.51-7.48 (m, 2H), 7.32-7.36 (m, 3H), 6.93 (d, JH,P = 
717.2 Hz, 1H, H-P), 5.55 (s, 1H, CHPh), 4.87, 4.72 (2d, J = 6.3 Hz, 2H, 
methoxymethyl-CH2), 4.45-4.50 (m, 1H, H-3), 4.38 (d, J = 3.7 Hz, 1H, H-4), 4.32 (dd, 
J6,6’ = 12.4, J6,5 = 1.2 Hz, 1H, H-6), 4.28 (d, J1,2 = 7.7 Hz, 1H, H-1), 4.05 (dd, J6’,6 = 
12.5, J6’,5 = 1.6 Hz, 1H, H-6’), 3.90 (dd, J2,3 = 9.8, J2,1 = 7.7 Hz, 1H, H-2), 3.70 (d, J = 
12.1 Hz, 3H, POCH3), 3.54 (s, 3H, OCH3), 3.44 (s, 1H, H-5), 3.38 (s, 3H, 
methoxymethyl-CH3); 
13
C NMR (150.9 MHz, CDCl3) δC 137.73, 129.33, 128.40, 126.57, 104.17 (C-1), 101.43 
(benzylidene-CH), 97.64 (methoxymethyl-CH2), 76.25 (d, J3,P = 5.9 Hz, C-3), 75.85 (C-
4), 73.98 (d, J2,P = 5.7 Hz, C-2), 69.14 (C-6), 66.13 (C-5), 57.23 (OCH3), 56.42 
(methoxymethyl-CH3), 51.90 (d, J = 5.8 Hz, POCH3);  
31
P NMR (161.9 MHz, CDCl3) δP (8.19), 9.92; 
HR-ESI-MS calculated for C17H25O9P (M+Na)
+
 427.1143900, found 427.1128400. 
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Methyl (methyl 2-O-methoxymethyl-4,6-O-benzylidene-β-D-galactopyranos-3-yl) 
[(3R,4R,5S)-4-acetamido-3-(1,1-dimethylethyloxycarbonylamino)-5-(1-
ethylpropoxy)-1-cyclohexene-1-phosphonate] (51) 
 
 
 
 
 
 
 
 
The phosphinic acid 50, tetrakis triphenylphosphine palladium (7 mg, 6.3 µmol) and 
vinyl iodide 32 (20 mg, 0.042 mmol) were mixed under an atmosphere of dry nitrogen. 
The mixture was dissolved in anhydrous toluene (3 mL) and triethylamine (8.8 µL, 
0.063 mmol) was added. The mixture was stirred at 85°C for 2.5 hours. After cooling to 
room temperature, the reaction was quenched by addition of saturated aqueous NH4Cl 
(10 mL). CH2Cl2 (15 mL) was added to the solution which was then extracted with 
NH4Cl (5 mL), washed with brine (2x5 mL), the organic phase was dried over MgSO4 
and the solvent was evaporated. Purification by flash chromatography (Tol:EA:MeOH 
1:2:0 -> 0:10:1) gave a mixture of phosphonate diastereoisomers 51 (9 mg, 0.012 mmol, 
30%). Rf = 0.34 (EA:MeOH 10:1). The product contains a cyclohexenenyl 
diphenylphosphine oxide impurity which could be separated and characterised only 
after the following synthetic step (compound 52). 
1
H NMR (500 MHz, CDCl3) δH 6.66/6.53 (2d, J2a,P = 22 Hz, 1H, H-2a of the 2 
diastereoisomers); 
31
P NMR (161.9 MHz, CDCl3) δP 18.93/18.07 (2 diastereoisomers); 
HR-ESI-MS calculated for C35H55N2O13P (M+Na)
+
 765.3321640, found 765.3333975. 
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Diphenyl [(3R,4R,5S)-4-acetamido-3-(1,1-dimethylethyloxycarbonylamino)-5-(1-
ethylpropoxy)-1-cyclohexene] phosphine oxide (52) 
 
 
 
 
 
1
H NMR (500 MHz, CDCl3) δH 7.72-7.62 (m, 4H), 7.58-7.42 (m, 6H), 6.22 (d, J = 19 
Hz, 1H, H-2), 5.71 (d, J = 8.95 Hz, 1H, NHAc), 4.93 (d, J = 8.95 Hz, 1H, NHBoc), 
4.13-4.03 (m, 1H, H-4), 3.88 (d, J = 7.3 Hz, 1H, H-3), 3.85-3.78 (m, 1H, H-5), 3.21-
3.15 (m, 1H, H-7), 2.68-2.59 (m, 1H, H-6), 2.21-2.12 (m, 1H, H-6’), 1.94 (s, 3H, 
NHAc), 1.46-1.39 (m, 4H), 1.37 (s, 9H), 0.82 (t, J = 7.2 Hz, 3H), 0.69 (t, J = 7.2 Hz, 
3H).
 
31
P NMR (161.9 MHz, CDCl3) δP 28.12. 
HR-ESI-MS calculated for C30H41N2O5P (M+Na)
+
 563.2635950, found 563.2645300. 
 
(Methyl 2-O-methoxymethyl-4,6-O-benzylidene-β-D-galactopyranos-3-yl) 
[(3R,4R,5S)-4-acetamido-3-(1,1-dimethylethyloxycarbonylamino)-5-(1-
ethylpropoxy)-1-cyclohexene-1-phosphonate] (53) 
 
 
 
 
 
 
 
Under an atmosphere of dry nitrogen, compound 51 (8 mg; 0.011 mmol) was dissolved 
in anhydrous THF (1 mL). Anhydrous NEt3 (22 µL, 0.156 mmol) and thiophenol (8 µL, 
0.078 mmol) were added to the solution. After 48 h of stirring at room temperature, 
more anhydrous NEt3 (22 µL, 0.156 mmol) and thiophenol (8 µL, 0.078 mmol) were 
added to the mixture which was stirred for another 24 h at room temperature. After 
evaporation of the solvent, purification by flash chromatography (EA:MeOH 10:1->1:5) 
afforded compound 53 (6 mg, 8.2 µmol, 74%). 
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1
H NMR (600 MHz, CD3OD) δH 7.56-7.52 (bs, 2H), 7.38-7.33 (bs , 3H), 6.48 (d, J2a,P = 
19.8 Hz, 1H, H-2a), 5.65 (s, 1H, CHPh), 4.89-4.82 (2d, J = 5.9 Hz, 1H, methoxymethyl-
CH2), 4.41-4.36 (m, 2H, H-1b, H-4b), 4.23 (d, J6b,6b’ = 12.4 Hz, 1H, H-6b), 4.21-4.14 
(m, 2H, H-6b’, H-2b/H-3b), 4.08 (d, J = 6.7 Hz, 1H, H-3a), 3.89 (dd, J = 10.0 Hz, 1H, 
H-4a), 3.81 (dd, J = 8.7 Hz, 1H, H-2b/H-3b), 3.77-3.71 (m, 1H, H-5a), 3.57 (s, 4H, H-
5b, OCH3), 3.46 (s, 3H, methoxymethyl-CH3), 3.45-3.42 (m, 1H, pentyl-CH), 2.77-2.70 
(m, 1H, H-6a), 2.43-2.35 (m, 1H, H-6a’), 1.97 (s, 3H), 1.60-1.43 (m, 4H), 1.41 (s, 9H), 
0.95-0.88 (m, 6H); 
13
C NMR (150.9 MHz, CD3OD) δC 173.71 (NHCOCH3), 158.09 (NHCOOC(CH3)3), 
139.95, 137.66 (m, C-2a), 129.85, 129.04, 127.76, 105.40 (C-1b), 102.27 (benzylidene-
CH), 98.20 (methoxymethyl-CH2), 83.39 (pentyl-CH), 80.12, 78.10 (d, J3a,P = 19.85 Hz, 
C-3a), 77.04 (C-4b), 76.05 (d, J3b-C/2b-C,P = 5.1 Hz, C-3b/C-2b), 74.88 (d, J3b-C/2b-C,P = 
5.95 Hz, C-3b/C-2b), 70.19 (C-6b), 67.86 (C-5b), 57.31 (OCH3), 56.94 (d, J4a,P = 2.6 
Hz, C-4a), 56.64 (methoxymethyl-CH3), 51.20 (d, J5a,P = 13.6 Hz, C-5a), 32.96 (d, J6a,P 
= 9.6 Hz, C-6a), 28.91, 27.55, 26.91, 23.19, 10.44, 9.84; 
31
P NMR (161.9 MHz, CD3OD) δP 10.87; 
HR-ESI-MS calculated for C34H53N2O13P (M+Na)
+
 775.3140430, found 775.3153421. 
 
(Methyl-β-D-galactopyranos-3-yl) [(3R,4R,5S)-4-acetamido-3-amino-5-(1-
ethylpropoxy)-1-cyclohexene-1-phosphonate] (54) 
 
 
 
 
 
Compound 53 (6 mg, 8.2 µmol) was dissolved in a solution of 1:1 TFA/H2O (2 mL) and 
the mixture was stirred at room temperature for 3 hours. The mixture was lyophilized 
and the residue was purified by gel permeation chromatography to afford compound 54 
(2.5 mg, 5µmol, 61%) as a white powder after lyophilization. 
1
H NMR (600 MHz, D2O) δH 6.42 (d, J2a,P = 20.4 Hz, 1H, H-2a), 4.39 (d, J1b,2b = 8.3 
Hz, 1H, H-1b), 4.22 (d, J3a,4a = 8.5 Hz, 1H, H-3a), 4.08 (d, J4b,3b = 3.3 Hz, 1H, H-4b), 
4.02 (ddd, J3b,2b = 8.8, J3b,4b = 3.4 Hz, 1H, H-3b), 3.89 (dd, J4a,5a = 11.0, J4a,3a = 9.4 Hz, 
1H, H-4a), 3.84-3.71 (m, 3H, H-6b, H-6b’, H-5b), 3.64 (dd, J = 9.6, 8.2 Hz, 1H, H-2b), 
3.60 (s, 3H, OCH3), 3.54 (tt, J = 5.6 Hz, 1H, pentyl-CH), 3.27 (s, 1H, H-5a), 2.81-2.73 
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(m, 1H, H-6a), 2.45-2.37 (m, 1H, H-6a’), 2.10 (s, 3H, COCH3), 1.63-1.54 (m, 3H), 
1.52-1.44 (m, 1H), 0.92 (t, J = 7.4 Hz, 3H, pentyl-CH3), 0.87 (t, J2,P = 7.4 Hz, 3H, 
pentyl-CH3); 
13
C NMR (150.9 MHz, D2O) δC 174.92 (NHCOCH3), 136.77 (d, J2a,P = 7.3 Hz, C-2a), 
103.52 (C-1b), 84.08 (pentyl-CH), 81.14, 76.61 (d, J3b,P = 5.8 Hz, C-3b), 76.32 (d, J3a,P 
= 20.4 Hz, C-3a), 74.68 (C-5b), 69.66 (d, J2b,P = 5.6 Hz, C-2b), 68.35 (C-4b), 60.80 (C-
6b), 57.12 (OCH3), 49.49 (C-5a), 31.15 (C-6a), 25.45, 25.10, 22.26 (NHCOCH3), 8.51, 
8.48; 
31
P NMR (242.9 MHz, D2O) δP 13.06; 
HR-ESI-MS calculated for C19H35N2O10P (M+Na)
+
 519.2078, found 519.2062. 
 
Toluene-4-sulfonic acid 6-(triisopropylsilyloxy) hexyl ester (55) 
 
 
 
 
Under an atmosphere of dry nitrogen, 6-(Triisopropylsilyloxy) hexan-1-ol (3.86 g, 
14.06 mmol) was dissolved in dry pyridine (12 mL). DMAP (172 mg, 1.406 mmol) and 
p-toluene sulfonyl chloride (4.02 g, 21.09 mmol) were added to the solution and the 
mixture stirred a 0°C for 4 hours. The reaction was quenched by addition of saturated 
aqueous NH4Cl (5 mL). After evaporation to dryness of the mixture, the residue was 
dissolved in DCM (15 mL) which was then extracted with NH4Cl (5 mL), washed with 
brine (2x5 mL), the organic phase was dried over MgSO4 and the solvent evaporated. 
Purification by flash chromatography (Tol:EA ; 1:0 -> 10:1) gave compound 55 (4.792 
g, 0.011 mol, 80%) as an incolored oil. Rf = 0.19 (Tol). 
1
H NMR (500 MHz, CDCl3) δ  7.77 (d, J= 8.1, 3.3 Hz, 2H), 7.32 (d, J= 7.7, 2.7 Hz, 
2H), 4.04-3.96 (m, 2H), 3.65-3.57 (m, 2H), 2.43 (d, J= 3.2 Hz, 3H), 1.63 (bs, 2H), 1.46 
(bs, 2H), 1.34-1.24 (m, 4H), 1.07-0.98 (m, 21H).  
13
C NMR (150.9 MHz, CDCl3) δ 144.79, 133.58, 129.99, 128.08, 70.83, 63.39, 32.93, 
29.09, 25.47, 25.44, 21.86, 18.23, 12.23. 
HR-ESI-MS calculated for C22H40O4SSi (M+Na)
+
 451.2295600, found 451.2308781. 
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6-(triisopropylsilyloxy) hexyl thioacetate (56) 
 
 
 
Compound 55 (4.792 g, 0.011 mol) was dissolved in pyridine (65 mL), then KSAc (3.83 
g, 0.033 mol) was added to the solution. The mixture was stirred for 5 hours at room 
temperature. Pyridine was removed under high vacuum and the residue was dissolved in 
DCM (50 mL). The solution was washed with saturated aqueous NH4Cl (2x15 mL), 
NaCl (20 mL), the organic phase was dried over MgSO4 and the solvent evaporated. 
Purification by flash chromatography (Tol) afforded compound 56 (3.208 g, 0.0096 
mol, 86%) as an incolored oil. Rf = 0.46 (Tol). 
1
H NMR (500 MHz, CDCl3) δH 3.65 (t, J= 6.5 Hz, 2H), 2.85 (t, 7.3 Hz, 2H), 2.30 (s, 
3H), 1.60-1.48 (m, 4H), 1.39-1.31 (m, 4H), 1.08-1.00 (m, 21H). 
13
C NMR (150.9 MHz, CDCl3) δC 196.17, 63.53, 33.06, 30.84, 29.75, 29.36, 28.89, 
25.62, 18.26, 12.27. 
HR-ESI-MS calculated for C17H36O2SSi (M+Na)
+
 355.2095450, found 355.2097487. 
 
Thioacetate hexanol (57) 
 
 
Compound 56 (0.874 g, 2.63 mmol) was dissolved in THF (20 mL), then AcOH (1 mL) 
and TBAF (3.32 g, 10.51 mmol) were successively added. The mixture was stirred 
overnight. The solution was washed with saturated aqueous NaHCO3 (2x15 mL), NaCl 
(20 mL), the organic phase was dried over MgSO4 and the solvent evaporated. 
Purification by flash chromatography (Tol) afforded compound 57 (0.333 g, 1.889 mol, 
72%) as an incolored oil. Rf = 0.17 (Tol:EA ; 5:1). 
1
H NMR (500 MHz, CDCl3) δH 3.53 (t, J= 6.5 Hz, 2H), 2.79 (t, 7.4 Hz, 2H), 2.24 (s, 
3H), 2.10 (s, 1H, OH), 1.54-1.44 (m, 4H), 1.35-1.26 (m, 4H). 
13
C NMR (150.9 MHz, CDCl3) δC 196.23, 62.69, 32.59, 30.68, 29.53, 29.09, 28.59, 
25.32. 
HR-ESI-MS calculated for C8H16O2S (M+H20+H)
+
 195.1048370, found 195.1049416. 
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O-methyl O-(hexyl thioacetate) phosphonic acid (58) 
 
 
 
Under an atmosphere of nitrogen, compound 57 (333 mg, 1.89 mmol) was dissolved in 
dry DCM (5 mL) at 0°C. N,N-diisopropyl ethyl amine (0.99 mL, 5.67 mmol) was added 
to the solution. Chloro(dimethyl)phosphine 49 (0.6 mL) was added drop by drop, the 
reaction mixture was allowed to come up to room temperature and stirred overnight. 
Solid NaHCO3 (a spatula) was added to the reaction mixture, followed by MeOH (2 
mL) and silica (a few spatula). The mixture was evaporated to dryness. Purification by 
flash chromatography (Tol:EA ; 5:1 -> 1:3) gave compound 58 (208 mg, 0.818 mmol, 
41%) as a yellowish liquid-oil. Rf = 0.15 (Tol:EA ; 1:1). 
1
H NMR (500 MHz, CDCl3) δH 6.75 (d, J= 694.5 Hz, 1H, PH), 4.09-3.99 (m, 2H, -O-
CH2-), 3.74 (d, J= 12.4 Hz, 3H, POMe), 2.84 (t, J= 7.3 Hz, 2H, -CH2-S-), 2.29 (s, 3H), 
1.71-1.62 (m, 2H), 1.60-1.52 (m, 2H), 1.38 (s, 4H). 
13
C NMR (150.9 MHz, CDCl3) δC 196.06, 65.92 (d, J= 6.1 Hz), 52.14 (d, J= 5.6 Hz, 
POMe), 30.83 (COCH3), 30.45 (d, J= 6.2 Hz), 29.59, 29.14, 28.41, 25.23. 
31
P NMR (161.9 MHz, CDCl3) δP 9.15. 
HR-ESI-MS calculated for C9H19O4PS (M+Na)
+
 277.0629110, found 277.0633874. 
 
O-O-di(hexyl thioacetate) phosphonic acid (59) 
 
 
 
By-product 59 (83 mg, 0.208 mmol, 11%) from the formation of compound 58. 
1
H NMR (500 MHz, CDCl3) δH 6.75 (d, J= 692.8 Hz, 1H, PH), 4.08-3.96 (m, 4H, -O-
CH2-), 2.86 (t, J= 7.3 Hz, 4H, -CH2-S-), 2.28 (s, 6H), 1.69-1.62 (m, 4H), 1.58-1.50 
(m,4H), 1.36 (s, 8H). 
13
C NMR (150.9 MHz, CDCl3) δC 195.97, 65.76 (d, J= 6.0 Hz), 30.79 (COCH3), 30.42 
(d, J= 6.3 Hz), 29.56, 29.10, 28.39, 25.22. 
31
P NMR (161.9 MHz, CDCl3) δP 7.69. 
HR-ESI-MS calculated for C16H31O5PS2 (M+Na)
+
 421.1243, found 421.1240. 
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Methyl (hexyl thioacetate) [(3R,4R,5S)-4-acetamido-3-(1,1-
dimethylethyloxycarbonylamino)-5-(1-ethylpropoxy)-1-cyclohexene-1-
phosphonate] (60) 
 
 
 
 
Under an atmosphere of dry nitrogen, were added to the phosphinic acid 58, 
tetrakistriphenylphosphine palladium (14 mg, 0.012 mmol) and vinyl iodide 32 (37 mg, 
0.078 mmol). The mixture was dissolved in anhydrous toluene (3 mL), then 
triethylamine (8.8 µL, 0.063 mmol) was added. The mixture was heated to 80°C, stirred 
and maintained at this temperature for 3 hours. After cooling down at room temperature, 
the reaction was quenched by addition of saturated aqueous NH4Cl (3 mL). DCM (15 
mL) was added to the solution which was then extracted with NH4Cl (3 mL), washed 
with brine (2x3 mL), the organic phase was dried over MgSO4 and the solvent 
evaporated. Purification by flash chromatography (EA:MeOH ; 1:0 -> 5:1) gave the 
desired vinyl phosphonate 60 (17 mg, 0.0287 mmol, 36%). Rf = 0.38 (EA:MeOH ; 
20:1). 
1
H NMR (500 MHz, CDCl3) δH 6.58 (d, J= 21.8 Hz, 1H, H2), 5.76, 5.73 (2d, J= 10.0 
Hz, 1H, NHAc),  5.12, 5.06 (2d, J= 8.9 Hz, 1H, NHBoc), 4.08-3.92 (m, 3H, H4, -O-
CH2-), 3.89 (s, 1H, H3), 3.81-3.72 (m, 1H, H5), 3.68, 3.67 (2dd, J= 11.0, 1.9 Hz, 3H, 
POMe), 3.31 (bs, 1H, H7), 2.84 (t, J= 7.3 Hz, 2H, -S-CH2-), 2.62-2.54 (m, 1H, H6), 
2.29 (s, 3H, thioacetate), 2.23-2.13 (m, 1H, H6’), 1.95 (s, 3H, acetamide), 1.63 (bs, 2H), 
1.59-1.52 (m, 2H), 1.51-1.43 (m, 4H), 1.39 (s, 9H), 1.36 (bs, 4H), 0.89-0.81 (m, 6H). 
13
C NMR (150.9 MHz, CDCl3) δC 196.25, 171.01 (acetamide), 156.50 (carbamate), 
142.29 (m, C2), 82.37 (C7), 79.92, 76.52 (m, C3), 66.19 (m, -OCH2-), 54.73 (d, J= 11.8 
Hz, C4), 52.69 (2d, J= 5.9 Hz, POMe), 49.42 (2d, J= 14.2 Hz, C5), 31.49 (m, C6), 
30.84 (SCOCH3), 30.48 (m), 29.59, 29.13 (d, J= 4.2 Hz), 28.55 (Boc), 28.43 (d, J= 4.2 
Hz), 26.33, 25.79, 25.25, 23.57 (NHCOCH3), 9.77, 9.33. C1 missing. 
31
P NMR (161.9 MHz, CDCl3) δP 18.29, 18.27. 
HR-ESI-MS calculated for C27H49N2O8PS (M+Na)
+
 615.2829770, found 615.2839449. 
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I.8.3. Inhibition of neuraminidase activity of influenza viruses from 
allantoic fluid from infected eggs 
Neuraminidase (NA) enzymatic activity was studied using the fluorescent substrate 2’-
4-methylumbelliferyl-α-D-N-acetylneuraminic acid (MUNANA). Measurements were 
made at 37°C in 32.5 mM MES (pH 6.5) + 4 mM CaCl2 using a JASCO FP-6300 
fluorimeter with excitation at 365 nm and emission at 450 nm. Michaelis-Menten 
constants for enzyme, Km = (k2 + k1)/k1, were determined using standard initial rate 
measurements with estimated neuraminidase concentrations in the range 0.1 to 0.5 nM 
and MUNANA concentrations in the range 2 to 200 µM. 
Inhibition constants (Ki) were determined by measuring the extent to which different 
concentrations of inhibitor reduced the steady-state rate of MUNANA hydrolysis. The 
data were interpreted using the following simple model for competitive inhibition in 
which E, S, and I represent neuraminidase, MUNANA, and inhibitor, respectively: 
 
 
 
 
 
 
 
The reduced rate of hydrolysis of MUNANA observed in the presence of inhibitor is 
predicted by the following equation (Rameix-Welti et al.) 
 
 
 
 
Where V1 is the steady-state rate for MUNANA hydrolysis in the presence of inhibitor 
at concentration [I], V0 is the steady-state rate for MUNANA hydrolysis in the absence 
of inhibitor, [S] is the MUNANA concentration, Km is the Michaelis-Menten constant 
for hydrolysis of MUNANA and Ki is the dissociation constant for the enzyme-inhibitor 
complex. Because these inhibitors show a slow approach to the new-steady state rate 
(see Collins et al.) it is necessary to confirm that the new-steady state rate had been 
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reached; this was done by demonstrating that the first derivative of the fluorescence 
change (proportional to the NA activity) became constant at long times. 
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Appendix 1 : Crystal structures 
ORTEP-generated structure of (3R,4S,5R)-tri-acetoxy-1 
cyclohexene-1-phosphonate 9 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Crystal data and structure refinement of compound 9. 
 
Empirical formula  C14 H21 O9 P 
Formula weight  364.28 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21  (No.4) 
Unit cell dimensions a = 7.6921(3) Å  = 90°. 
 b = 8.6347(2) Å β = 91.420(1)°. 
 c = 13.5463(4) Å  = 90°. 
Volume 899.46(5) Å3 
Z 2 
Density (calculated) 1.35 Mg/m3 
Absorption coefficient 0.20 mm-1 
F(000) 384 
Crystal size 0.15 x 0.15 x 0.05 mm3 
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Theta range for data collection 3.55 to 26.71°. 
Index ranges -9<=h<=9, -10<=k<=10, -16<=l<=16 
Reflections collected 11218 
Independent reflections 3572 [R(int) = 0.069] 
Reflections with I>2sigma(I) 2817 
Completeness to theta = 26.71° 95.7 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3572 / 1 / 222 
Goodness-of-fit on F2 1.013 
Final R indices [I>2sigma(I)] R1 = 0.051, wR2 = 0.098 
R indices (all data) R1 = 0.074, wR2 = 0.107 
Absolute structure parameter 0.01(12) 
Largest diff. peak and hole 0.26 and -0.28 e.Å-3 
 
Data collection KappaCCD, Program package WinGX, Abs correction not applied,  
Refinement using SHELXL-97, Drawing using ORTEP-3 for Windows.  
 
Table 2.  Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
__________________________________________________________________ 
 x y z U(eq) 
__________________________________________________________________ 
P 3928(1) 2471(1) 3821(1) 25(1) 
O(1) 4327(3) 2441(3) 4883(2) 38(1) 
O(2) 4198(3) 862(2) 3276(2) 34(1) 
O(3) 1993(3) 2858(2) 3493(2) 33(1) 
O(4) 9170(3) 5809(2) 3457(2) 26(1) 
O(5) 9512(3) 8298(3) 3006(2) 44(1) 
O(6) 8326(3) 4079(3) 1763(2) 33(1) 
O(7) 10543(4) 5279(4) 1060(3) 71(1) 
O(8) 4626(3) 6682(2) 1701(2) 32(1) 
O(9) 4629(6) 7251(5) 110(2) 113(2) 
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C(1) 5114(4) 3844(3) 3126(2) 22(1) 
C(2) 6368(4) 4674(3) 3583(2) 23(1) 
C(3) 7419(4) 5839(4) 3036(2) 24(1) 
C(4) 7445(4) 5536(4) 1942(2) 29(1) 
C(5) 5614(4) 5281(4) 1525(2) 27(1) 
C(6) 4718(4) 3942(4) 2031(2) 29(1) 
C(7) 5893(5) 142(4) 3361(3) 45(1) 
C(8) 573(5) 2027(5) 3918(3) 50(1) 
C(9) 10095(4) 7149(4) 3375(3) 32(1) 
C(10) 11915(4) 6947(5) 3783(3) 39(1) 
C(11) 9809(5) 4099(5) 1270(3) 37(1) 
C(12) 10417(5) 2504(5) 1051(3) 49(1) 
C(13) 4153(5) 7539(5) 920(2) 41(1) 
C(14) 2984(5) 8831(5) 1182(3) 45(1) 
 
Table 3.   Bond lengths [Å] and angles [°]. 
 
P-O(1)  1.463(2) 
P-O(3)  1.578(2) 
P-O(2)  1.590(2) 
P-C(1)  1.780(3) 
O(2)-C(7)  1.446(4) 
O(3)-C(8)  1.439(4) 
O(4)-C(9)  1.364(4) 
O(4)-C(3)  1.450(4) 
O(5)-C(9)  1.193(4) 
O(6)-C(11)  1.337(4) 
O(6)-C(4)  1.452(4) 
O(7)-C(11)  1.203(5) 
O(8)-C(13)  1.334(4) 
O(8)-C(5)  1.452(4) 
O(9)-C(13)  1.192(4) 
C(1)-C(2)  1.341(4) 
C(1)-C(6)  1.508(4) 
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C(2)-C(3)  1.498(4) 
C(3)-C(4)  1.506(5) 
C(4)-C(5)  1.520(5) 
C(5)-C(6)  1.518(5) 
C(9)-C(10)  1.503(5) 
C(11)-C(12)  1.486(6) 
C(13)-C(14)  1.481(5) 
 
O(1)-P-O(3) 117.04(13) 
O(1)-P-O(2) 114.47(15) 
O(3)-P-O(2) 100.76(12) 
O(1)-P-C(1) 115.75(14) 
O(3)-P-C(1) 101.64(13) 
O(2)-P-C(1) 105.17(14) 
C(7)-O(2)-P 117.8(2) 
C(8)-O(3)-P 120.1(2) 
C(9)-O(4)-C(3) 115.7(2) 
C(11)-O(6)-C(4) 118.7(3) 
C(13)-O(8)-C(5) 117.8(3) 
C(2)-C(1)-C(6) 123.3(3) 
C(2)-C(1)-P 118.9(2) 
C(6)-C(1)-P 117.6(2) 
C(1)-C(2)-C(3) 121.4(3) 
O(4)-C(3)-C(2) 107.5(2) 
O(4)-C(3)-C(4) 110.4(2) 
C(2)-C(3)-C(4) 112.9(3) 
O(6)-C(4)-C(3) 109.4(3) 
O(6)-C(4)-C(5) 104.2(2) 
C(3)-C(4)-C(5) 110.8(3) 
O(8)-C(5)-C(6) 108.4(3) 
O(8)-C(5)-C(4) 107.6(2) 
C(6)-C(5)-C(4) 111.7(3) 
C(1)-C(6)-C(5) 113.8(3) 
O(5)-C(9)-O(4) 123.2(3) 
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O(5)-C(9)-C(10) 126.0(3) 
O(4)-C(9)-C(10) 110.8(3) 
O(7)-C(11)-O(6) 122.7(3) 
O(7)-C(11)-C(12) 125.8(3) 
O(6)-C(11)-C(12) 111.4(3) 
O(9)-C(13)-O(8) 122.0(4) 
O(9)-C(13)-C(14) 125.5(3) 
O(8)-C(13)-C(14) 112.5(3) 
 
ORTEP-generated structure of (3R,4S,5R)-3-[(tert-
butyldimethylsilyl)oxy]-4,5-(2,3-dimethoxy-butan-2,3-dioxy)-
cyclohex-1-ene-1-carboxylic acid 13 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Crystal data and structure refinement of compound 13. 
 
Empirical formula  C19 H34 O7 Si 
Formula weight  402.55 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 (No.1) 
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Unit cell dimensions a = 6.9400(5) Å  = 97.908(4)°. 
 b = 11.6981(9) Å β = 94.516(4)°. 
 c = 14.0445(9) Å  = 90.602(3)°. 
Volume 1125.59(14) Å3 
Z 2 
Density (calculated) 1.19 Mg/m3 
Absorption coefficient 0.14 mm-1 
F(000) 436 
Crystal size 0.15 x 0.10 x 0.01 mm3 
Theta range for data collection 3.40 to 22.95° 
Index ranges -7<=h<=7, -12<=k<=12, -15<=l<=15 
Reflections collected 11214 
Independent reflections 5933 [R(int) = 0.058] 
Reflections with I>2sigma(I) 4705 
Completeness to theta = 22.95° 99.0 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5933 / 3 / 513 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.053, wR2 = 0.111 
R indices (all data) R1 = 0.079, wR2 = 0.125 
Absolute structure parameter 0.11(17) 
Largest diff. peak and hole 0.20 and -0.29 e.Å-3 
The very thin crystal gave weak and limited diffraction. 
Two essentially identical independent molecules labeled equivalently. 
 
Data collection KappaCCD, Program package WinGX, Abs correction not applied, 
Refinement using SHELXL-97, Drawing using ORTEP-3 for Windows  
 
Table 2.  Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
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_____________________________________________________________________ 
 x y z U(eq) 
_____________________________________________________________________ 
Si(1) 3340(2) 8794(1) 1870(1) 45(1) 
O(1) 5074(5) 7982(3) 2251(2) 40(1) 
O(2) 9602(6) 8596(3) 5115(3) 50(1) 
O(3) 11642(5) 7252(3) 4546(2) 45(1) 
O(4) 7685(4) 4815(3) 1751(2) 34(1) 
O(5) 3902(4) 5640(3) 1921(2) 32(1) 
O(6) 6039(4) 5291(3) 341(2) 38(1) 
O(7) 4338(4) 3697(3) 2093(2) 35(1) 
C(1) 5104(7) 7296(4) 3019(3) 35(1) 
C(2) 6756(7) 7738(4) 3738(3) 36(1) 
C(3) 8464(7) 7222(4) 3774(3) 33(1) 
C(4) 8908(7) 6149(4) 3118(3) 35(1) 
C(5) 7418(7) 5938(4) 2272(3) 32(1) 
C(6) 5426(7) 6042(4) 2643(3) 31(1) 
C(7) 10063(8) 7685(4) 4515(3) 37(1) 
C(8) 1321(9) 7879(6) 1217(5) 77(2) 
C(9) 2423(9) 9741(5) 2908(4) 63(2) 
C(10) 4570(9) 9626(4) 1027(4) 49(1) 
C(11) 6397(9) 10260(5) 1569(5) 68(2) 
C(12) 3201(11) 10528(5) 655(5) 75(2) 
C(13) 5214(13) 8785(6) 177(5) 82(2) 
C(14) 4212(7) 4537(4) 1438(3) 33(1) 
C(15) 6196(7) 4484(4) 1004(3) 33(1) 
C(16) 2521(7) 4274(5) 680(4) 43(1) 
C(17) 6696(7) 3282(4) 538(4) 41(1) 
C(18) 7735(8) 5468(5) -139(4) 47(1) 
C(19) 2622(8) 3563(5) 2595(4) 53(2) 
Si(1B) 3939(2) 4623(1) 6485(1) 39(1) 
O(1B) 2164(4) 3659(3) 6143(2) 37(1) 
O(2B) -2382(6) 3278(3) 3312(3) 48(1) 
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O(3B) -4449(5) 2090(3) 3875(2) 46(1) 
O(4B) -477(4) 661(3) 6695(2) 33(1) 
O(5B) 3313(4) 1453(3) 6494(2) 34(1) 
O(6B) 1233(5) 1606(3) 8094(2) 39(1) 
O(7B) 2876(5) -557(3) 6326(2) 37(1) 
C(1B) 2108(7) 2721(4) 5389(3) 36(1) 
C(2B) 437(7) 2902(4) 4675(3) 38(1) 
C(3B) -1273(7) 2361(4) 4648(3) 33(1) 
C(4B) -1719(7) 1519(4) 5320(3) 36(1) 
C(5B) -192(7) 1616(4) 6166(3) 31(1) 
C(6B) 1768(7) 1591(4) 5784(3) 32(1) 
C(7B) -2857(8) 2543(4) 3918(3) 37(1) 
C(8B) 5986(8) 3945(5) 7121(5) 64(2) 
C(9B) 4810(8) 5197(5) 5418(4) 56(2) 
C(10B) 2776(8) 5748(4) 7311(4) 47(1) 
C(11B) 916(9) 6163(5) 6800(4) 60(2) 
C(12B) 4144(10) 6805(5) 7615(5) 71(2) 
C(13B) 2252(10) 5241(6) 8212(4) 68(2) 
C(14B) 1033(7) 585(4) 7434(3) 35(1) 
C(15B) 3004(7) 504(4) 6989(3) 33(1) 
C(16B) 508(8) -473(4) 7893(4) 43(1) 
C(17B) 4690(7) 510(5) 7728(4) 42(1) 
C(18B) -419(8) 1943(5) 8598(4) 50(1) 
C(19B) 4574(8) -822(5) 5817(4) 54(2) 
 
Table 3.   Bond lengths [Å] and angles [°]. 
 
Si(1)-O(1)  1.643(3) 
Si(1)-C(8)  1.857(6) 
Si(1)-C(9)  1.864(6) 
Si(1)-C(10)  1.880(5) 
O(1)-C(1)  1.429(5) 
O(2)-C(7)  1.323(6) 
O(3)-C(7)  1.213(6) 
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O(4)-C(15)  1.424(5) 
O(4)-C(5)  1.435(5) 
O(5)-C(14)  1.400(6) 
O(5)-C(6)  1.434(5) 
O(6)-C(15)  1.414(6) 
O(6)-C(18)  1.428(6) 
O(7)-C(14)  1.435(6) 
O(7)-C(19)  1.448(6) 
C(1)-C(2)  1.504(7) 
C(1)-C(6)  1.514(6) 
C(2)-C(3)  1.336(7) 
C(3)-C(4)  1.501(6) 
C(3)-C(7)  1.503(7) 
C(4)-C(5)  1.504(6) 
C(5)-C(6)  1.516(7) 
C(10)-C(13)  1.537(8) 
C(10)-C(12)  1.544(8) 
C(10)-C(11)  1.552(8) 
C(14)-C(16)  1.520(7) 
C(14)-C(15)  1.547(6) 
C(15)-C(17)  1.522(7) 
Si(1B)-O(1B)  1.658(3) 
Si(1B)-C(8B)  1.861(6) 
Si(1B)-C(9B)  1.863(5) 
Si(1B)-C(10B)  1.866(5) 
O(1B)-C(1B)  1.414(6) 
O(2B)-C(7B)  1.346(6) 
O(3B)-C(7B)  1.214(6) 
O(4B)-C(14B)  1.429(5) 
O(4B)-C(5B)  1.443(5) 
O(5B)-C(15B)  1.411(5) 
O(5B)-C(6B)  1.432(5) 
O(6B)-C(14B)  1.406(6) 
O(6B)-C(18B)  1.425(6) 
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O(7B)-C(19B)  1.440(6) 
O(7B)-C(15B)  1.443(6) 
C(1B)-C(2B)  1.509(7) 
C(1B)-C(6B)  1.525(6) 
C(2B)-C(3B)  1.335(7) 
C(3B)-C(7B)  1.481(7) 
C(3B)-C(4B)  1.501(6) 
C(4B)-C(5B)  1.520(6) 
C(5B)-C(6B)  1.500(6) 
C(10B)-C(13B)  1.536(7) 
C(10B)-C(12B)  1.542(8) 
C(10B)-C(11B)  1.543(8) 
C(14B)-C(16B)  1.525(7) 
C(14B)-C(15B)  1.547(7) 
C(15B)-C(17B)  1.501(7) 
 
O(1)-Si(1)-C(8) 110.2(3) 
O(1)-Si(1)-C(9) 110.2(2) 
C(8)-Si(1)-C(9) 109.4(3) 
O(1)-Si(1)-C(10) 102.8(2) 
C(8)-Si(1)-C(10) 111.0(3) 
C(9)-Si(1)-C(10) 113.0(3) 
C(1)-O(1)-Si(1) 128.9(3) 
C(15)-O(4)-C(5) 113.0(3) 
C(14)-O(5)-C(6) 113.2(3) 
C(15)-O(6)-C(18) 115.8(4) 
C(14)-O(7)-C(19) 115.1(4) 
O(1)-C(1)-C(2) 107.4(4) 
O(1)-C(1)-C(6) 110.4(4) 
C(2)-C(1)-C(6) 109.2(4) 
C(3)-C(2)-C(1) 122.5(4) 
C(2)-C(3)-C(4) 123.6(4) 
C(2)-C(3)-C(7) 120.6(4) 
C(4)-C(3)-C(7) 115.8(4) 
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C(3)-C(4)-C(5) 110.5(4) 
O(4)-C(5)-C(4) 109.1(4) 
O(4)-C(5)-C(6) 111.5(4) 
C(4)-C(5)-C(6) 108.6(4) 
O(5)-C(6)-C(1) 109.1(4) 
O(5)-C(6)-C(5) 113.2(3) 
C(1)-C(6)-C(5) 108.8(4) 
O(3)-C(7)-O(2) 123.6(5) 
O(3)-C(7)-C(3) 121.9(5) 
O(2)-C(7)-C(3) 114.5(5) 
C(13)-C(10)-C(12) 110.2(5) 
C(13)-C(10)-C(11) 108.2(5) 
C(12)-C(10)-C(11) 108.9(5) 
C(13)-C(10)-Si(1) 109.5(4) 
C(12)-C(10)-Si(1) 110.6(4) 
C(11)-C(10)-Si(1) 109.4(4) 
O(5)-C(14)-O(7) 111.2(4) 
O(5)-C(14)-C(16) 106.1(4) 
O(7)-C(14)-C(16) 111.6(4) 
O(5)-C(14)-C(15) 111.1(4) 
O(7)-C(14)-C(15) 103.9(4) 
C(16)-C(14)-C(15) 113.0(4) 
O(6)-C(15)-O(4) 111.5(4) 
O(6)-C(15)-C(17) 112.9(4) 
O(4)-C(15)-C(17) 105.9(4) 
O(6)-C(15)-C(14) 103.5(4) 
O(4)-C(15)-C(14) 109.4(4) 
C(17)-C(15)-C(14) 113.8(4) 
O(1B)-Si(1B)-C(8B) 109.9(2) 
O(1B)-Si(1B)-C(9B) 110.4(2) 
C(8B)-Si(1B)-C(9B) 109.2(3) 
O(1B)-Si(1B)-C(10B) 102.9(2) 
C(8B)-Si(1B)-C(10B) 111.8(3) 
C(9B)-Si(1B)-C(10B) 112.5(2) 
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C(1B)-O(1B)-Si(1B) 127.9(3) 
C(14B)-O(4B)-C(5B) 112.8(3) 
C(15B)-O(5B)-C(6B) 112.7(3) 
C(14B)-O(6B)-C(18B) 116.4(4) 
C(19B)-O(7B)-C(15B) 115.0(4) 
O(1B)-C(1B)-C(2B) 107.5(4) 
O(1B)-C(1B)-C(6B) 110.1(4) 
C(2B)-C(1B)-C(6B) 108.9(4) 
C(3B)-C(2B)-C(1B) 122.8(4) 
C(2B)-C(3B)-C(7B) 121.0(4) 
C(2B)-C(3B)-C(4B) 123.5(4) 
C(7B)-C(3B)-C(4B) 115.5(4) 
C(3B)-C(4B)-C(5B) 110.3(4) 
O(4B)-C(5B)-C(6B) 111.3(4) 
O(4B)-C(5B)-C(4B) 108.2(3) 
C(6B)-C(5B)-C(4B) 108.6(4) 
O(5B)-C(6B)-C(5B) 113.6(4) 
O(5B)-C(6B)-C(1B) 108.5(4) 
C(5B)-C(6B)-C(1B) 108.5(4) 
O(3B)-C(7B)-O(2B) 122.8(5) 
O(3B)-C(7B)-C(3B) 123.5(4) 
O(2B)-C(7B)-C(3B) 113.7(5) 
C(13B)-C(10B)-C(12B) 109.5(5) 
C(13B)-C(10B)-C(11B) 108.9(5) 
C(12B)-C(10B)-C(11B) 107.9(5) 
C(13B)-C(10B)-Si(1B) 109.5(4) 
C(12B)-C(10B)-Si(1B) 110.7(4) 
C(11B)-C(10B)-Si(1B) 110.2(4) 
O(6B)-C(14B)-O(4B) 111.6(4) 
O(6B)-C(14B)-C(16B) 113.5(4) 
O(4B)-C(14B)-C(16B) 105.3(4) 
O(6B)-C(14B)-C(15B) 103.2(3) 
O(4B)-C(14B)-C(15B) 109.5(3) 
C(16B)-C(14B)-C(15B) 113.8(4) 
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O(5B)-C(15B)-O(7B) 110.5(3) 
O(5B)-C(15B)-C(17B) 106.1(4) 
O(7B)-C(15B)-C(17B) 111.5(4) 
O(5B)-C(15B)-C(14B) 110.9(4) 
O(7B)-C(15B)-C(14B) 104.9(3) 
C(17B)-C(15B)-C(14B) 113.1(4) 
 
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
  
D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
O2-H2X         0.78     2.09    153       2.814    O7B_a [ x+1, y+1, z ] 
O2B-H2Y_a      0.73     2.11    171       2.827    O7 [ x-1, y, z ] 
 
ORTEP-generated structure of Dimethyl (3R,4S,5R)- 3-hydroxy-
4,5-(2,3-dimethoxy-butan-2,3-dioxy)-cyclohex-1-ene-1-
phosphonate 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Crystal data and structure refinement of compound 16. 
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Empirical formula  C14 H25 O8 P 
Formula weight  352.31 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21  (No.4)  
Unit cell dimensions a = 7.5515(2) Å  = 90°. 
 b = 9.4704(4) Å β = 100.943(2)°. 
 c = 11.8545(4) Å  = 90°. 
Volume 832.37(5) Å3 
Z 2 
Density (calculated) 1.41 Mg/m3 
Absorption coefficient 0.20 mm-1 
F(000) 376 
Crystal size 0.20 x 0.15 x 0.10 mm3 
Theta range for data collection 3.50 to 26.04° 
Index ranges -8<=h<=9, -11<=k<=11, -14<=l<=14 
Reflections collected 12562 
Independent reflections 3257 [R(int) = 0.046] 
Reflections with I>2sigma(I) 2997 
Completeness to theta = 26.04° 99.2 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3257 / 1 / 218 
Goodness-of-fit on F2 1.054 
Final R indices [I>2sigma(I)] R1 = 0.034, wR2 = 0.080 
R indices (all data) R1 = 0.040, wR2 = 0.083 
Absolute structure parameter 0.04(9) 
Largest diff. peak and hole 0.26 and -0.29 e.Å-3 
The hydroxyl H atom was refined. 
 
Data collection KappaCCD, Program package WinGX, Abs correction not applied,  
Refinement using SHELXL-97, Drawing using ORTEP-3 for Windows  
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Table 2.  Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
____________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________ 
P 3514(1) 7841(1) 3229(1) 25(1) 
O(1) -1550(2) 7421(2) 5265(1) 37(1) 
O(2) 2500(2) 8886(2) 2303(1) 29(1) 
O(3) 3055(2) 6441(2) 2519(1) 40(1) 
O(4) 5445(2) 8120(2) 3628(1) 37(1) 
O(5) 3463(2) 7222(2) 7552(1) 22(1) 
O(6) 167(2) 8639(2) 7339(1) 24(1) 
O(7) 1425(2) 6178(2) 8555(1) 26(1) 
O(8) 2607(2) 9793(2) 8478(1) 30(1) 
C(1) -316(3) 8554(3) 5273(2) 26(1) 
C(2) 707(3) 8412(3) 4292(2) 27(1) 
C(3) 2333(3) 7828(3) 4408(2) 23(1) 
C(4) 3353(3) 7241(2) 5533(2) 25(1) 
C(5) 2219(3) 7244(2) 6465(2) 22(1) 
C(6) 1067(3) 8559(2) 6384(2) 23(1) 
C(7) 2612(3) 7326(2) 8521(2) 23(1) 
C(8) 1385(3) 8649(3) 8413(2) 25(1) 
C(9) 216(3) 8733(3) 9320(2) 32(1) 
C(10) 4140(3) 7367(3) 9562(2) 32(1) 
C(11) 1818(4) 11164(3) 8329(2) 41(1) 
C(12) 2210(3) 4812(2) 8587(2) 33(1) 
C(13) 2760(4) 10404(3) 2472(2) 40(1) 
C(14) 3924(4) 5138(3) 2916(3) 47(1) 
 
 
 
 
149 
 
Table 3.   Bond lengths [Å] and angles [°]. 
 
P-O(4)  1.4687(16) 
P-O(2)  1.5655(16) 
P-O(3)  1.5732(18) 
P-C(3)  1.7952(19) 
O(1)-C(1)  1.420(3) 
O(2)-C(13)  1.459(3) 
O(3)-C(14)  1.434(3) 
O(5)-C(7)  1.423(2) 
O(5)-C(5)  1.443(2) 
O(6)-C(8)  1.422(2) 
O(6)-C(6)  1.429(2) 
O(7)-C(7)  1.414(3) 
O(7)-C(12)  1.420(3) 
O(8)-C(8)  1.416(3) 
O(8)-C(11)  1.425(3) 
C(1)-C(6)  1.518(3) 
C(1)-C(2)  1.519(3) 
C(2)-C(3)  1.330(3) 
C(3)-C(4)  1.513(3) 
C(4)-C(5)  1.522(3) 
C(5)-C(6)  1.511(3) 
C(7)-C(10)  1.522(3) 
C(7)-C(8)  1.549(3) 
C(8)-C(9)  1.518(3) 
 
O(4)-P-O(2) 115.83(9) 
O(4)-P-O(3) 115.32(10) 
O(2)-P-O(3) 97.44(9) 
O(4)-P-C(3) 111.09(9) 
O(2)-P-C(3) 107.55(9) 
O(3)-P-C(3) 108.58(11) 
C(13)-O(2)-P 119.42(15) 
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C(14)-O(3)-P 120.65(16) 
C(7)-O(5)-C(5) 113.74(14) 
C(8)-O(6)-C(6) 112.66(15) 
C(7)-O(7)-C(12) 115.92(17) 
C(8)-O(8)-C(11) 115.93(19) 
O(1)-C(1)-C(6) 110.52(18) 
O(1)-C(1)-C(2) 110.89(19) 
C(6)-C(1)-C(2) 107.34(16) 
C(3)-C(2)-C(1) 123.50(18) 
C(2)-C(3)-C(4) 123.30(17) 
C(2)-C(3)-P 120.14(15) 
C(4)-C(3)-P 116.36(14) 
C(3)-C(4)-C(5) 112.15(16) 
O(5)-C(5)-C(6) 109.77(17) 
O(5)-C(5)-C(4) 106.72(16) 
C(6)-C(5)-C(4) 110.60(17) 
O(6)-C(6)-C(5) 110.33(17) 
O(6)-C(6)-C(1) 109.60(16) 
C(5)-C(6)-C(1) 110.22(18) 
O(7)-C(7)-O(5) 110.85(16) 
O(7)-C(7)-C(10) 112.59(18) 
O(5)-C(7)-C(10) 105.50(16) 
O(7)-C(7)-C(8) 104.59(16) 
O(5)-C(7)-C(8) 110.08(16) 
C(10)-C(7)-C(8) 113.33(18) 
O(8)-C(8)-O(6) 111.03(18) 
O(8)-C(8)-C(9) 112.43(19) 
O(6)-C(8)-C(9) 105.66(16) 
O(8)-C(8)-C(7) 103.97(16) 
O(6)-C(8)-C(7) 110.12(18) 
C(9)-C(8)-C(7) 113.74(18) 
 
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
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D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
O1-H1X         0.76    2.02   175       2.772    O4 [x-1, y, z] 
 
ORTEP-generated structure of (3R,4R,5S)-4-acetylamino-5-azido-
3-(1-ethylpropoxy)-1-iodocyclohexene 25 
 
 
 
 
 
 
 
 
 
Table 1.  Crystal data and structure refinement of compound 25. 
 
Empirical formula  C13 H20 I N4 O2 
Formula weight  391.23 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121  (No.19)  
Unit cell dimensions a = 4.8452(1) Å  = 90°. 
 b = 19.0439(5) Å β = 90°. 
 c = 36.6182(9) Å  = 90°. 
Volume 3378.82(14) Å3 
Z 8 
Density (calculated) 1.54 Mg/m3 
Absorption coefficient 1.90 mm-1 
F(000) 1560 
Crystal size 0.50 x 0.25 x 0.02 mm3 
Theta range for data collection 3.51 to 26.00° 
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Index ranges -3<=h<=5, -23<=k<=23, -45<=l<=45 
Reflections collected 25623 
Independent reflections 6531 [R(int) = 0.069] 
Reflections with I>2sigma(I) 4539 
Completeness to theta = 26.00° 99.2 %  
Tmax. and Tmin.  0.9634 and 0.8497 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6531 / 0 / 360 
Goodness-of-fit on F2 1.075 
Final R indices [I>2sigma(I)] R1 = 0.050, wR2 = 0.122 
R indices (all data) R1 = 0.088, wR2 = 0.144 
Absolute structure parameter 0.03(3) 
Largest diff. peak and hole 1.17 and -0.85 e.Å-3 
There are two independent molecules, one of which has disorder in the ethyl groups.. 
The disordered C atoms in the ethyl groups of molecule B were left isotropic. 
 
Data collection KappaCCD, Program package WinGX, Abs correction MULTISCAN  
Refinement using SHELXL-97, Drawing using ORTEP-3 for Windows  
 
Table 2.  Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103). 
βU(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
____________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________ 
I(1) 8324(1) 7250(1) 4302(1) 71(1) 
O(1) 12634(8) 4203(3) 5393(1) 46(1) 
O(2) 8652(9) 4551(2) 4503(1) 39(1) 
N(1) 9812(15) 5848(3) 5606(2) 59(2) 
N(2) 8786(16) 6200(3) 5851(2) 57(2) 
N(3) 8100(19) 6509(4) 6102(2) 83(2) 
N(4) 8193(10) 4549(3) 5311(1) 37(1) 
C(1) 8086(14) 6356(4) 4637(2) 46(2) 
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C(2) 9013(16) 6460(3) 5020(2) 53(2) 
C(3) 8209(16) 5841(3) 5260(2) 44(2) 
C(4) 8854(12) 5139(3) 5074(2) 35(1) 
C(5) 7269(12) 5065(3) 4713(2) 37(1) 
C(6) 7228(14) 5750(3) 4501(2) 47(2) 
C(7) 10165(14) 4134(3) 5449(2) 39(2) 
C(8) 9123(13) 3550(3) 5695(2) 49(2) 
C(9) 6898(14) 4099(3) 4288(2) 47(2) 
C(10) 6025(15) 3474(4) 4506(2) 60(2) 
C(11) 8452(17) 3010(4) 4631(2) 64(2) 
C(12) 8520(20) 3941(4) 3938(2) 71(2) 
C(13) 8900(30) 4586(5) 3702(2) 94(3) 
I(1B) 3850(2) 6438(1) 3456(1) 97(1) 
O(1B) -2344(9) 5300(4) 1677(2) 78(2) 
O(2B) 2419(8) 4429(2) 2470(1) 46(1) 
N(1B) 253(15) 6791(4) 2065(2) 71(2) 
N(2B) 905(17) 6887(3) 1743(2) 74(2) 
N(3B) 1280(20) 7036(4) 1447(2) 97(3) 
N(4B) 2150(9) 5389(3) 1834(1) 39(1) 
C(1B) 3134(18) 6046(4) 2928(2) 57(2) 
C(2B) 1603(17) 6541(4) 2682(2) 54(2) 
C(3B) 2201(14) 6346(3) 2281(2) 46(2) 
C(4B) 1712(13) 5565(3) 2215(2) 39(1) 
C(5B) 3558(14) 5113(3) 2454(2) 40(1) 
C(6B) 3947(16) 5421(4) 2828(2) 59(2) 
C(7B) 109(15) 5256(4) 1600(2) 50(2) 
C(8B) 1003(16) 5055(5) 1223(2) 62(2) 
C(9B) 4350(15) 3851(4) 2405(2) 56(2) 
C(10B) 4490(30) 3647(9) 2012(4) 63(5) 
C(11B) 1840(20) 3413(5) 1851(3) 87(3) 
C(12B) 3640(40) 3224(9) 2671(4) 72(5) 
C(13B) 4000(30) 3374(5) 3044(3) 102(4) 
C(9C) 4350(15) 3851(4) 2405(2) 56(2) 
C(10C) 2630(30) 3268(8) 2231(4) 52(4) 
154 
 
C(11C) 1840(20) 3413(5) 1851(3) 87(3) 
C(12C) 5840(40) 3661(11) 2721(5) 87(6) 
C(13C) 4000(30) 3374(5) 3044(3) 102(4) 
 
Table 3.   Bond lengths [Å] and angles [°]. 
 
I(1)-C(1)  2.101(7) 
O(1)-C(7)  1.221(7) 
O(2)-C(5)  1.414(7) 
O(2)-C(9)  1.443(7) 
N(1)-N(2)  1.228(8) 
N(1)-C(3)  1.485(9) 
N(2)-N(3)  1.139(9) 
N(4)-C(7)  1.338(8) 
N(4)-C(4)  1.456(8) 
C(1)-C(6)  1.324(9) 
C(1)-C(2)  1.486(9) 
C(2)-C(3)  1.521(9) 
C(3)-C(4)  1.531(8) 
C(4)-C(5)  1.536(8) 
C(5)-C(6)  1.518(9) 
C(7)-C(8)  1.518(9) 
C(9)-C(10)  1.496(10) 
C(9)-C(12)  1.534(11) 
C(10)-C(11)  1.539(11) 
C(12)-C(13)  1.513(12) 
I(1B)-C(1B)  2.104(7) 
O(1B)-C(7B)  1.224(9) 
O(2B)-C(5B)  1.418(7) 
O(2B)-C(9B)  1.463(9) 
N(1B)-N(2B)  1.232(9) 
N(1B)-C(3B)  1.495(9) 
N(2B)-N(3B)  1.134(9) 
N(4B)-C(7B)  1.333(8) 
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N(4B)-C(4B)  1.450(7) 
C(1B)-C(6B)  1.306(10) 
C(1B)-C(2B)  1.499(10) 
C(2B)-C(3B)  1.544(9) 
C(3B)-C(4B)  1.527(9) 
C(4B)-C(5B)  1.517(9) 
C(5B)-C(6B)  1.504(9) 
C(7B)-C(8B)  1.497(10) 
C(9B)-C(10B)  1.492(17) 
C(9B)-C(12B)  1.577(18) 
C(10B)-C(11B)  1.481(18) 
C(12B)-C(13B)  1.407(18) 
 
C(5)-O(2)-C(9) 115.5(5) 
N(2)-N(1)-C(3) 114.7(6) 
N(3)-N(2)-N(1) 172.1(9) 
C(7)-N(4)-C(4) 121.5(5) 
C(6)-C(1)-C(2) 124.5(6) 
C(6)-C(1)-I(1) 120.2(5) 
C(2)-C(1)-I(1) 115.3(5) 
C(1)-C(2)-C(3) 111.4(6) 
N(1)-C(3)-C(2) 110.6(6) 
N(1)-C(3)-C(4) 106.2(5) 
C(2)-C(3)-C(4) 111.6(5) 
N(4)-C(4)-C(3) 111.3(5) 
N(4)-C(4)-C(5) 109.5(5) 
C(3)-C(4)-C(5) 111.1(5) 
O(2)-C(5)-C(6) 108.8(5) 
O(2)-C(5)-C(4) 107.2(5) 
C(6)-C(5)-C(4) 111.6(5) 
C(1)-C(6)-C(5) 123.4(6) 
O(1)-C(7)-N(4) 124.9(6) 
O(1)-C(7)-C(8) 120.3(6) 
N(4)-C(7)-C(8) 114.7(6) 
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O(2)-C(9)-C(10) 110.4(6) 
O(2)-C(9)-C(12) 105.7(6) 
C(10)-C(9)-C(12) 115.8(6) 
C(9)-C(10)-C(11) 113.5(6) 
C(13)-C(12)-C(9) 112.3(7) 
C(5B)-O(2B)-C(9B) 115.8(5) 
N(2B)-N(1B)-C(3B) 115.4(7) 
N(3B)-N(2B)-N(1B) 172.0(9) 
C(7B)-N(4B)-C(4B) 123.6(5) 
C(6B)-C(1B)-C(2B) 123.8(7) 
C(6B)-C(1B)-I(1B) 122.0(6) 
C(2B)-C(1B)-I(1B) 114.2(5) 
C(1B)-C(2B)-C(3B) 109.0(6) 
N(1B)-C(3B)-C(4B) 111.8(6) 
N(1B)-C(3B)-C(2B) 104.5(6) 
C(4B)-C(3B)-C(2B) 110.8(5) 
N(4B)-C(4B)-C(5B) 109.7(5) 
N(4B)-C(4B)-C(3B) 110.8(5) 
C(5B)-C(4B)-C(3B) 111.7(5) 
O(2B)-C(5B)-C(6B) 111.5(5) 
O(2B)-C(5B)-C(4B) 108.5(5) 
C(6B)-C(5B)-C(4B) 112.3(6) 
C(1B)-C(6B)-C(5B) 124.8(7) 
O(1B)-C(7B)-N(4B) 124.1(7) 
O(1B)-C(7B)-C(8B) 120.6(7) 
N(4B)-C(7B)-C(8B) 115.3(6) 
O(2B)-C(9B)-C(10B) 112.4(8) 
O(2B)-C(9B)-C(12B) 109.3(8) 
C(10B)-C(9B)-C(12B) 114.0(10) 
C(11B)-C(10B)-C(9B) 115.0(11) 
C(13B)-C(12B)-C(9B) 114.7(12) 
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ORTEP-generated structure of (3R,4R,5S)-4-acetylamino-5-N-
tert-Butoxycarbonyl-amino-3-(1-ethylpropoxy)-1-
iodocyclohexene 32 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Crystal data and structure refinement of compound 32. 
 
Empirical formula  C18 H31 I N2 O4 
Formula weight  466.35 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21  (No.4) 
Unit cell dimensions a = 12.2334(15) Å  = 90°. 
 b = 4.9607(6) Å β = 105.910(7)°. 
 c = 18.6244(19) Å  = 90°. 
Volume 1086.9(2) Å3 
Z 2 
Density (calculated) 1.43 Mg/m3 
Absorption coefficient 1.50 mm-1 
F(000) 476 
Crystal size 0.30 x 0.02 x 0.01 mm3 
Theta range for data collection 3.41 to 25.95° 
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Index ranges -14<=h<=15, -6<=k<=5, -22<=l<=22 
Reflections collected 7090 
Independent reflections 3663 [R(int) = 0.092] 
Reflections with I>2sigma(I) 2313 
Completeness to theta = 25.95° 95.8 %  
Tmax. and Tmin.  0.9809 and 0.7795 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3663 / 1 / 238 
Goodness-of-fit on F2 1.044 
Final R indices [I>2sigma(I)] R1 = 0.074, wR2 = 0.148 
R indices (all data) R1 = 0.133, wR2 = 0.177 
Absolute structure parameter -0.01(6) 
Largest diff. peak and hole 1.28 and -0.76 e.Å-3  (near I) 
The H atoms on N were refined. 
 
Data collection KappaCCD, Program package WinGX, Abs correction MULTISCAN  
Refinement using SHELXL-97, Drawing using ORTEP-3 for Windows  
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
____________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________ 
I 2724(1) 5924(3) 4507(1) 75(1) 
O(1) 2482(7) 3805(15) 1689(4) 46(2) 
O(2) 5185(11) 6756(17) 1530(6) 59(3) 
O(3) 6576(8) -1655(16) 3359(6) 49(3) 
O(4) 8009(7) 1432(15) 3443(4) 51(2) 
N(1) 6280(10) 2800(20) 3424(7) 44(3) 
N(2) 4896(9) 2590(20) 1934(5) 43(2) 
C(1) 3354(10) 4330(20) 3659(6) 42(3) 
C(2) 4672(9) 4130(20) 3877(6) 37(3) 
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C(3) 5051(9) 2540(20) 3301(6) 40(3) 
C(4) 4401(9) 3530(20) 2512(6) 36(3) 
C(5) 3183(10) 2700(20) 2369(6) 44(3) 
C(6) 2731(9) 3640(20) 3011(6) 40(3) 
C(7) 5312(13) 4280(30) 1504(8) 49(4) 
C(8) 5876(13) 2980(20) 972(8) 63(4) 
C(9) 1873(12) 1830(20) 1161(6) 56(4) 
C(10) 1591(15) 3260(30) 392(7) 82(5) 
C(11) 2634(15) 3940(40) 118(10) 105(6) 
C(12) 829(11) 700(40) 1374(7) 75(4) 
C(13) -52(12) 2830(40) 1380(9) 82(5) 
C(14) 6926(8) 610(30) 3399(5) 42(3) 
C(15) 8895(11) -630(20) 3408(8) 57(4) 
C(16) 9101(11) -2310(20) 4126(7) 54(3) 
C(17) 9921(10) 1150(30) 3454(8) 70(4) 
C(18) 8508(12) -2220(30) 2705(7) 58(3) 
 
Table 3.   Bond lengths [Å] and angles [°]. 
 
I-C(1)  2.093(11) 
O(1)-C(5)  1.430(12) 
O(1)-C(9)  1.441(13) 
O(2)-C(7)  1.242(14) 
O(3)-C(14)  1.196(16) 
O(4)-C(14)  1.368(14) 
O(4)-C(15)  1.504(14) 
N(1)-C(14)  1.355(16) 
N(1)-C(3)  1.464(15) 
N(2)-C(7)  1.351(17) 
N(2)-C(4)  1.449(14) 
C(1)-C(6)  1.284(14) 
C(1)-C(2)  1.553(15) 
C(2)-C(3)  1.504(15) 
C(3)-C(4)  1.546(15) 
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C(4)-C(5)  1.499(15) 
C(5)-C(6)  1.522(15) 
C(7)-C(8)  1.498(19) 
C(9)-C(12)  1.543(19) 
C(9)-C(10)  1.548(17) 
C(10)-C(11)  1.54(2) 
C(12)-C(13)  1.51(2) 
C(15)-C(18)  1.489(18) 
C(15)-C(17)  1.517(19) 
C(15)-C(16)  1.539(18) 
 
C(5)-O(1)-C(9) 114.6(8) 
C(14)-O(4)-C(15) 119.5(10) 
C(14)-N(1)-C(3) 120.4(10) 
C(7)-N(2)-C(4) 122.9(10) 
C(6)-C(1)-C(2) 122.4(10) 
C(6)-C(1)-I 124.2(9) 
C(2)-C(1)-I 113.4(7) 
C(3)-C(2)-C(1) 110.4(8) 
N(1)-C(3)-C(2) 110.2(9) 
N(1)-C(3)-C(4) 111.0(9) 
C(2)-C(3)-C(4) 109.4(9) 
N(2)-C(4)-C(5) 112.2(9) 
N(2)-C(4)-C(3) 113.2(9) 
C(5)-C(4)-C(3) 108.0(8) 
O(1)-C(5)-C(4) 112.1(9) 
O(1)-C(5)-C(6) 108.6(9) 
C(4)-C(5)-C(6) 109.5(8) 
C(1)-C(6)-C(5) 124.7(10) 
O(2)-C(7)-N(2) 121.3(15) 
O(2)-C(7)-C(8) 122.4(16) 
N(2)-C(7)-C(8) 116.2(11) 
O(1)-C(9)-C(12) 112.3(11) 
O(1)-C(9)-C(10) 105.4(10) 
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C(12)-C(9)-C(10) 114.4(11) 
C(11)-C(10)-C(9) 114.4(13) 
C(13)-C(12)-C(9) 113.0(14) 
O(3)-C(14)-N(1) 123.8(11) 
O(3)-C(14)-O(4) 127.5(11) 
N(1)-C(14)-O(4) 108.7(12) 
C(18)-C(15)-O(4) 109.8(10) 
C(18)-C(15)-C(17) 114.6(12) 
O(4)-C(15)-C(17) 101.5(10) 
C(18)-C(15)-C(16) 114.4(11) 
O(4)-C(15)-C(16) 106.2(10) 
C(17)-C(15)-C(16) 109.3(11) 
 
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
N1-H1          0.91     1.99    144       2.779    O3 [ x, y+1, z ] 
N2-H2          0.96     2.12    159       3.035    O2 [ x, y-1, z ] 
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SED-NMR (600 MHz, D2O) of compound 54 
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Appendix 3 : 
31
P NMR Spectra 
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31
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P-NMR (121.4 MHz, CDCl3) of compound 9 
 
 
31
P-NMR (161.9 MHz, CDCl3) of compound 15 
 
TBDMSO
O
O
OMe
MeO
P
O
OMe
OMe
AcO
AcO
OAc
P
O
OMe
OMe
194 
 
 
31
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31
P-NMR (161.9 MHz, D2O) of compound 34 
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31
P-NMR (161.9 MHz, D2O) of compound 36 
 
 
31
P-NMR (242.9 MHz, CDCl3) of compound 38 
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31
P-NMR (161.9 MHz, D2O) of compound 40 
 
 
31
P-NMR (161.9 MHz, CD3OD) of compound 44 
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31
P-NMR (161.9 MHz, CD3OD) of compound 45 
 
 
31
P-NMR (161.9 MHz, D2O) of compound 46 
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31
P-NMR (161.9 MHz, CDCl3) of compound 49 
 
 
31
P-NMR (161.9 MHz, CDCl3) of compound 50 
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31
P-NMR (161.9 MHz, CDCl3) of compound 51 + side product 52 
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P-NMR (161.9 MHz, CD3OD) of compound 53 
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31
P-NMR (242.9 MHz, D2O) of compound 54 
 
 
31
P-NMR (161.9 MHz, CDCl3) of compound 58 
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31
P-NMR (161.9 MHz, CDCl3) of compound 59 
 
 
31
P-NMR (161.9 MHz, CDCl3) of compound 60 
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